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The following conventions have been used throughout this thesis to ensure 
consistency throughout: 
1. Protein symbols are written in standard font, with all letters in uppercase: e.g. 
MYC, MAX and MDM2. 
2. Gene symbols for human genes are written in italics, with all letters uppercase: 
e.g. MYC, MAX and MDM2; gene symbols for mouse and rat genes are written in 
italics, with the first letter uppercase, followed by all lowercase letters: e.g. Myc, 
Max and Mdm2; gene symbols for other organisms are written in italics, with all 
letters lowercase: e.g. myc, max, and mdm2. 
3. The term ‗exenatide‘ also refers to exendin-4 when no ambiguity exists.  
4. Glucose levels presented in the result section refer to fed glucose levels when no 
ambiguity exists.  
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Abstract 
 
Injection of 4-hydroxytamoxifen (4-OHT) activates the oncogene c-myc in 
transgenic pIns-c-MycER
TAM
 mice, triggering -cell proliferation in the short term as 
well as apoptosis and reduced insulin secretion, leading to hyperglycaemia. This 
hyperglycaemia is preceded by a short period of hypoglycaemia, which may be 
caused by: (i) increased insulin secretion or release from dying cells; (ii) rapid -cell 
proliferation; and (iii) increased insulin sensitivity. This thesis characterizes the 
initial stages of the expression of c-MYC in the plns-c-MycER
TAM
 mouse model and 
attempts to identify the causes of the transient hypoglycaemia using mathematical 
models. Furthermore, microarray data were analysed to investigate the early 
hypoglycaemia from the point of view of transcriptomics. The size and mass of 
-cells were quantified during the transient period of hypoglycaemia by means of 
immunohistochemistry. These data were incorporated in a detailed mathematical 
model of -cell dynamics.  
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Chapter 1. Introduction 
The vertebrate pancreas has two functions. One is the secretion of digestive 
enzymes (exocrine function), and the other is glucose homeostasis (endocrine 
function). Pancreatic islets are composed of α, β, δ, and pancreatic peptide (PP) 
endocrine cells. The α-cells secrete glucagon, which stimulates gluconeogenesis and 
glycogenolysis, whereas the β-cells secrete insulin, which promotes glucose disposal 
in the periphery and inhibits gluconeogenesis and glycogenolysis. Insulin plays a 
critical role in reducing plasma glucose levels following feeding. The balance 
between glucagon and insulin is important in maintaining glucose concentration, 
energy homeostasis, and energy balance, as reviewed in Gromada et al. (2007). In 
response to the stimuli that would result in rising plasma glucose, normal β-cells will 
secrete insulin at appropriate levels to maintain normal blood glucose levels. 
Conversely, when the blood glucose levels tend to drop, such as during prolonged 
fasting or extended exercise, insulin secretion is inhibited (Cryer, 1993). Diabetes is 
characterised by hyperglycaemia and β-cell failure or destruction. Type 1 diabetes 
mellitus (T1DM) is ascribed to an autoimmune assault against -cells causing 
extrinsic apoptosis, whereas Type 2 diabetes mellitus (T2DM) is associated with 
metabolic disorders, such as insulin resistance and dysfunction of glucose stimulated 
insulin secretion (GSIS) in β-cells. Both T1DM and T2DM possess an absolute or 
relative deficiency of -cells triggered by apoptosis (Bouwens and Rooman, 2005; 
Butler et al., 2003). Current treatments for diabetes include injection of exogenous 
insulin or oral glucose-lowering drugs but incur the side effects of iatrogenic 
hypoglycaemia and destruction of -cells. Although the islet transplantation is a 
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potential treatment for T1DM, the number of patients who can receive the treatment 
is limited. While most of the current treatments do not significantly arrest the 
decreasing -cell number or -cell dysfunction, the study of -cell regeneration and 
proliferation endogenous has become an important field. 
 
1.1.  The c-Myc oncogene 
The proto-oncogene c-myc, a cellular homolog oncogene of v-myc (Alitalo et al., 
1983; Crews et al., 1982; Sheiness et al., 1978), is a member of the myc family 
(c-myc, N-myc, and L-myc; Kohl et al., 1983; Nau et al., 1985; Schwab et al., 1984), 
which encodes a basic (b) helix-loop-helix (HLH) leucine zipper (LZ) transcriptional 
factor, c-MYC. It was the first studied oncogene in Burkitt‘s lymphoma (Spencer 
and Groudine, 1991). In up to 70% of human tumours, c-MYC is implicated (Nilsson 
and Cleveland, 2003), including bladder, breast, cervix, colon, gastric, hepatocellular, 
small-cell lung, ovarian carcinomas, lymphoma, leukaemia, osteosarcomas, and 
glioblastomas. MYC protein has also been reported as an important regulator in 
metazoan growth, proliferation, and apoptosis (Green and Evan, 2002; Henriksson 
and Luscher, 1996; Oster et al., 2002). This section will describe the role of c-MYC 
in proliferation, apoptosis, and glucose homeostasis. 
 
1.1.1 MYC protein 
The transcriptional factor, c-MYC, plays an important role in cell proliferation, 
cell growth, differentiation, and apoptosis (Amati and Land, 1994), as reviewed in 
Pelengaris et al. (2002a), Dang et al. (2006) and Vita and Henriksson (2006).  
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There are several distinct functional domains in c-MYC; they are shown in 
Figure 1.1.1. The carboxy-terminal domain (CTD) of c-MYC contains a bHLHLZ 
motif, which can dimerize another nuclear protein, MAX. The MYC-MAX 
hereodimers initiate transcriptional activities by binding to specific DNA sequences 
such as the E-box sequence (CACGTG; Blackwood and Eisenman, 1991). MIZ1 
(Myc-interacting zinc-finger protein 1), as MAX, binds to the CTD. The 
amino-terminal domain (NTD) contains conserved domains known as Myc boxes 
(MB). Myc Boxes I and II (MBI and MBII) are important for the transactivation of 
MYC‘s target genes, and MBII is required for all known c-MYC biological functions 
and is also involved in most of c-MYC target genes‘ activation or deactivation 
(Bahram et al., 2000; Stone et al., 1987). After c-MYC has bound to the target 
gene‘s promoter region, the MBII domain recruits co-activating proteins, such as 
TIP48/49 and TRRAP (transformation/transcription domain-associated protein), 
which constitute a common unit of numerous complexes. One example is the TIP60 
and GCN5 complex, possessing histone acetyltransferase (HAT) activity (McMahon 
et al., 1998) which acetylates the K residue of the chromosomal histone and results 
in a more open chromosome structure (Bouchard et al., 2001; Davie and Hendzel, 
1994; Frank et al., 2001). Another example that contains TRRAP is the complex 
containing the p400 and E1A binding protein (Fuchs et al., 2001). This complex 
possesses ATPase and helicase activities and suppresses HAT activity.  
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Figure 1.1.1. Functional domains of c-MYC. Image was adapted from Pelengaris et al. (2002a), 
figure 1. 
(A) functional domains of c-MYC, and  (B) MYC interacting proteins. The carboxy-terminal domain 
(CTD) contains the basic (b) helix-loop-helix (HLH) leucine zipper (LZ) motif, which can form a 
heterodimer with MYC‘s partner protein, MAX. MIZ1, as MAX, binds to the CTD. The 
amino-terminal domain (NTD) contains conserved components, MBI and MBII, which are important 
for the c-MYC target genes transactivation. MYC-MAX heterodimer binds to the promoter region of 
target genes, and recruits other cofactors, i.e. TRRAP (transformation/transcription domain-associated 
protein), TIP48/49, and SP1 (Sp1 transcription factor), to these conserved domains. TRRAP is able to 
activate the histone acetyltransferase (HAT) activity to remodel the chromatin whereas TIP48 and 
TIP49 are hexameric ATPases and contribute to the chromatin remodelling by their ATP-hydrolyzing 
and helicase activities. SP1 interacts with c-MYC by binding to the central region.  
 
1.1.2 MYC and proliferation 
The transcriptional regulation of c-MYC target genes relies on its partner protein, 
MAX. MYC and MAX are dimerized through the bHLHLZ motif. After the 
complex binds to the E-box sequence of target DNA, the transcriptional process is 
initiated. MYC-MAX heterodimers recruit TRRAP, which is a complex with HAT 
activity, as a co-activator, so that MYC-MAX heterodimers are able to enter the 
chromosome to activate transcription (Amati et al., 1993a; Amati et al., 1993b). 
MAX also binds with MAD, which replaces the original MYC after it degrades 
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rapidly after activating transcription (Hurlin et al., 1996; Zervos et al., 1993). MAD 
family members (MAD1, MXI1, MAD3 and MAD4), MNT (also known as ROX) 
and MGA, which act as antagonists to MYC, dimerize with MAX through bHLHz 
motifs and bind at E-box sequences (Ayer et al., 1993; Hurlin et al., 1997). The 
MYC/MAX/MAD network has been recognised as a standard model to describe the 
competition of MAX between MYC and MAD (Ayer et al., 1995; Grandori et al., 
2000; Schreiber-Agus et al., 1995). Whereas the MYC-MAX heterodimer activates 
transcription, the MAD-MAX or MNT-MAX heterodimer acts as a suppressor. The 
MAD-MAX dimer binds to the E-box and recruits histone deacetylases (HDACs), 
which result in histone deacetylation, through the adaptor protein SIN3 (Ayer et al., 
1995; Schreiber-Agus et al., 1995). Therefore, the MAD-MAX dimer represses the 
transcription of genes. This dimerization has also been confirmed as necessary for 
oncogenic MYC‘s dual functions (Amati et al., 1993b). 
One of the main functions of c-MYC is the regulation of cell proliferation, in 
particular progressing the cell cycle from the G0 phase into G1 and S phase (Amati et 
al., 1998; Freytag, 1988). After the MYC-MAX heterodimer binds directly to the 
E-box sequence, it subsequently activates the transcription of CCND2, which 
encodes cyclin D2, and CDK4, which encodes cyclin-dependent kinase 4 (Bouchard 
et al., 1999; Hermeking et al., 2000). KIP1 (also known as p27), which is a 
cyclin-dependent kinase (CDK) inhibitor (Kiyokawa et al., 1996), is sequestrated 
from the cyclin D2-CDK4 complex by the expression of CCND2 and CDK4 
(Bouchard et al., 1999); after which p27
KIP1
 is degraded by two other c-MYC target 
genes, i.e. CUL-1 (cullin 1) and CKS (CDC28 protein kinase regulatory subunit; 
Coller et al., 2000; O'Hagan et al., 2000a). c-MYC also phosphorylates the cyclin 
E-CDK2 complex by cyclin-activating kinase to prevent the binding of p27
KIP1
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(Perez-Roger et al., 1999). c-MYC regulates the increase of CDK4 and CDK2 and 
hyperphosphorylates the retinoblastoma protein (RB); as a consequence, the release 
of E2F from RB induces cell proliferation (Weintraub et al., 1995; Weintraub et al., 
1992). Furthermore, the tumour suppressor p21
CIP1
, which is a CDK inhibitor, is also 
suppressed by MYC after DNA damage, which renders p21
CIP1
 unable to activate 
cell cycle arrest in the G1 phase (Herold et al., 2002; Seoane et al., 2002). 
The ability to induce cell proliferation and hence to hamper cell terminal 
differentiation is another characteristic of c-MYC (La Rocca et al., 1994; Ryan and 
Birnie, 1997). The protein MYC and apoptosis will be discussed in more detail 
Section 1.1.3. 
 
1.1.3 MYC and apoptosis 
MYC-induced apoptosis demonstrates the dual function of this oncogene, as 
reviewed in Prendergast (1999). Apoptosis is programmed cell death, which is an 
intrinsic mechanism in metazoan organisms (Kerr et al., 1972). There are typical 
characteristics of apoptosis with morphological changes. It begins with condensation 
of the nuclear materials, followed by cell shrinkage. Cytoplasmic blebbing is the 
next event, and eventually the apoptotic cell detaches from other cells (Kerr et al., 
1972). Adhikary and Eilers (2005) concluded that MYC triggers apoptosis through 
two distinct pathways and both of them trigger cytochrome c release from 
mitochondria; one is MYC-ARF/p53 independent signalling, and another is the 
MYC-ARF/p53 dependent pathway. Figure 1.1.2 summarises the key known and 
hypothesised pathways involving c-MYC. 
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Figure 1.1.2. c-MYC regulated cell proliferation and apoptosis network. 
One of the most well-known functions of MYC is its ability to transit cell cycle into the S phase. 
MYC binds to its partner protein, MAX, on the c-terminal basic-helix-loop-helix-zipper (bHLHZ) 
domain; after which they are able to bind a specific DNA sequence, E-box (CAGTG). MYC activates 
CCNDK2 and CDK4, and thus suppresses p27
KIP1
. The sequestration of p27
KIP1
 from cyclin D/CDK4 
and cyclin E/CDK2 complexes consequently results in the increase of CDK4 and CDK2, which 
enables hyperphosphorylation of retinoblastoma protein (RB) and causes cell proliferation. However, 
MYC-induced apoptosis or cell cycle arrest is another pivotal event in anti-carcinogenesis. 
MYC-induced apoptosis is mediated by ARF/p53-dependent and ARF/p53-independent signalling 
pathways, both of which release cytochrome c from mitochondria into cytosol during apoptosis. In the 
MYC-ARF/p53-independent pathway, MYC activates BAX and BH3 (BCL-2 homology 
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domain 3)-only protein, i.e. BIM1, to sequester the anti-apoptotic protein BCL-2/BCL-xL, which 
suppresses mitochondrial-outer-membrane permeabilization (MOMP). On the other hand, in the 
MYC-ARF/p53-dependent pathway, MYC activates p19
ARF
, which inhibits MDM2 (murine double 
minute 2) and thus stabilises and activates p53. The activation of p53 induces pro-apoptotic genes, 
such as BAX, PUMA and FAS receptor; thus, they inhibit anti-apoptotic genes, such as BCL-2 and 
BCL-xL, finally resulting in apoptosis. Moreover, MYC-induced DNA damage, DNA double-strand 
breaks (DSBs) or single-strand breaks (SSBs), through reactive oxygen species (ROS)-dependent or 
ROS-independent system also play an important role in evoking apoptosis through ATM-dependent 
pathway. It is also believed that p53 at low levels of DSBs is able to activate p21
CIP1
 and trigger cell 
cycle arrest before the S phase. 
 
The TP53 gene (also called p53, which is the protein product of TP53) has 
been studied for more than 20 years. It was first described as a tumour suppressor 
gene in 1979 (Lane and Crawford, 1979; Linzer and Levine, 1979). Only when cells 
are stressed, for example by DNA damage, hypoxia, nucleotide depletion, viral 
infection, heat shock, or oncogenic stimuli, will this tumour suppressor be activated 
to repair the damage of DNA, to induce apoptosis, and to arrest cell cycle, as 
reviewed in Vogelstein et al. (2000). This is why TP53 has been called ―the guardian 
of the genome‖ (Lane, 1992; Macdonald, 2004). The connectivity of p53 in its 
cellular regulatory network has the properties of a ‗scale-free network‘: a small 
group of proteins, i.e. p53, MDM2 (murine double minute 2), p14
ARF
 /p19
ARF
 (p14 in 
human and p19 in mouse), and E2F-4 are highly connected and control most proteins 
in this system (Vogelstein et al., 2000).  
MDM2, a negative regulator limiting the tumour suppressor function of p53 
(Chen et al., 1996; Momand et al., 1992), is a key regulator of p53 stability and 
activity. When the level of MDM2 rises, MDM2 serves as an E3 ubiquitin ligase for 
23 
 
p53 and binds to p53 directly and ubiquitinates p53, thus causing p53 proteolysis 
(Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997). Liberating p53 from 
MDM2 is a critical step in the activation of p53, and there are different ways to 
achieve this purpose by blocking MDM2 expression (Chen et al., 1998; Tortora et 
al., 2000), inhibiting MDM2-p53 binding (Kussie et al., 1996), or limiting MDM2 
ubiquitin ligase activity (Sun, 2003). When p53 is activated, it activates 
pro-apoptotic genes, i.e. BAX, PUMA (p53-upregulated modulator of apoptosis) and 
FAS receptor (Lane, 1992). 
One of the events that triggers the activation of p53 is ATM 
(ataxia-telangiectasia mutated)-dependent DNA damage, which is detected by 
checkpoints. This involves certain DNA damage-inducible kinases, i.e. ATM, CHK1, 
and CHK2.  ATM is pivotal in DNA damage response (DDR), which directly 
phosphorylates p53 to weaken the MDM2-p53 complex, hence activates p53 (Banin 
et al., 1998; Canman et al., 1998; Khanna et al., 1998). In addition, ATM activates 
CHK2, which phosphorylates MDM2, and subsequently enhances the degradation of 
p53 (Khosravi et al., 1999). c-MYC also causes DNA damage, DNA double-strand 
breaks (DSBs) or single-strand breaks (SSBs), through the reactive oxygen species 
(ROS)-dependent (Vafa et al., 2002) or the ROS-independent pathway (Ray et al., 
2006) before S phase. Oncogene-induced DDR triggers the activation of ATM, 
CHK2, ATR (ataxia telangiectasia and Rad3 related)-H2AX/CHK1, and p53 
(Bartkova et al., 2005; Gorgoulis et al., 2005; Ismail et al., 2005), and has been 
suggested as a defence system against carcinogenesis in early stage cancer 
(Venkitaraman, 2005). Some studies found that p53 is able to activate p21
CIP1
 at a 
low level of DBSs, resulting in cell cycle arrest (Sherr and Roberts, 1995). 
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Another mechanism that activates p53 is oncogenic stress, such as E1A (de 
Stanchina et al., 1998) and MYC (Zindy et al., 1998). MYC stimulates ARF protein 
to inactivate MDM2; in this manner, it inhibits MDM2-p53 interaction, which 
stabilizes and activates p53 (Kamijo et al., 1998; Stott et al., 1998). p19
ARF
 is one of 
the protein products of the alternate reading frame of the mouse INK4a/ARF locus 
(Quelle et al., 1995). It is well known that p19
ARF
 regulates apoptosis by inhibiting 
MDM2 to induce a p53-dependent pathway under oncogenic stress elicited from 
c-MYC deregulation (Kamijo et al., 1998; Zhang et al., 1998; Zindy et al., 1998; 
Zindy et al., 2003). MYC-ARF/p53 axis-induced apoptosis has been well studied 
(Sherr et al., 2005). 
Adhikary and Eilers (2005) conclude that MYC triggers apoptosis through two 
distinct pathways, both of which trigger cytochrome c release from mitochondria; 
one is MYC-ARF/p53 dependent signalling, the other is the 
MYC-ARF/p53-independent pathway. In the latter one, c-MYC regulates BAX (Juin 
et al., 2002; Soucie et al., 2001). The BCL-2 family proteins suppress 
mitochondrial-outer-membrane permeabilization (MOMP) to prevent apoptosis 
(Martinou and Green, 2001). BIM is a BH3-only protein (where BH3 stands for 
BCL-2 homology domain 3), which is indirectly induced by MYC (Egle et al., 2004). 
It works together with BAX and promotes apoptosis by suppressing the protective 
action of BCL2/BCL-xL (O'Connor et al., 1998; Soucie et al., 2001) which results in 
MOMP and release of cytochrome c from mitochondria into cytosol (Soucie et al., 
2001); after which cytochrome c reacts with apoptotic protease-activating factor 1 
(APAF1) triggering apoptosis (Juin et al., 1999).  
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1.1.4 MYC and glycaemic regulation 
Glycolysis is one of the major pathways producing ATP (adenosine 
triphosphate), which stores energy for various molecular functions. Insulin secretion 
is pulsatile and occurs in response to a raised plasma glucose level (Goodner et al., 
1977; Lang et al., 1979). The regulation of glucose stimulated-insulin secretion 
(GSIS) depends on glucose metabolism and the activity of -cell plasma membrane 
ion channels (Ashcroft and Rorsman, 1989).  
In the GSIS model, insulin is secreted by the following events. Glucose moves 
from the blood plasma into the -cells through the glucose transporter II (GLUT2; 
Orci et al., 1989; Thorens et al., 1988). In the -cell, high-Km glucokinase (GK) acts 
as a glucose sensor, which phosphorylates glucose to glucose-6-phospate and is a 
rate-limiting step in glycolysis (Matschinsky, 1996). Furthermore, studies indicate 
that mutation of GK results in hypoglycaemia or hyperglycaemia as gain-of-function 
or loss-of-function, respectively (Christesen et al., 2002; Glaser et al., 1998; Gloyn, 
2003). ATP is produced by glycolysis; an increasing ATP/ADP (adenosine 
diphosphate) ratio closes the ATP-sensitive K
+
 (KATP) channels (Ashcroft et al., 
1984; Cook and Hales, 1984; Misler et al., 1986). In -cells, this potassium channel 
is composed of four inward-rectifier K
+
 channel subunits, KIR6.2, and four outward 
sulphonylurea receptor subunits (SUR1), as reviewed in Aguilar-Bryan and Bryan 
(1999) and Ashcroft and Gribble (1999). The closed potassium channels gradually 
depolarize the cell membrane from the resting potential, which is -70 mV (Matthews 
and Sakamoto, 1975; Meissner and Schmelz, 1974), and trigger an action potential 
that activates the voltage-dependent calcium channels (VDCCs), resulting in a flux 
of extracellular Ca
2+
 into the -cell (Misler et al., 1986). The entrance of calcium 
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triggers exocytosis of insulin-secreting granules and releases insulin into the plasma, 
as reviewed in Ashcroft et al. (1994). Exocytosis is regulated by soluble 
N-ethylmaleimide-sensitive fusion (NSF) attachment protein receptor (SNARE) 
proteins, which fuse the exocytotic vesicles to the plasma membrane. These SNARE 
proteins interact with VDCCs, which regulate Ca
2+ 
entry and exocytosis of insulin 
secretion (Barg et al., 2002b). Some studies suggest that depolarization of membrane 
potential will open the voltage-dependent potassium (Kv) channel to repolarize the 
action potentials. In this way calcium influx and insulin secretion are restricted, as 
reviewed in MacDonald and Wheeler (2003). Figure 1.1.3 depicts the scheme of 
GSIS. 
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Figure 1.1.3. Scheme of GSIS. 
Glucose is transported into the -cell through the glucose transporter II (GLUT2), and is subsequently 
phosphorylated by the high-Km glucokinase (GK) into glucose-6-phospate. As a result of glycolysis, 
the concentration of ATP/ADP is increased, which triggers the closure of KATP channels. The closed 
potassium channels gradually depolarise cell membrane from the resting potential and trigger an 
action potential that activates the voltage-dependent calcium channels (VDCCs) and causes the influx 
of extracellular calcium into the -cell. The increased calcium concentration triggers the exocytosis of 
insulin-secreting granules from the ‗readily releasable pool‘ (RRP) and releases insulin into the 
plasma. 
 
About 1-5% of the granules in -cells are able to release insulin immediately 
when required, a process completed in a few seconds (Barg et al., 2002a; Barg et al., 
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2001; Barg et al., 2002b). More than 95% of the granules are in the reverse pool and 
require mobilization. After the consumption of this ‗readily releasable pool‘ (RRP), 
the -cells require some time to refill the pool (Barg et al., 2002a; Barg et al., 2002b; 
Gromada et al., 1999). The time difference of the insulin secretion from RRP (1
st
 
phase) and refilling (2
nd
 phase) is responsible for the well-known biphasic secretion 
of insulin in the face of elevated extracellular glucose (Rorsman et al., 2000), as 
reviewed in Rorsman and Renström (2003). The 1
st
 phase insulin secretion is 
released by the Ca
2+
-entry influx (Barg et al., 2002a) whereas the refilling of RRP in 
2
nd
 phase needs a ‗primer‘, namely ATP, Ca2+ and temperature, and only fuel 
secretagogues, i.e. glucose, are able to initiate the 2
nd
 phase secretion.  
In addition to glucose, arginine and sulphonylurea may also act as insulin 
secretagogues. Insulin may itself play an important role in GSIS, through an 
autocrine or paracrine loop. Insulin activates insulin receptors on the surface of 
-cells (Verspohl and Ammon, 1980). Insulin secreted from GSIS feedback loop 
activates insulin receptors in an autocrine fashion (Rothenberg et al., 1995; Xu et al., 
1998) and this may contribute to increased insulin biosynthesis  Aspinwall et al. 
(1999) detected 5-hydroxytryptamine (5-HT) in a single mouse pancreatic -cell in 
vitro system to observe the insulin secretion stimulated by exogenous insulin. They 
also found similar secretions in human, porcine, and canine -cells and suggested 
that insulin activates the insulin receptor. In a β-cell-specific insulin receptor 
knockout (βIRKO) mice model, the loss of insulin receptors resulted in the loss of 1st 
phase insulin secretion in GSIS (Kulkarni et al., 1999) but gradual 2
nd
 phase 
secretion was retained. However, in arginine-treated βIRKO mice (Srivastava and 
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Goren, 2003), the two phases of insulin secretion can still be detected. These results 
suggest the importance of insulin in GSIS. 
Cell cycle entry or tumorigenesis consume a considerable amount energy which 
implies that the mitochondrial biogenesis and glycolysis signalling are important to 
these bioenergetic needs (Herzig et al., 2000; Sweet and Singh, 1995; Warburg, 1956; 
Warburg and Dickens, 1930). Although there is no direct evidence linking MYC to 
mitochondrial biogenesis, some studies have pointed out a relationship between 
MYC and glycolysis (Dang and Semenza, 1999; Li et al., 2005; Osthus et al., 2000; 
Zhang et al., 2007).  
Osthus et al. (2000) suggested that MYC regulates glycolytic genes to increase 
glucose metabolism by using chromatin immunoprecipitation (ChIP) assays. 
Evidence shows that MYC regulates the activation of lactate dehydrogenase-A 
(LDH-A; Hu et al., 2011; Osthus et al., 2000; Shim et al., 1997), whose activity is 
important in tumour cells because it converts pyruvate to lactate in the final step of 
anaerobic glycolysis (Robey et al., 2005; Zhong et al., 1999); this is known as the 
Warburg effect (Warburg, 1956). However, recent studies demonstrate the link 
between MYC and mitochondrial biogenesis (Li et al., 2005; Osthus et al., 2000; 
Zhang et al., 2007). Further investigation of how MYC links the metabolic processes 
to the cell cycle entry is still pending (Morrish et al., 2008).  
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1.1.5 MYC and -cell regulation 
Interest in β-cell regeneration has increased recently as it has been proposed as a 
potential treatment for diabetes (Butler et al., 2007). The change of -cell mass 
results from -cell proliferation, size (hypertrophy or atrophy), and apoptotic 
deletion (Bouwens and Rooman, 2005) triggered by different physiological or 
pathological conditions, such as injury, pregnancy (Parsons et al., 1995; Parsons et 
al., 1992), obesity (Bruning et al., 1997; Cho et al., 2001a; Okada et al., 2007), 
insulin resistance (Bruning et al., 1997; Pick et al., 1998), or diabetes (Butler et al., 
2003). It was reported that -cell mass expands fast after birth, especially in infancy, 
in both humans and rodents mainly because of proliferation (Dor et al., 2004; 
Kassem et al., 2000; Meier et al., 2008; Teta et al., 2007) but -cell replication rate 
is decreased in an age-dependent manner because of epigenetic modification of 
aging -cells (Finegood et al., 1995; McEvoy, 1981; Meier et al., 2008). Several 
studies also pointed out -cell mass gradually increases in adult rodents throughout 
their life time and is linearly correlated to its body weight after the first month of life 
(Bonner-Weir, 2000a; Finegood et al., 1995; Montanya et al., 2000). Montanya et al. 
(2000) showed that in male Lewis rats, the expansion of -cell mass was mainly 
from the increased -cell numbers (hyperplasia) before the age of 15 months, and an 
increase in -cell size (hypertrophy) afterwards. Hypertrophy has also been 
recognised by many diabetic rodent models as a rapid and economical -cell 
compensatory mechanism to maintain euglycaemia (Bonner-Weir et al., 1989; Jonas 
et al., 1999; Montanya et al., 2000; Pick et al., 1998). 
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Apart from the continuous growth of -cells throughout the lifespan, direct or 
indirect -cell turnover has been observed and widely studied in both humans and 
rodents (Bonner-Weir, 2000b). According to apoptopic and replication rate of -cells 
in vivo, Finegood et al. (1995) used a mathematical model to estimate the lifespan of 
rat -cell, which is about 58 days, and suggested the interplay of proliferation and 
apoptosis contributes to the maintenance of -cell mass. Indirect evidence also 
showed the -cell turnover in the human pancreas (Meier et al., 2005) but the 
replication rate of human -cells is much lower than that in rodents (Bouwens et al., 
1997; Bouwens and Pipeleers, 1998). An issue of great interest has been focused on 
the source of new -cells in adults under different physiological demands. Two 
controversial hypotheses suggest that new -cells are from self-replication (Dor et al., 
2004; Nir et al., 2007; Teta et al., 2007) or neogenesis, such as from stem cells, 
progenitor cells from ductal epithelium (Bonner-Weir et al., 1993; Rooman et al., 
2002), non--cell progenitors (Abouna et al., 2010), or transdifferentiation from 
pancreatic acinar cells (Lipsett and Finegood, 2002). However, some studies 
suggested that both -cell proliferation and neogenesis contribute to -cell 
regeneration (Rooman and Bouwens, 2004; Thyssen et al., 2006; Waguri et al., 
1997). 
c-MYC induced -cell proliferation is similar to other cell types, and has been 
described in Section 1.1.2. Studies showed that different glucose concentrations 
stimulate -cell proliferation or apoptosis (glucotoxicity; Efanova et al., 1998; 
Swenne, 1982; Yki-Jarvinen, 1992). Moreover, gene knockout studies, i.e. 
-cell-specific insulin receptor knockout (IRKO) mice, presented a deficiency of 
-cell mass (Kulkarni et al., 1999; Otani et al., 2004). Thus the hypothesis of 
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insulin-induced -cell proliferation has become widely studied (Beith et al., 2008; 
Okada et al., 2007).  
 
1.2. MYC-regulated gene network 
The targets of c-MYC are currently listed as 647 directly interacting genes 
(Zeller et al., 2003). If one expands the gene network by including indirect targets, 
c-MYC can be regarded as regulating 10-15% of cellular genes (Dang et al., 2006; 
Knoepfler, 2007) but with little overlap of the identified targets in different groups. 
In view of the complexity of the situation, it is necessary to use all available 
information and techniques to integrate the large amount of related information. 
Techniques such as microarray, chromatin immunoprecipitation (ChIP), and 
promoter microarrays (ChIP-on-chip) are used to study the gene expression levels 
and transcriptional promoters (Lee et al., 2002; Lockhart and Winzeler, 2000; Ren et 
al., 2000).  
Studies based on using high-throughput analysis, such as serial analysis of 
gene expression (SAGE; Velculescu et al., 1995) and microarray, have pointed to 
genes that were up- or down-regulated by MYC in vitro (Coller et al., 2000; Guo et 
al., 2000; Hermeking et al., 2000; Menssen and Hermeking, 2002; O'Hagan et al., 
2000b; Schuhmacher et al., 2001). Genes relating to cell cycle, signalling, growth, 
and cell adhesion were found regulated by MYC (Coller et al., 2000). Lawlor et al. 
(2006) applied microarray to study MYC-induced carcinogenesis in pancreas 
systematically in vivo using the plns-c-MycER
TAM
/RIP-BclxL transgenic mouse model. 
It is not surprising that the genes involved in gene ontological cell cycle and 
proliferation, e.g. cyclin D1 and cyclin D2, were found within 24 hours of MYC 
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activation. Furthermore, they also found the islet-specific genes, i.e. Gad1, Ptprn, 
Slc2a2 (which encodes GLUT2) and Ipf1 (which encodes PDX1; Schwitzgebel et al., 
2003; Stoffers et al., 1997) were deregulated within 2-4 hours after switching MYC 
on. Robson et al. (2011) applied the c-MycER
TAM
 transgenic mouse model to study 
MYC activation in two different tissues in vivo, i.e. pancreas and skin, and showed 
that within 24 hours of MYC activation in -cell, genes relating to DNA damage, 
intrinsic apoptosis, and the cell cycle were activated. These might provide clues 
about the linkage between MYC-induced proliferation and dedifferentiation in the 
early stage after MYC activation. However, the study of MYC-regulated genes in 
vivo has still been limited and the topic awaits further investigation. 
 
1.3. Diabetes and treatment 
Diabetes is characterised by a loss of -cell function and hyperglycaemia, and 
carries an increased risk of cardiovascular disorder, adult blindness, stroke, limb 
amputation, and early death (Krolewski and Warram, 2005). There are two major 
types of diabetes, Type 1 (T1DM) and Type 2 (T2DM). The former one results from 
the autoimmune destruction of -cells, whereas the latter is caused by peripheral 
insulin resistance and deregulated -cell compensatory function. 
Current treatment for T1DM is the injection of insulin or islet transplantation 
(Shapiro et al., 2000; Street et al., 2004). The treatment of T2DM includes 
maintaining a healthy life style and treatment with glucose-lowering agents, such as 
sulfonylureas, metformin, or thiazolidinediones, which are common oral antidiabetic 
drugs. Side effects of these drugs include increased -cell death, weight gain, or 
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hypoglycaemia (Gerstein et al., 2008; Kahn et al., 2006). Hypoglycaemia is the most 
common and recognisable side effect of diabetes treatment (Cryer, 2002) and 
iatrogenic hypoglycaemia causes frequent morbidity. Symptoms are seizure and 
coma and sometimes hypoglycaemia is fatal (Feltbower et al., 2008; Gerich, 1989; 
Jacobson et al., 2007; Skrivarhaug et al., 2006). In a healthy, non-diabetic, adult, 
hypoglycaemia can be prevented or corrected by three physiological responses that 
defend against the progression of hypoglycaemia, namely reducing endogenous 
insulin secretion and increasing counterregulatory factors, such as glucagon, which 
stimulates hepatic glycogenolysis, and adrenaline, which also contributes to 
glycogenolysis and decreases the glucose clearance by tissues, to maintain the 
euglycaemia (Fanelli et al., 1994; Schwartz et al., 1987). 
In comparison to intravenous glucose administration, oral glucose 
administration incurs the incretin effect, which has a different insulin secretion 
action, namely the gut-derived hormone enhances GSIS. Around 50-70% insulin is 
secreted after the oral glucose ingestion (Baggio and Drucker, 2007). Two 
gut-derived hormones have been defined and can result in the incretin effect: one is 
glucose-dependent insulinotropic polypeptide (GIP), which is secreted by K-cells 
mainly located in the upper small intestine (duodenum and jejunum, and some are 
presented in distal ileum). The other one is glucagon-like peptide (GLP)-1, which is 
produced by L-cells located in the small intestine and colon (Buchan et al., 1978; 
Buffa et al., 1975; Eissele et al., 1992; Kauth and Metz, 1987; Mortensen et al., 
2003). Both are able to stimulate insulin secretion and thus reduce the glucose level 
after a meal (Ebert and Creutzfeldt, 1980; Orskov, 1992). Incretin-stimulated insulin 
secretion is the result of incretins binding to receptors on -cells: GIP binds to 
glucose-dependent insulinotropic peptide receptor (GIPR; Maletti et al., 1984) and 
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GLP-1 binds to glucagon-like peptide-1 receptor (GLP-1R). This interaction triggers 
an increase of intracellular Ca
2+
 through voltage-dependent Ca
2+
 channels (Lu et al., 
1993) and stimulation of exocytosis through the cAMP (cyclic adenosine 
monophosphate)/PKA (protein kinase A) signalling pathway (Ding and Gromada, 
1997). 
GLP-1 has been suggested as a possible treatment in T2DM (Holst, 1999), and 
recent studies suggest that GLP-1 is involved in -cell regulation and increasing 
-cell mass (Burcelin and Dejager, 2010). In T2DM patients it was observed that the 
incretin effect is reduced or absent (Nauck et al., 1986), but after administration of 
GLP-1, insulin secretion was restored (Hojberg et al., 2009). Furthermore, in vitro 
and in vivo data support that GLP-1 can prevent -cell apoptosis in diabetic rodents, 
mouse insulinoma cell lines, and rat islets (Farilla et al., 2002; Hui et al., 2003; Li et 
al., 2003; Wang and Brubaker, 2002). New drugs based on GLP-1 have already been 
used clinically (Lovshin and Drucker, 2009). Exenatide, which is an analogue of 
GLP-1 and has been reported to stimulate -cell proliferation in vitro and in vivo. It 
also enhances GSIS, induces satiety, and reduces the glucose level without causing 
hypoglycaemia (Baggio and Drucker, 2007; Drucker, 1998) whereas other drugs 
have to compromise with side effects, such as glucose counterregulation (Gerich, 
1989), which is the mechanism preventing or correcting hypoglycaemia. 
 
1.4.  Transgenic mouse model 
In several animal diabetes models, a deficiency of -cell functions was 
hypothesised to result from -cell dedifferentiation (Jonas et al., 1999; Laybutt et al., 
2002), or from apoptosis (Pelengaris et al., 2002b; Pick et al., 1998). NOD 
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(non-obese diabetic) mouse (Atkinson and Leiter, 1999; Makino et al., 1980) or 
streptozotocin (STZ) induced -cell deletion mouse model (Kolb, 1987; Like and 
Rossini, 1976) have been used to study T1DM. Apart from pancreatectomy or 
obese-induced diabetes mice, gene knockout mice, such as insulin receptor knockout 
mice, have also been widely applied to study the role of insulin resistance in T2DM 
(LeRoith and Gavrilova, 2006; Pattaranit et al., 2008). 
A chimeric protein, c-MycER
TAM
, in which human c-MYC has been fused to a 
mutated form of the estrogen receptor (ER; ER
TAM
), can induce the activation of 
c-MYC by the injection of 4-hydroxytamoxifen (4-OHT; Littlewood et al., 1995; 
Pelengaris et al., 1999), and it has been set up as a transgenic animal model to turn 
MYC on or off. Pelengaris et al. (2002b) used plns-c-MycER
TAM
 transgenic mice, in 
which the c-MycER
TAM
 is regulated by the insulin promoter (pIns) so that this fusion 
transcriptional factor is specifically targeted to insulin producing -cells, to explore 
the role of c-MYC in apoptosis and proliferation in -cells. Activation of c-MYC 
induces proliferation in a short transition but this proliferation is subsequently 
overwhelmed by apoptosis in -cells. As a result, the transgenic mice become 
hyperglycaemic and unable to control the glucose homeostasis. However, 
deactivation of c-MYC by withdrawing 4-OHT leads to the regeneration of -cells in 
this c-MYC activated transgenic mouse. Thus this animal model can be applied to 
the study of -cells regeneration. Pelengaris et al. (2002b) also presented the doubly 
transgenic plns-c-MycER
TAM
/RIP-BclxL mice by giving c-MYC activation with 
co-expression of Bcl-xL (which encodes an anti-apoptotic BCL-2 family protein). 
This triggers carcinogenesis without apoptosis but shows hyperglycaemia in the 
early stage (6-9 days). They also found indications that the in vivo effects of c-MYC 
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are reversible, i.e. deactivation of c-MycER
TAM 
elicits -cell and islet regeneration 
and deactivation of c-MycER
TAM
 in c-MycER
TAM
/Bcl-xL doubly transgenic model 
triggers regression of cancerous cells to normal cells with normal cell behaviour. 
Furthermore, using the plns-c-MycER
TAM
 transgenic mice, Cano et al. (2008) 
confirmed -cell regeneration after withdrawing tamoxifen in the transgenic animal 
system and suggested that retention of -cells results from replication of surviving 
-cells. However, Cano et al. (2008) also found early hypoglycaemia in this 
transgenic mouse and suggested that the low glucose level might be due to passive 
release of insulin because of on-going -cell apoptosis. However, this appears not to 
be the case since hyperinsulinaemia precedes any significant decrease in -cell mass 
in plns-c-MycER
TAM
 mice. This view is supported by further functional studies in our 
group showing that hypoglycaemia is not prevented when MYC-induced apoptosis is 
fully prevented by co-expression of the anti-apoptotic protein BCLxL in 
plns-c-MycER
TAM
/RIP-BclxL doubly transgenic mice (see Figure 1.4.1; Dr. Linda 
Cheung, unpublished data). 
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Figure 1.4.1. Glucose level in plns-c-MycER
TAM
/RIP-BclxL doubly transgenic mice. (Dr. Linda 
Cheung, unpublished data). Solid lines refer to the objects with treatment (4-OHT), whereas dash 
lines refer to the control group (WT littermates treated with peanut oil). 4-OHT, 4-hydroxytamoxifen; 
P.oil, a vehicle in which 4-OHT is made and acts as a control; ♂, male; ♀, female; ↑, the glucose 
level is higher than the measurement range, which is 0.6-33.3 mmol/l. 
 
Figure 1.4.1 shows the glucose level in the plns-c-MycER
TAM
/RIP-BclxL doubly 
transgenic mice after treating with 4-OHT (treatment, n=4) or the same amount of 
vehicle (control, n=2). The glucose level is different (p<0.05, paired t-test) between 
control and treatment mice in day 1. The difference (p<0.01, paired t-test) between 
day 0 and day 1 in the treatment group indicates a decrease of glucose level on day1, 
whereas there is no significant difference (p=0.9126, paired t-test) in the glucose 
level in the control group. Apart from hyperglycaemia, which is regarded as a 
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characteristic of diabetes, sudden hypoglycaemia was observed within 24 hours after 
c-MYC activation. This indicates that c-MYC-activated hypoglycaemia might not be 
directly linked to insulin released from apoptopic -cells because apoptosis was 
blocked by the expression of BCLxL. 
MYC-activated diabetes animal models suggest that the activation of c-MYC 
reduces the expression of insulin, pancreatic duodenal homeobox factor-1 (PDX1), 
NKX6.1, GLUT2, and prepoinsulin I+II (PPI; Kaneto et al., 2002; Laybutt et al., 
2002; Pascal et al., 2008; Pelengaris et al., 2002b). PDX1, also known as STF1, 
IDX1, IPF1, IUF1, which binds to A-box (Ohlsson et al., 1993), is an important 
transcriptional factor in pancreatic development and insulin transcription (Ahlgren et 
al., 1996; Ahlgren et al., 1998; Chakrabarti et al., 2002; Ohlsson et al., 1993). In 
PDX1-deficient animal models, impaired glucose tolerance and GSIS were found 
(Brissova et al., 2002; Johnson et al., 2003; Leibowitz et al., 2001; Seufert et al., 
1998). Deficiency of PDX1 is further related to GLUT2, glucokinase (GK), MAFA, 
NKX6.1, and insulin, whose products are key factors in GSIS (reviewed in Babu et 
al., 2007). The plns-c-MycER
TAM
 transgenic mouse can therefore be adopted for the 
study of -cell regeneration or diabetes treatment without other confounding factors, 
such as obesity. There are many studies related to -cell regeneration but a robust 
animal model is still necessary to demonstrate the process of -cell regulations in 
vivo.  
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1.5.  Mathematical model of physiological dynamics 
The homeostasis between glucose, insulin, and -cell mass plays an important 
role in the study of diabetes, which is characterized by hyperglycaemia, insulin 
resistance, and the persistence of -cell dysfunction. Several mathematical models 
have been formulated to study glucose-insulin dynamics, in order to contribute to the 
understanding of the aetiology of diabetes. The main idea of formulating 
mathematical models is to preserve biologically relevance by referring to 
experimental data and subsequently testing the biological hypothesis by subjecting 
the predictive results from mathematical simulations to further experimentation. A 
mathematical model can also help the design of experiments by defining specific 
parameters which were ill-defined numerically by previous experiments. A simple 
mathematical model of the insulin-glucose feedback loop was proposed by Bolie 
(1961), describing the relationship between glucose and insulin by means of ordinary 
differential equations (ODEs). Based on this glucose-insulin fundamental feedback 
loop, the model can be extended. A three-ODE model of glucose-insulin dynamics, 
which is also known as the standard minimal model, was built by Bergman et al. 
(1981). It further extended the two-compartment glucose-insulin model into a 
three-compartment model, i.e. glucose, insulin, and remote insulin. Other 
physiological parameters relating to glycaemic homeostasis, such as glucagon, 
NEFAs (non-esterified fatty acids), TAGs (triacylglycerides), and leptin, can be also 
be incorporated into more extensive mathematical models (Pattaranit and van den 
Berg, 2008).  
Absolute or relative deficiency of -cell mass depicts the pathogenesis of T1DM 
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or T2DM. More details of -cell mass regulation have been described in 
Section 1.1.5. Mathematical models of -cell turnover have been introduced to 
simulate the phenomenon as well. Finegood et al. (1995) formulated a mathematical 
model to stimulate -cell mass of adult rats between the ages of one and three month 
using the relationship between -cell number, size, proliferation, neogenesis, and 
apoptosis. Using the human IAPP (islet amyloid polypeptide) transgenic (HIP) rat, 
Manesso et al. (2009) presented the dynamics of -cell turnover, which was detected 
by immunostaining of Ki67, which is a marker for proliferation, and the terminal 
deoxynucleotidyl (TdT)-mediated dUTP nick-end labeling (TUNEL), which is a 
marker for apoptosis, and suggested that -cell regeneration is contributed by 
neogenesis other than -cell replication.  
Apart from those physiological parameters, other perturbations of computational 
modelling can be implemented to suit the actual physiological situation, for example, 
introducing a time delay to describe insulin secretion in response to glucose 
stimulation or hepatic glycogenesis in response to insulin secretion (Bennett and 
Gourley, 2004; Giang et al., 2008; Li et al., 2006; Tolic et al., 2000). 
As more experimental data were obtained, more sophisticated and robust 
mathematical models could be constructed to address biological questions. Several 
models were formulated to understand the relationship between glycaemic control 
and insulinemia within a limited time duration of the object‘s lifespan, i.e. the model 
is only representing a short-term simulation of the experimental period (Bergman et 
al., 1979; Bolie, 1961; Li et al., 2006; Panunzi et al., 2007). Thus, mathematical 
models combing long-term effect, such as -cell regulation, with glycaemic controls, 
i.e. glucose level and insulin level, have been published as well to study the 
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aetiology of diabetes (Chen et al., 2010; de Winter et al., 2006; Hamren et al., 2008; 
Ribbing et al., 2010; Topp et al., 2000). 
Neuroendocrine control systems, such as glucose homeostasis, respond rapidly 
to physiological challenges while concurrently undergoing adaptation on much 
slower time scales, such as -cells adaption or decompensation during the progress 
of diabetes, e.g. Schmidt and Thews (1989) and Frayn (1996). Moreover, an 
interplay prevails between processes at disparate scales: the slow adaptation is 
dependent on the fast events. Such an interplay is a pervasive characteristic of many 
biological systems.  
As is well known, the dynamics of such systems can be analysed by considering 
separate and distinct dynamical systems that correspond to the biological system as it 
operates on two or more ―time scales‖. In such procedures, the approximation 
usually is exact if the slower component is ―infinitely slower‖ than the faster 
component, see Keener and Sneyd (1998) for examples and applications. On a given 
time scale, the slower variables are ―frozen‖ and appear as constant parameters, 
whereas the faster ones can often be treated using a quasi-steady state approximation 
(up to boundary or transition layers) in which the fast variable is essentially replaced 
by a function which relates its (fast-time system) equilibrium value to the prevailing 
values of the slower variables. Similarly, in those cases where the fast-time system 
does not equilibrate but tends to a periodic solution (e.g., a limit cycle or the 
stationary response to periodic forcing), intuition would suggest that the fast 
variables might be replaced by a long-term average. However, this intuition need not 
be correct. This thesis outlines a general method to tackle such problems on two time 
scales. The type of system describes the dynamics of an organism's physiology (or 
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the relevant part thereof) together with the dynamics of the (neuro)endocrine system 
that regulates this physiology. The method is applied to a well-established model of 
the regulation of glucose concentration in the blood plasma, which was extended 
with a slow component, viz. the dynamics of the mass of endocrine cells. 
 
1.6.  Aims and hypotheses 
The thesis proposes to investigate the hypothesis that c-MYC regulates the 
expression of key genes required for regulation of insulin secretion, including those 
for differentiation and for glucose stimulation of insulin secretion (GSIS). This 
c-MYC-mediated regulation may have major implications, since c-MYC regulated 
insulin secretion is a potentially important mechanism coupling -cell mass increases 
in pre-diabetic states to eventual depletion/reduction in insulin stores and aberrant 
GSIS. The aim of this thesis is to characterize the initial stage of the expression of 
c-MYC from the plns-c-MycER
TAM
 mouse model. In particular, the objectives are to 
understand insulin secretion and glucose levels after c-MYC has been switched on in 
an in vivo experiment, and to analyse the experimental observations by means of an 
in silico analysis based on microarray analysis and a mathematical model. 
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Chapter 2. Material and Methods 
2.1 Transgenic animal model 
2.1.1. Genotyping of pIns-c-MycERTAM mouse 
Mouse ear snips were collected using the ear-punch technique for DNA 
extraction. Subsequently, 75 μl hotshot reagent (25 mM NaOH and 0.2 mM 
disodium ethylenediaminetetra acetic acid (EDTA), pH 12), the alkaline lysis reagent, 
was added to each sample for 30 minutes at 95 °C. After the biopsy samples had 
been incubated with hotshot reagent, neutralizing reagent (40 mM Tris-HCl, pH 5) 
was added at the same volume to neutralize the reaction and the samples were 
subsequently kept at 4 °C overnight. These DNA samples were stored at 4 °C, 
or -20 °C for longer storage. A master mix was prepared of 15.25 μl sterile H2O, 
2.5 μl ×10 PCR buffer (Invitrogen, Carlsbad, CA), 0.75 μl MgCl2 (50mM; 
Invitrogen, Carlsbad, CA), 0.5 μl MYC5 3‘-primer (10 pm/μl; sequence (5‘ to 3‘) 
AGG GTC AAG TTG GAC AGT GTC AGA GTC), 0.5 μl MERTM 5‘-primer (10 
pm/μl; sequence (5‘ to 3‘) CCA AAG GTT GGC AGC CCT CAT GTC), 0.25 μl 
Taq polymerase (500 U/μl; Invitrogen, Carlsbad, CA) and 0.25 μl dNTPs (10 mM; 
Invitrogen, Carlsbad, CA) for each DNA sample. An aliquot of 5 μl of each DNA 
sample was mixed with 20 μl master mix and subsequently processed using a 
PTC-100 Programmable Thermal Controller (MJ Research, Inc., Waltham, MA). 
The PCR programme procedure was as follows: step 1: 2 minutes at 94 °C; step 2: 
30 cycles of 1 minute at 94 °C, 1 minute at 57 °C, and 2 minutes at 72 °C; and step 3: 
10 minutes at 72 °C. The positive control DNA sample was 
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plns-c-MycER
TAM
-positive DNA, the false-positive control DNA sample was 
wild-type (WT) mouse DNA, and the negative control sample was water. 
Agarose (Sigma-Aldrich, St. Louis, MO) was diluted into Tris/borate/EDTA 
buffer (TBE; 0.89 M Tris base, 0.02 M EDTA-Na2-salt, 0.89 M boric acid) 1× at 
10 mg/ml to make a 1% agarose gel by means of microwave irradiation. After the 
agarose had dissolved and the solution had cooled sufficiently, ethidium bromide 
(10 mg/l; Sigma-Aldrich, St. Louis, MO) was added at 0.04 μl/ml. 
PCR products, positive, false-positive, and negative control samples were 
loaded on the 1% agarose gel with 6X loading buffer (0.25 % bromophenol blue, 
0.25 % xylene cyanol FF and 30 % glycerol in water at 4 °C). A 1 kb DNA ladder 
(Invitrogen, Carlsbad, CA) was loaded alongside the samples. Gel electrophoresis 
was carried out at 100 Volts/cm for 1.5-2 hours. The gel was subsequently imaged 
by means of the Gene Genius Bio Imaging System with the GeneSnap Image 
Capture Suite (Syngene, Frederick, MD). The product size of a plns-c-MycER
TAM
 
positive sample was expected to be 413 base pairs (Pelengaris et al., 2004) whereas 
there was no band at this a size in WT. 
 
2.1.2. Administration of pIns-c-MycERTAM mouse model 
The switchable transgenic plns-c-MycER
TAM
 mouse model (Pelengaris et al., 
2002b), in which c-MYC is switched on by means of daily intraperitoneal (IP) 
injection of 4-Hydroxytamoxifen (4-OHT; Sigma-Aldrich, St. Louis, MO), was 
employed in this study. 4-OHT was sonicated in peanut oil (Sigma-Aldrich, St. 
Louis, MO) at 1 mg/0.1 ml. Then 100 μl was applied to the positive control objects 
in both plns-c-MycER
TAM
 mice and their WT littermates every 24 hours through IP 
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injection. For negative controls, 100 μl vehicle was applied to both transgenic mice 
and their WT littermates. Male mice aged 2-3 months were used. All mice were 
housed and treated in accordance with protocols and regulations sanctioned by the 
Home Office under the Animals Act of 1986. 
 
2.1.3. Experimental design 
A. Dynamics of glucose and energy expenditure 
Transgenic plns-c-MycER
TAM
 mice were administered 4-OHT (MYC-ON) daily 
by intraperitoneal (IP) injection. Controls included vehicle (peanut oil) treatment of 
plns-c-MycER
TAM
 mice (MYC-OFF) and their WT littermates (WT), as well as 
4-OHT treatment of WT mice (WT-4-OHT). Whole-body plasma glucose was 
measured by means of the oxidase method (Accuchek®  Advantage Plus Test Strips; 
Roche, Basel, Switzerland) at 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36 hours after 
activation of c-MYC in vivo. Each experiment was performed in triplicate. Since 
ethical constraints limit blood sampling to no more than 0.01 ml per day (NC3Rs, 
2011), the same individual cannot be measured at all time points. Therefore, it was 
found necessary to divide this experiment into three groups (it is assumed that the 
volume of blood needed to measure glucose level is about 5 μl), namely Time Line 1 
(TL1), Time Line 2 (TL2), and Time Line 3 (TL3). In TL1, the blood glucose level 
was measured at 0, 12, 24, and 36 hours after the first IP injection of 4-OHT or 
vehicle; in TL2, the blood glucose level was measured before those objects were 
fasted (which is defined as -4 hours in this thesis), and 8, 20, and 32 hours after the 
first IP injection; and in TL3, the blood glucose level was tested at 4, 16, and 
28 hours after the first IP injection. It was assumed that the glucose level at the start 
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point of each TL experiment is the same. A detailed experimental protocol is given 
in Figure 2.1.1. 
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Figure 2.1.1. Experimental design for glucose and energy expenditure dynamics in vivo. 
Glucose and energy expenditure dynamics within 36 hours of c-MYC activation of three different 
groups of mice were studied, i.e. plns-c-MycER
TAM
 mice treated with 4-OHT (MYC-ON), 
plns-c-MycER
TAM
 mice treated with peanut oil (MYC-OFF) and WT treated with peanut oil (WT). 
Each group contained three mice (n=3). The treatment of 4-OHT or peanut oil was given to the 
plns-c-MycER
TAM
 mice or their WT littermates every 24 hours through IP injection. In compliance 
with ethical prescriptions, a grid floor, which separates mice from the food debris and excreta and 
which enables the tracing of food intake (relevant to parameters g1-g4 when mice were on a grid floor) 
and faeces production (relevant to parameters pg1-pg4 when mice were on a grid floor), was applied 
to each cage for at most 16 hours. Since a grid floor could not be used for the entire experimental 
period, a limited amount of food (assumed 5 g/mouse/day) was provided from the start of each time 
line (TL) experiment until the last 16 hours so that food intake (relevant to parameters f1-f4) and 
faeces production (relevant to parameters pf and pf1-pf4) were still able to be traced during this period 
every 4 or 8 hours. Mice were fasted 4 hours prior to the initial time point zero in each TL group; this 
time point was labelled as -4 hour in this experiment. The body weight was recorded every 4 or 
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8 hours throughout the experimental period. Blood serum and pancreata were collected at the end of 
each TL experiment and final pancreatic weight was also recorded.  
 
The energy balance is depicted diagrammatically Figure 2.1.2. Food intake 
(relevant to parameters f1-f4 or g1-g4 when mice were on a grid floor, see 
Figure 2.1.1) and faeces production (relevant to parameters pf and pf1-pf4 or 
pg1-pg4 when mice were on a grid floor, see Figure 2.1.1) were recorded during the 
TL experiments. Assimilation, which is the sum of body weight change (w) and 
energy usage, was evaluated as food intake less faeces production. Therefore, energy 
usage is defined as w - production feces - intake food . This thesis assumes the 
energy metabolism in rodents and man are similar. 
 
 
Figure 2.1.2. Energy usage scheme. 
Food is ingested and subsequently transported into the gut. After the food is assimilated, energy is 
used for various biological activities, generation of heat, or CO2. The net energy stored in the animal, 
w, is the difference of body weight before and after food utilization. If the energy used by the animal 
is bigger than this input, w is negative. 
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B. Insulin dynamics and morphological information 
In the TLs experiment mentioned in Section 2.1.3. A, morphological data 
related to the pancreas, and physiological data, for example related to blood serum, 
were collected at 28, 32, and 36 hours after the first IP injection. In order to obtain 
more detailed information about the events that follow c-MYC activation, the 
following time points were further studied: before fasting (which is defined 
as -4 hours), and 8 and 16 hours after the first IP injection. In each group, the 
experiment was performed in triplicate on both plns-c-MycER
TAM
 mice and their WT 
littermates, and each type of mouse was injected with either 4-OHT as treatment or 
the same volume of vehicle as control. 
 
2.1.4. Treatment with exenatide 
Plns-c-MycER
TAM
 male mice (n=3) were treated with exenatide at 50μg/kg by 
means of subcutaneous (SC) injection. Stock solution was prepared by dissolving 
5 mg exenatide (Amylin, San Diego, CA) in 5 ml H2O. When mice were given the 
injection, 50 μl stock solution was mixed with H2O up to 5 ml. Because the 
degradation of GLP-1 is very fast (Hansen et al., 1999), and the half-life of GLP-1 is 
< 2 minutes (Baggio and Drucker, 2007), it is necessary to make sure the exentide 
has circulated in mice when the experiment starts, such as the treatment with 4-OHT. 
Two days pre-treatment was applied to acclimatize these mice and two injections 
were administered at 8am and 4pm daily (Samuel Robson, unpublished data). In the 
MYC-ON group, plns-c-MycER
TAM
 mice treated with exenatide or vehicle were 
51 
 
defined as M
+
/E
+
 or M
+
/E
-
, whereas in the MYC-OFF group, mice treated with 
exenatide or vehicle were defined as M
-
/E
+
 or M
-
/E
-
. 
The negative control consisted of plns-c-MycER
TAM
 WT male littermates (n=3) 
treated with exenatide (EW) or the same volume of water vehicle (WW) by means of 
SC injection. 
 
2.2 Morphological and physiological analysis 
Mice were sacrificed by means of cervical dislocation (CD) after c-MYC 
activation according to the schedule outlined in Section 2.1.3. Blood and pancreata 
were collected. Blood was collected through cardiac puncture, put on ice for 
30 minutes, and subsequently centrifuged (Centrifuge 5415R; Eppendorf, Hamburg, 
Germany) for 10 minutes at 4 °C. The supernatant was collected for insulin analysis 
(Ultrasensitive Mouse Insulin ELISA, Mercodia, Uppsala, Sweden) following the 
protocol provided by the supplier.  
Pancreata were dissected out as soon as the blood collection was finished, and 
were processed into frozen blocks for cryo-sectioning by the following steps: 
1) Immersion in 4% formaldehyde (Formaldehyde-methanol free 16% w/v 
solution; TAAB, Berks, England; diluted in phosphate buffered saline 
(PBS)) for 2 hours at room temperature (RT); 
2) Transferral to 30% sucrose (Sigma-Aldrich, St. Louis, MO; diluted in PBS) 
at 4 °C overnight; 
3) Placing the pancreas into a small cubic mode, which was made of foil, to 
make sure the cryo-tissue is made into a cubic shape and ensuring the whole 
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organ is arranged in a crescent shape, then embedding in Tissue-Tek O.C.T. 
mounting medium (Sakura, Alphen a/d Rijn, The Netherlands), and placed 
on dry ice and ethanol; 
4) Storage at -80 °C. 
 
Every 100 μm was defined as one level in a pancreas; accordingly the tissue 
was sectioned by a cryostat (OTF 5000 Cryostat; Bright, Huntingdon, England) at a 
thickness of 10 μm. Three continuous sections were collected on a single slide. After 
3 slides were finished, the 10
th
 section was discarded to complete the section of one 
level because 3 slides were only able to support 9 sections, and sectioning of next 
level was continued in the same manner. 
  
2.2.1. Immuno-staining 
Immunohistochemistry (IHC), in which the basic concept is the identification of 
antigens in a biological tissue section by means of specific antibodies, has been 
applied to the diagnostic pathology for many years (Coons et al., 1941; Nakane and 
Pierce, 1966; Robinson and Dawson, 1975). It is a staining method that comprises 
tissue selection, fixation, sectioning, processing of staining, and interpretation of the 
staining result by microscopy. The use of IHC includes fluorophore-labelled 
(immunofluorescence) and enzyme-labelled (immunoperoxidase) antibodies to 
identify specific proteins or molecule of interest in cells or tissues. The staining 
results are studied under fluorescence-microscopy (for immunofluorescence) or 
light-microscopy (for immunoperoxidase). In this thesis, both methods were used to 
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identify β-cells (Section 2.2.1 A) and proliferating cells (Section 2.2.1 B) in mouse 
pancreatic islets. 
 
A. Immunoperoxidase and haematoxylin staining 
There were three sections on each slide, but only two sections were used for the 
DAB (3,3'-diaminobenzidine) and haematoxylin (H) staining; the first section was 
treated as control in staining and the third one was regarded as treatment. The second 
section was discarded so that more space was created between the first section and 
the third section to avoid cross-contamination during staining. A wax pen (Dako, 
Glostrup, Denmark) was used to draw a circle, which formed a hydrophobic barrier, 
around each section. Slides were post-fixed in 4 % formaldehyde for 10 minutes at 
4 °C, and were washed in PBS 2 times, 3 minutes for each wash on a shaker (at 
50 rpm). Hydrogen peroxide (H2O2; Thermo Fisher Scientific, Pittsburgh, PA; 
diluted in sterile H2O at 1/100) was applied to each section to bleach the samples for 
30 minutes at RT, after which slides were washed in PBS for 5 minutes on a shaker 
(at 50 rpm). Goat serum solution was made of 150 μl goat serum (Sigma-Aldrich, St. 
Louis, MO) and 10 ml PBS. Triton (50 μl; Sigma-Aldrich, St. Louis, MO) was added 
into the goat serum solution to make the blocking solution, then applied to each 
tissue section for 30 minutes at RT to block tissues, after which the liquid covering 
the tissues was drained by means of gentle tapping. The primary antibody 
(Insulin-polyclonal guinea anti-swine; Dako, Glostrup, Denmark; diluted by goat 
serum solution at 1/200) was applied onto the treatment section, whereas the goat 
serum solution was applied onto the control section, and both were incubated for 
1 hour at RT. The slides were subsequently washed in PBS+0.1% tween 3 times for 
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a duration of 5 minutes each time on a shaker (at 50 rpm). The secondary antibody 
(Guinea pig IgG (H and L) pre-absorbed antibody (HRP); Novus Biologicals, 
Littleton, CO; diluted by the goat serum solution at 1/500) was applied for 
30 minutes onto the treatment section, and so was the goat serum solution to the 
control section, at RT. After slides were washed in PBS+0.1% tween 3 times, each 
time for a duration of 5 minutes on a shaker (50 rpm), DAB kit (DAB substrate kit 
for peroxidise; Vector Laboratories, Burlingame, CA) was applied onto each section 
for 2 minutes, as specified by the protocol supplied by the manufacturer. Slides were 
washed in sterile H2O 2 times for 3 minutes on a shaker (50 rpm). The next step was 
the haematoxylin staining, which was carried out according to the following steps: 
1) Bathe in haematoxylin (Carl Roth, Karlsruhe, Germany) for 1.5 minutes; 
2) Wash under running water for 10 minutes; 
3) Transfer into 70% ethanol for 1 minute; 
4) Transfer into 80% ethanol for 1 minute; 
5) Transfer into 90% ethanol for 1 minute; 
6) Transfer into 100% ethanol for 2 minutes; 
7) Immerse into xylene 2 times for 5 minutes under a fume hood; 
8) Mount slides with mount medium (Leica, Wetzlar, Germany) and apply 
coverslips. 
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B. Immunofluorescence staining 
Primary antibodies for Ki-67 and insulin were counterstained on the specimen, 
which was followed by the staining with fluorophore-labelled secondary antibodies, 
i.e. fluorescein isothiocyanate (FITC) and Alexa-633. Each slide contained three 
sections. The first specimen was the treatment, in which target antigens, i.e. insulin 
and Ki-67, could be recognised and the second section was treated to identify insulin 
only. In order to show that the fluorescent staining result was genuine, i.e. resulting 
from the specific antigen, a negative control was carried out in the third section, to 
which only the secondary antibody was applied. Immunofluorescence staining was 
carried out according to the following steps:  
1) Circle each section by a wax pen, and post-fix slides in 4% formaldehyde for 
10 minutes at 4 °C, and sequentially rinse the slides in distilled water; 
2) Prepare goat serum solution and blocking buffer, as described in 
Section 2.2.1 A;  
3) Block tissue for 1 hour at RT, and after 30 minutes incubation under RT, 
remove the liquid by means of gentle tapping; 
4) Apply primary antibody (NovocastraTM Lyophilized Rabbit Polyclonal 
Antibody Ki-67 Antigen; Leica, Wetzlar, Germany) diluted by goat serum 
solution at 1/100 and incubate for 2 hours at RT; 
5) Process the wash step, in which slides are washed in PBS+0.1% tween 
3 times for a duration of 5 minutes on a shaker (at 50 rpm); 
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6) Apply secondary antibody, which is FITC goat anti-Rabbit IgG (H+L; 1/200 
dilutions; Vector Laboratories, Burlingame, CA) and incubate for 
30 minutes at RT; 
7) Process the wash step; 
8) Apply another primary antibody (Insulin-polyclonal guinea anti-swine; Dako, 
Glostrup, Denmark) diluted by goat serum solution at 1/100 and incubate 
for 1 hour at RT; 
9) Process the wash step; 
10) Apply another secondary antibody (Alexa 633 goat anti-Guinea pig; 
Invitrogen, Carlsbad, CA) diluted by the goat serum solution at 1/200 and 
incubate for 30 minutes at RT; 
11) Process the wash step; 
12) Mount slides with a drop of 4',6-diamidino-2-phenylindole (DAPI; Vector 
H-1200; Vector Laboratories, Burlingame, CA) onto each section to stain 
the nuclei as blue and apply coverslips; 
13) Examine the fluorescent stained slides using confocal microscopy (Leica 
SP2). 
 
The immunofluorescence staining of Caspase-3 (Cleaved Caspase-3 (Asp175) 
antibody; Cell Signaling, Danvers, MA) and insulin followed the same procedure. 
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2.2.2. -cell mass analysis 
The whole-slide image was captured by an automatic slide scanner (Mirax Midi; 
Carl Zeiss, Jena, Germany) located in the University Hospitals Coventry and 
Warwickshire with a ×20 objective. Mirax Viewer 1.12, developed by 3DHISTECH 
(Carl Zeiss, Jena, Germany), was used to view the scanning results at various digital 
magnifications. 
At least five slides, which represented five different levels, from each individual 
mouse pancreas were studied. The following images were obtained to carry out 
-cell mass analysis: 
1) Whole cross-sectional area of a single pancreatic tissue with an optimal 
digital objective, which varied among different tissue sections; 
2) Insulin-stained cross sectional area with a ×2 digital objective. 
 
After images had been obtained with different magnifications, ImageJ 1.44p 
(Abramoff, 2004) was used to analyse the cross sectional area by measuring the 
pixels of the target area. The -cell mass was then calculated as follows: 
-cell mass .
 tissuepancreatic of area sectional-cross
area stainedinsulin  of area sectional-cross
 weightpancreas


 (1) 
Because the cross-sectional area of the whole pancreatic area and the insulin-stained 
area were acquired at different digital magnifications, it was necessary to adjust them 
to a common scale. Therefore, the cross sectional area of the pancreatic tissue was 
adjusted by 
2
area pancreatic  wholeofion magnificat
area stainedinsulin  ofion magnificat






. 
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2.2.3. -cell number and -cell size 
-cell number data were analysed under the digital objective of ×20 at Mirax 
Viewer 1.12. The insulin-stained cross sectional area was obtained as described in 
Section 2.2.2. Accordingly, -cell size was calculated as 


numbers cell-
area sectional cross stained-insulin

. 
 
2.3 Microarray analysis 
Two sets of microarray data were obtained from Dr. Samuel Robson. The first 
set of microarray data was designed to see the effects of c-MYC with time points of 
4, 8, 16, and 32 hours after the first IP injection of 4-OHT, or the same volume of 
vehicle as control. Each time point and treatment was present in triplicate. Total 
RNA was extracted from islets, which were isolated by laser capture microdissection 
(Molecular Machines and Industries, Rockledge, FL) from pancreas sections. Total 
RNA was then processed using the two-cycle target labelling reaction and hybridized 
to Affymetrix MOE430 Plus 2.0 GeneChip microarrays (Robson, 2008). GeneSpring 
GX software (Agilent, Santa Clara, CA) was used for array analysis to study the 
MycER on/off mice system. These arrays were experiments of plns-c-MycER
TAM
 
mice treated with vehicle (M
-
/E
-
) and plns-c-MycER
TAM
 mice treated with 4-OHT 
(M
+
/E
-
). 
Another set of microarray data, kindly provided by Dr. Robson (unpublished), 
was used to study the effect of exenatide under the following conditions. 
Condition 1 (M
-
/E
-
 vs M
-
/E
+
): transgenic mice were given peanut oil through IP 
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injection, then treated with exenatide (M
-
/E
+
) or the water vehicle (M
-
/E
-
) by SC 
injection to study the effect of exenatide only; condition 2 (M
+
/E
+
 vs M
+
/E
-
): c-MYC 
was switched on for 4, 8, 16, and 32 hours with the injection of 4-OHT, and mice 
were also given exenatide (M
+
/E
+
) or the same volumes of vehicle (M
+
/E
-
). 
Details of the principles of microarray experiments and microarray data 
analysis are given in Appendix A. 
 
2.3.1. Pre-processing of data 
A number of quality-control measures were undertaken to ensure the arrays 
were sufficiently reliable for analysis. The first was the experimental quality, which 
ensured the RIN value of each array is above than 5 and the cRNA yields are more 
than 10 μg. After the cRNA generated from sample had been hybridized on the 
Affymetrix GeneChips, a 3‘/5‘ ratio was detected to show the hybridization quality. 
After the quality control steps, the following samples were removed from the early 
effects of c-MYC analysis: M
-
/E
-
8(2), M
+
/E
-
16(3), and M
+
/E
-
32(1); and the 
following samples were removed from the exenatide array analysis: M
+
/E
+
16(2), 
M
+
/E
+
32(3), M
-
/E
+
4(2), and M
+
/E
+
72(1). 
 
2.3.2. Data normalisation and annotation 
Data were normalized across all samples at the probe-level GC-RMA 
(GeneChip robust multiarray average summarization algorithm), as described in 
Section 1.2.3, and subsequently normalised by the median of all samples. Fold 
change ratios are used by this thesis by normalising the treatment arrays to their 
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control counterparts, for instance, 4-OHT treated mouse arrays (M
+
/E
-
) were 
normalized by their peanut oil treated experiment arrays (M
-
/E
-
) to ensure the 
expression of a gene presented in fold change, which was incurred by c-MYC 
activation.  
 
2.3.3. Gene filtering and clustering 
Affymetrix MOE430 Plus 2.0 GeneChip microarrays contains 
45,101 transcripts, which are measured by different probe sets, from the mouse 
transcriptome. Microarray analysis aims to identify genes that exhibit different 
expression in response to the experimental treatment. This thesis focuses on genes 
that were differentially expressed in response to treatment with 4-OHT and exenatide.  
Affymetrix GeneChips contain control probes, which are designed for the 
measurement of housekeeping genes and the spike-in control transcripts expression 
changes to ensure the quality of hybridisation. The first step was to remove these 
control probes because they are designed probes and the outcomes are predictable, 
which are used for quality control or error corrections (Gautier et al., 2004). The 
following step was identifying transcripts which were up- or down-regulated by 
2 folds because of the treatment.  All ratios, which are the expression levels of 
treatment divided by the expression levels of control, presented in this thesis have 
been transformed as by log2(ratio) because it generates a symmetric up- and 
down-regulated gene expression levels. For example, log2(1)=0, means that the 
treatment did not change the gene expression level; log2(2)=1, means that the 
specific transcript was up-regulated by 2 folds because of the treatment whereas 
log2(1/2)=-1 indicates that the specific transcript was down-regulated by 2 folds in 
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response to the treatment. The last step was to apply a two-way (time and treatment) 
ANOVA analysis to filter out the statistically significant differentially expressed 
genes, and a post-hoc analysis (Benjamini Hochberg FDR) was carried out. This 
candidate gene list was used as the starting point for further analysis. Finally, 
k-means clustering (Tavazoie et al., 1999) was applied to this candidate gene list, in 
order to categorise different gene expression patterns. 
 
2.3.4. Functional analysis 
Annotation of gene ontology (GO) and pathway analysis was carried out. GO 
classification defines the attributes of gene products in three non-overlapping 
domains of biological functions, namely biological processes, cellular components, 
and molecular function (Harris et al., 2004). Enrichment of GO terms was 
determined by using the GO browser in GeneSpring GX, using a standard 
hypergeometric distribution. A corrected p-value was computed according to the 
Benjamini-Hochberg correction (Benjamini and Hochberg, 1995) to compensate for 
the false positive rate. Pathway analysis provided by GeneSpring GX was applied for 
functional analysis. The pathway database constructed by GeneSpring GX is based 
on natural language processing (NLP; Joshi, 1991), and the majority of the pathway 
database is derived from Pubmed abstract by means of text-mining. 
 
2.4 Mathematical model 
A mathematical model was developed to describe the physiological 
mechanisms and various hypothetical scenarios to account for the observations. A 
method used to analyse the model is given in Appendix B. Section 2.4.1 outlines the 
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formulation of a model of glucose and insulin dynamics. Section 2.4.2 models the 
glucose input as a time-varying function. Apoptosis and proliferation rates of -cells 
will be presented in Section 2.4.3 whereas neogenesis will be taken into account in 
Section 2.4.4. Finally, the procedure employed for parameter estimation for -cell 
turnover will be outlined in Section 2.4.5. 
 
2.4.1. Formulation of the model of glucose and insulin 
dynamics 
Mathematical models have been applied to understand glycaemic feedback 
loops for many years (Bergman et al., 1979; Bolie, 1961). The time-scale 
homogenization method was applied to glycaemic homeostasis to ensure that fast 
and slow responses interact in a physiologically realistic way. Sturis et al. (1991) 
described the oscillation between plasma insulin and plasma glucose with a time 
delay system and was subsequently developed by Tolic et al. (2000).  In this thesis, 
the Sturis-Tolic system was used as the starting point. The model is described by 
ordinary differential equations.  
The dynamics of plasma insulin (Ip(t), mU) is presented as Eqn (2). This is 
related to glucose-stimulated insulin secretion (GSIS; )(GIS , see Eqn (8)), the 
intercellular exchange of insulin and insulin degradation. Interstitial insulin 
dynamics (Ii(t), mU) is presented as Eqn (3). The state variable G(t) denotes the 
blood plasma glucose content whereas Ip(t) denotes the blood plasma insulin content 
and Ii(t) denotes the remote insulin content (insulin in the interstitial spaces of the 
body tissues). Thus, 
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where Ii denotes the remote insulin level (mU), Φ (l/hr) denotes the insulin 
transportation rate between two compartments, Vp denotes the insulin distribution 
volume in plasma (l), and Vi denotes the effective volume (l) in the intercellular 
space. τp and τi denote the mean life time (hr) of an insulin molecular in the blood 
plasma or in the interstitial space, respectively. Glucose dynamics is described by the 
following equation: 
).(),(),()( 3IDII GGIGG
dt
dG
GXGRiin     (4) 
The dynamics of glucose is determined by glucose influxes, i.e. glucose infusion 
rate (ψin, mg/hr) and hepatic glucose ( ),( 3 GGR ), which is secreted by the liver and 
dependent on both plasma glucose and plasma insulin, and glucose usage, i.e. 
insulin-independent ( )(GII ) and insulin-dependent ( ),( iID IG ) glucose 
consumptions. In addition to Sturis-Tolic‘s original definition, glucose excretion by 
kidneys ( )(GGX ) when the glucose level becomes very high was also taken into 
account in order to model hyperglycaemic excursions realistically. 
This model describes the time delay caused by the fact that it takes time for 
insulin to transit to different compartments, being produced by GSIS, and inhibiting 
hepatic glucose production. A duration τd is defined. The delay is modelled as 
follows:  
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where τd denotes a time constant, and ω1(t) to ω3(t) denote auxiliary parameters for 
the time delay (Pattaranit and van den Berg, 2008).  
The dependencies in the Sturis-Tolic system are listed in Eqn (8) to Eqn (11). 
The  s are fluxes and rates modelled by empirical functions: IS  denotes the 
insulin secretion from pancreatic -cells: 
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with positive parameters ISˆ , IS , IS  and gV . The insulin-independent glucose 
uptake by cells is represented by II : 
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with positive parameters IIˆ , loII , , hiII , , II  and  . The insulin-dependent glucose 
uptake is represented by ID : 
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with positive parameters 0 , IDˆ , ID , ID  and ID . The endogenous release of 
glucose is represented by GR : 
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with positive parameters GRˆ , gGR, , iGR, , GR  and GR . Renal excretion of glucose, 
which becomes important at raised glucose levels, is represented by GX : 
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with positive parameters *GX , GX  and GX . 
All the values of the above parameters listed in this section are given in Table 2.4.1 
in Section 2.4.3. 
 
2.4.2. Introducing of glucose input oscillation 
In Sturis-Tolic‘s original model the glucose input ( in ) is a constant. To 
approximate the actual physiological situation better, this input is modelled here as a 
time-varying forcing function. In the top panel of Figure 2.4.1, in  was changed 
from a constant into a periodic function of three supplements a day, and applied to 
the original model. Accordingly, Eqn (4) is rewritten as follows: 
).(),(),()()( GX3GRIDIIin GwGIGGt
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i     (13) 
The middle and bottom panels of Figure 2.4.1 represent the standard reference cycle 
of glucose and insulin dynamics of the Sturis-Tolic model after the glucose infusion 
rate was divided into three meals a day. 
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Figure 2.4.1. Reference cycle. Top: glucose infusion rate is split into three meals a day; middle: 
plasma glucose content; bottom: plasma (black line) and interstitial (grey line) insulin content. 
 
2.4.3. Introducing of -cell turnover 
In this thesis, the -cell turnover, which is a slow state variable, was considered. 
The dynamics of the -cell mass is affected by -cell proliferation, apoptosis, and 
neogenesis (Bonner-Weir, 2000b), which is represented here as follows:  
).()) ,( )( ( NG GQIGμIρ
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ip      (14) 
Here ρ denotes the -cell proliferation rate depending on the plasma insulin, μ 
denotes the -cell apoptosis rate depending on the plasma glucose, and interstitial 
insulin. )(GNG denotes the flux of neogenesis and depends on plasma glucose. 
)(tQ expresses the ratio of -cell mass to the standard -cell mass: 
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where   denotes the -cell mass of a specific object, i.e. the experimental group, 
and ref  denotes the -cell mass of a reference object, i.e. the control group. 
Johnson and Alejandro (2008) proposed the insulin ‗sweet spot‘ hypothesis, 
which proposes that the relationship insulin between -cell proliferation or apoptosis 
is not linear, and at both low and high insulin concentration stimulate -cell 
proliferation (Beith et al., 2008). Therefore, this thesis assumes that the proliferation 
rate of -cells depends on plasma insulin according to the following equation:  
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with positive parameters 0 , 0 , and 0 , which represent the baseline of -cell 
proliferation rate, the insulin-sensitive portion of -cell proliferation, and the pivot 
point of -cell proliferation rate (see Table 2.4.1). The death rate of the -cells is 
assumed to be dependent on the glucose concentration (Efanova et al., 1998) and the 
interstitial insulin level as follows:  
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with positive parameters ˆ , 1 , 2 , 1 , and 2 , which represent the maximum 
-cell death rate, the first sensitivity coefficient of -cell death, the second sensitivity 
coefficient of -cell death, the first pivot point of -cell death rate, and the second 
pivot point of -cell death rate. 
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As the evidence of neogenesis remains controversial, this thesis analyses the 
model first with the assumption that this term is absent. The GSIS is also affected by 
the -cell dynamics. Accordingly, Eqn (2) is rewritten as follows: 
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The Sturis-Tolic‘s extended model is depicted in the form of a diagram in 
Figure 2.4.2. The values of the parameters are given in Table 2.4.1. 
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Figure 2.4.2. Diagram of Sturis-Tolic‘s extended model. Squares refer to variables, clouds denote to 
sources/sinks. Dotted lines refer to functional dependence (arrowheads: positive; blunt ends: negative). 
d denotes a delay line interfering between iI  and GR . The state variable Q is the relative -cell 
mass; with Q fixed at 1, the original Sturis-Tolic model is recovered. Li: liver, source of glucose 
derived from glycogen breakdown. Pa: pancreas, site of -cells which are a source of insulin. 
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Table 2.4.1. Notation and parameter values. 
 
Parameter Value Units Interpretation 
  0.2 l min
-1 blood/interstitial space permeability 
pV  
3 l insulin distribution volume 
iV  
11 l interstitial space volume 
gV  
10 l glucose distribution volume 
g  
6 min mean lifetime of insulin in plasma 
i  
100 min mean lifetime of insulin in interstitial space 
d  
36 min response delay of glucose release 
1  
1.86 — first sensitivity of -cell death 
2  
14.5 — second sensitivity of -cell death 
II  
4.8 — sensitivity of insulin-independent glucose uptake 
ID  
1.77 — sensitivity of insulin-dependent glucose uptake 
iGR,  
7.54 — insulin sensitivity of hepatic glucose release 
gGR,  
10 — glucose sensitivity of hepatic glucose uptake 
IS  
6.67 — sensitivity of insulin secretion 
GX  
0.00065 — renal excretion parameter 
iNG,  
0.5 — sensitivity of neogenesis to insulin 
gNG,  
0.5 — sensitivity of neogenesis to glucose 
1  
1.6 g l-1 first pivot point of -cell death rate 
2  
2.6 g l-1 second pivot point of -cell death rate 
loII ,  
144 mg l-1 pivot point of non-splanchnic insulin-independent glucose uptake 
hiII ,  
2 g l-1 pivot point of splanchnic insulin-independent glucose uptake 
ID  
1 g l-1 pivot point of insulin-dependent glucose uptake 
GR  
2 g l-1 pivot point of glucose release 
IS  
2 g l-1 pivot point of insulin secretion 
GX  
0.3 g l-1 renal excretion parameter 
NG  
1.3 g l-1 pivot point of neogenesis for glucose dependence 
  0.34 — contribution of non-splanchnic insulin-independent glucose uptake 
0  
0.64 — insulin-sensitive portion of -cell proliferation 
0  
115 mU l-1 pivot point of -cell proliferation rate 
ID  
80 mU l-1 pivot point of insulin-dependent glucose uptake 
GR  
26 mU l-1 pivot point of hepatic glucose release 
AI  
0.3 U l-1 Pivot point for apoptosis inhibition 
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NG  
30 mU l-1 pivot point for neogenesis for insulin dependence 
0  
40 mg min-1 baseline of insulin-dependent glucose uptake 
IIˆ  
0.21 g min-1 maximum flux: insulin-independent glucose uptake 
IDˆ  
0.94 g min-1 maximum flux: insulin-dependent glucose uptake 
GRˆ  
0.18 g min-1 maximum flux: hepatic glucose release 
ISˆ  
0.21 U min-1 maximum flux: insulin secretion 
NGˆ  
0.001 min-1 maximum flux: neogenesis of -cell mass 
*
GX  
29 mg min-1 renal excretion parameter 
0  
0.166 year-1 baseline -cell proliferation rate 
ˆ  0.311 year
-1 maximum -cell death rate 
The term ―pivot point‖ refers to midrange values, saturation constants etc. of saturating 
responses. Insulin units: 1U 6.67 nmol. 
72 
 
 
2.4.4. Model with neogenesis of -cell turnover 
There are several hypotheses concerning recovery of ablated -cells, one of 
which states that the ablated -cells are replenished by differentiation from the 
progenitor cells (De Leon et al., 2003), whereas some studies suggest that the -cells 
replenish themselves from differentiation -cells (Ackermann Misfeldt et al., 2008). 
A competing hypothesis is that -cells themselves are capable of rapid proliferation 
(Dor et al., 2004; Lee et al., 2006; Nir et al., 2007). These hypotheses can be 
reconciled if the rapidly proliferating pool of cells is derived from proliferating adult 
-cells that are triggered by activation of c-MYC. The neogenesis of -cells from 
progenitor cells, which are referred to as the proliferator pool in this thesis, was 
represented by the following equation: 
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with positive parameters NGˆ , gNG, , iNG, , NG , and NG , which represent the 
maximum influx of neogenesis of -cell mass, the sensitivity of neogenesis to 
glucose, the sensitivity of neogenesis to insulin, the pivot point for neogenesis for 
insulin dependence, and the pivot point of neogenesis for glucose dependence. The 
main assumption behind this equation is that the neogenesis is triggered by 
prolonged hyperglycaemia (Lipsett and Finegood, 2002) in association with raised 
insulin levels (Grossman et al., 2010). It can also be observed that the right-hand 
side of Eqn (19) behaves like a soft AND-gate, i.e. the flux NG  is larger when both 
glucose and insulin levels are raised. The synchronicity of the prolonged high 
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glucose and insulin levels may be indicative of regulatory insufficiency. It would 
therefore make sense to control -cell mass compensation as proposed by Eqn (19). 
From a mechanistic point of view, it is known that the pathway regulating -cell 
proliferation can act like an AND-gate. Specifically, c-MYC activation induces 
proliferation in a short transition but is overwhelmed by apoptosis in -cells, which 
leads to -cell mass depletion, unless the system is suppressed by co-expression of 
an anti-apoptotic signal, i.e. BCLxL (Pelengaris et al., 2002b). Jonas (2001) suggests 
that glucose induces the expression of c-MYC, whereas insulin induces an 
anti-apoptotic signal (Johnson et al., 2006). Thus, whereas glucose alone induces a 
net loss of -cells (Van de Casteele et al., 2003), the simultaneous presence of 
glucose and insulin would stimulate rapid proliferation, possibly via rapid 
dedifferentiation of existing adult -cells to the proliferative phenotype. It has been 
suggested that this dual proliferation/apoptosis pathway acting via c-MYC acts a 
fail-safe that defaults to -cell loss unless both glucose and insulin are elevated 
(Pelengaris et al., 2002a). 
The action of glucose is indirect and thought to be via GLP-1 (De Leon et al., 
2003), and incretin and cytokine which is secreted by enteroendocrine L-cells. Since 
the half-life of GLP-1 is extremely short (Deacon et al., 1996; Hansen et al., 1999), 
an instantaneous functional dependence on pVG /  appears warranted. In principle, 
NG  should also depend on, and be limited by, the amount of progenitor cells 
present in the pancreas; in the present model, this pool  is assumed to be non-limiting 
and is thought of as an unlimited source. 
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2.4.5. Parameter estimation for -cell turnover 
Our system was based on the Sturis-Tolic model for glucose and insulin 
dynamics. The parameters that concern the fast time-scale system are adopted from 
Tolic et al. (2000). The model was further extended with -cell dynamics, which is 
composed of the rate of proliferation, apoptosis and neogenesis of -cells. Data taken 
from the experimental literature were used to estimate these parameters. Although 
this model describes the human system, the parameters values are taken from the 
rodent experimental data, which is a limitation. This thesis assumes that the 
physiological behaviour of rodent and human is approximately similar on the 
molecular level, so the parameters are assumed to be transferrable. To transform 
values that are not intrinsic, such as blood volume, a scaling factor can be applied to 
adjust the difference between body weight and the effective distribution volume of a 
specific content etc. However, an exception is the parameter NGˆ , but our method of 
estimating this parameter inherently contains the required scaling.  
 
A. Death 
Efanova et al. (1998) provided data on cell death rate under different glucose 
concentrations over 40 hours. If the average death rate during this period is , then 
te  0N(%) cell alive , where 0N denotes the initial percentage of living cells, 
which is here assumed to be 100%. Table 2.4.2 shows how the data obtained from 
the literature were converted into the death rate. The death rate can be plotted as a 
function of the ambient glucose concentration in Figure 2.4.3. Eqn (17) was fitted to 
these data by non-linear least-squares. However, the death rates shown here were 
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several orders of magnitude larger than the accepted -cell turn-over rate that is 
obtained from literature (Dor et al., 2004; Topp et al., 2000). This can be attributed 
to the unfavourable ex vivo conditions under which these data were obtained. 
 
Table 2.4.2. Glucose-related cell death data. This thesis plotted and transferred data from the original 
graph, Efanova et al. (1998) figure 1, manually, which is shown as below table. Given the 11mM 
glucose concentration as an example to estimate the death rate in this cell culture, the percentage of 
alive cells is 86.47(%). This thesis assumes death rate as λ, then Alive cell (%)=N0 × e
-λt
, 
86.47(%)=100(%) × e
-λ×40, λ=0.0036 (1/hr). In this way the death rate for other concentrations can be 
estimated as well. 
Glucose (mM) Death cells(%) in 40 hrs Alive cell (%) in 40 hrs Death rate (1/hr) 
0 36.18 63.82 0.0112 
3 36.44 63.56 0.0113 
5 32.00 68.00 0.0096 
8 17.78 82.22 0.0049 
11 13.53 86.47 0.0036 
14 20.91 79.09 0.0059 
17 22.33 77.67 0.0063 
20 24.69 75.31 0.0071 
23 35.38 64.62 0.0109 
27 39.31 60.69 0.0125 
 
 
76 
 
 
Figure 2.4.3. Pancreatic -cell death rate data and least-squares fit of the formula used in the model. 
 
Johnson et al. (2006) used different measurements to show a direct 
anti-apoptotic effect of insulin and demonstrated that the anti-apoptotic effects of 
insulin are related to the insulin concentration, i.e. in mouse islets cell culture, the 
effect is biphasic, in which the anti-apoptotic effect is strong at low insulin levels but 
is less strong when the insulin is increased, and it is strong again when insulin level 
is as high as hyper-physiological levels. Johnson and Alejandro (2008) analysed the 
trends and found that the relative potency of anti-apoptotic effect drops off more or 
less hyperbolically with insulin concentration I, which is shown as follows: 
,
1
effect relative
AI I


      (20) 
where AI  is approximately 0.3 U l
-1
. The reciprocal of this protective effect appears 
as a prefactor of the death rate in Eqn (17). 
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B. Proliferation 
-cell proliferation is thought to be related to autocrine/paracrine secretion of 
insulin in recent studies (Beith et al., 2008; Okada et al., 2007). In this thesis, data 
from Beith et al. (2008) were used to derive the insulin-related proliferation rate. 
Data taken from the literature were used to fit a simple hyperbolic model, Eqn (16), 
shown in Figure 2.4.4. Table 2.4.3 shows the original data from Beith et al. (2008) 
and transfers the rates into the same time unit (hr
-1
). 
Table 2.4.3. Insulin-related cell proliferation data. This thesis further transfers the proliferation rate, 
obtained from  Beith et al. (2008) figure 2, from (day
-1
) to (hr
-1
). 
Insulin(nM) Proliferation rate(day-1) 
Proliferation 
rate(hr-1) 
0.2 (130/24274)/3 = 0.0018 0.000075 
2 (66/22206)/3 = 0.0010 0.000042 
20 (58/20489)/3 = 0.0009 0.000038 
200 (168/25585)/3 = 0.0022 0.000092 
 
 
 
Figure 2.4.4. Pancreatic -cell proliferation rate data and least-squares fit of the hyperbolic formula 
used in the model.  
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C. Neogenesis 
Neogenesis of -cells remains to be fully characterised in quantitative terms. 
The formula used in this thesis to represent the rate at which -cells are replenished 
is therefore speculative. Steil et al. (2001) found an initially doubled plasma glucose 
level in rats that were given infusions of glucose. Figure 2.4.5 shows a simulation of 
this experiment. Within a day, euglycaemia was re-established and the -cell mass 
had doubled. 
 
 
Figure 2.4.5. The Steil et al. (2001) experiment as simulated by the present model. After two control 
days, glucose is switched to an infusion. Top: plasma glucose content; middle: interstitial space 
insulin content; bottom: -cell mass. 
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Chapter 3. Results 
 
3.1 Microarray data 
In this section, the results of two different sets of microarray data will be 
presented. Section 3.1.1 describes the early effect of c-MYC activation whereas in 
Section 3.1.2, the early effects of exenatide, which is one of the common drugs for 
treatment of diabetes, will be presented. To the best of the authors‘ knowledge, this 
is the first detailed investigation of the early effect of c-MYC. 
 
3.1.1. Gene expression of c-MYC activation during 
hypoglycaemia 
In the M
+
/E
-
 vs M
-
/E
-
 microarray experiment, 426 probe sets  (~400 genes) 
were identified as statistically significant differentially expressed (p<0.01, 2-way 
ANOVA, Benjamini-Hochberg post-hoc analysis) in response to the activation of 
c-MYC. The k-means cluster method was applied to separate these differentially 
expressed transcripts (DETs) into two groups, which is shown in Figure 3.1.1. The 
majority of DETs were up-regulated after c-MYC activation. As shown in the left 
panel of Figure 3.1.1, cluster 1 was composed of 374 probe sets that were mainly 
up-regulated throughout the experiment, whereas most of the 52 probe sets in 
cluster 2, which is presented in the right panel of Figure 3.1.1, were down-regulated 
throughout the experiment. A detailed DETs list is show in Appendix C. 
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Figure 3.1.1. Differentially expressed transcripts in M
+
/E
-
 vs M
-
/E
- 
experiment. 
Statistically significant differentially expressed transcripts (DETs) were defined (p<0.01, 2-way 
ANOVA, Benjamini-Hochberg post-hoc analysis), and clustered into 2 different groups by means of 
k-means clustering. Left panel: cluster 1, most of DETs were up-regulated after c-MYC activation and 
right panel: cluster 2, most of DETs were down-regulated after c-MYC activation. The fold change 
ratio referred to the expression level of treatment divided by the expression level of control, and then 
was transformed by log2. If the transcript was up-regulated, the normalised fold change ratio was 
positive, whereas the negative value was applied to indicate the transcript was down-regulated 
because of treatment. 
 
Figure 3.1.2 shows biological processes GO terms of cluster 1. Significant 
biological process GO terms were defined by hypergeometric analysis (see 
Section 2.3.4), and 167 GO terms were deemed to be significant. These GO terms 
can be partitioned into three different categories according to their functions, in 
which were cellular process (such as RNA processing, ncRNA processing, and 
cellular metabolic process, DNA replication, cell cycle, and DNA duplex unwinding), 
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metabolic process (such as RNA metabolic process, amine metabolic process, DNA 
metabolic process, and mRNA metabolic process), and cellular component 
organization or biogenesis (such as ribonucleoprotein complex biogenesis, cellular 
component biogenesis at cellular level, and cellular component organization or 
biogenesis at cellular level). A detailed GO analysis result is listed in Appendix D. 
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Figure 3.1.2. GO terms of cluster 1. 
The biological process GO terms in cluster 1. The corrected p-value (see Section 2.3.4) is also shown 
to indicate the statistically significant GO terms in this cluster. Cellular process, metabolic process 
and cellular component organization or biogenesis were statistically significant GO terms. The 
number of transcripts mapping to a specific GO term is also presented, for example, in the cellular 
process term, the count was 132 (37.29%), which means 132 transcripts in cluster 1 were mapped to 
this GO term. These transcripts constituted 37.29% of whole transcripts in the mouse genome that 
were mapped to this term. 
 
Genes relating to those significant GO terms are shown in Appendix E. 
Table 3.1.1 presents some selected genes from Appendix E. The majority of 
up-regulated genes were involved in the metabolic processes, i.e. catalytic activity, 
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nitrogen compound metabolic process, biosynthetic process, cellular metabolic 
process, primary metabolic process, and small molecule metabolic process, in the 
early c-MYC activation, whereas the cellular process (cell cycle activities, cell cycle 
process, cell division and DNA conformation change) and cellular component 
organization or biogenesis were also observed in this cluster. 
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Table 3.1.1. Significant biological processes and selected genes in cluster 1. 
I. Cellular process 
Genes relating to cell cycle, cell cycle process, cell division and DNA conformation change 
Probe Set ID Gene Symbol 
Fold change ratio (Treatment/Control) at different time points 
Ref_seq_id 
4 8 16 32 
1417910_at Ccna2 -1.08  4.82  11.07  3.21 NM_009828 
1448205_at Ccnb1 1.09  3.82  9.56  3.63 NM_172301 
1416492_at Ccne1 2.10  4.16  5.80  1.28 NM_007633 
1441910_x_at Ccne1 1.93  8.88  1.74  1.6 NM_007633 
1422535_at Ccne2 2.17  8.20  6.32  5.7 
NM_001037134 /// 
NM_009830 
1417131_at Cdc25a 2.55  2.19  1.49  3.07 NM_007658 
1417132_at Cdc25a 2.29  2.07  1.24  1.76 NM_007658 
1452040_a_at Cdca3 -1.08  1.05  5.51  1.1 NM_013538 
1416802_a_at Cdca5 -1.42  22.18  21.74  8.58 NM_026410 
1424143_a_at Cdt1 5.79  24.94  11.12  6.83 NM_026014 
1449708_s_at Chek1 2.69  6.39  4.48  4.69 NM_007691 
1416698_a_at Cks1b 1.52  3.58  3.15  2.45 NM_016904 
1417457_at Cks2 -1.24  3.77  8.09  6.65 NM_025415 
1434079_s_at Mcm2 1.84  4.18  2.56  3.05 NM_008564 
1436708_x_at Mcm4 2.10  8.25  1.43  2.69 NM_008565 
1436808_x_at Mcm5 4.34  28.35  2.00  9.02 NM_008566 
1438320_s_at Mcm7 2.81  5.93  3.11  3.61 NM_008568 
1439269_x_at Mcm7 2.40  7.40  2.73  3.72 NM_008568 
1418281_at Rad51 1.09  4.62  9.60  1.58 NM_011234 
 
II. Metabolic process 
Genes relating to cellular metabolic process 
Probe Set ID Gene Symbol 
Fold change ratio (Treatment/Control) at different time points Ref_seq_id 
4 8 16 32 
1427197_at Atr 2.57  4.41  1.58  2.96  NM_019864 
1448205_at Ccnb1 1.09  3.82  9.56  3.63  NM_172301 
1416492_at Ccne1 2.10  4.16  5.80  1.28  NM_007633 
1441910_x_at Ccne1 1.93  8.88  1.74  1.60  NM_007633 
1422535_at Ccne2 2.17  8.20  6.32  5.70  
NM_001037134 /// 
NM_009830 
1424143_a_at Cdt1 5.79  24.94  11.12  6.83  NM_026014 
1449708_s_at Chek1 2.69  6.39  4.48  4.69  NM_007691 
1417457_at Cks2 -1.24  3.77  8.09  6.65  NM_025415 
1426351_at Hspd1 1.31  1.84  2.45  2.63  NM_010477 
1434079_s_at Mcm2 1.84  4.18  2.56  3.05  NM_008564 
1436708_x_at Mcm4 2.10  8.25  1.43  2.69  NM_008565 
1436808_x_at Mcm5 4.34  28.35  2.00  9.02  NM_008566 
1438320_s_at Mcm7 2.81  5.93  3.11  3.61  NM_008568 
1439269_x_at Mcm7 2.40  7.40  2.73  3.72  NM_008568 
1450376_at Mxi1 2.36  1.42  2.52  4.78  
NM_001008542 /// 
NM_001008543 /// 
NM_010847 
1423747_a_at Pdk1 4.74  4.40  2.45  5.13  NM_172665 
1423748_at Pdk1 5.64  6.35  4.16  6.23  NM_172665 
1435836_at Pdk1 3.28  2.66  1.76  3.01  NM_172665 
1451845_a_at Ptrh2 1.70  1.20  2.24  3.97  
NM_001098810 /// 
NM_175004 
1418281_at Rad51 1.09  4.62  9.60  1.58  NM_011234 
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III. Cellular component organization or biogenesis 
Genes relating to cellular component organization or biogenesis 
Probe Set ID Gene Symbol 
Fold change ratio (Treatment/Control) at different time points 
Ref_seq_id 
4 8 16 32 
1417910_at Ccna2 -1.08 4.82 11.07 3.21 NM_009828 
1448205_at Ccnb1 1.09 3.82 9.56 3.63 NM_172301 
1417131_at Cdc25a 2.55 2.19 1.49 3.07 NM_007658 
1417132_at Cdc25a 2.29 2.07 1.24 1.76 NM_007658 
1452040_a_at Cdca3 -1.08 1.05 5.51 1.1 NM_013538 
1416802_a_at Cdca5 -1.42 22.18 21.74 8.58 NM_026410 
1434079_s_at Mcm2 1.84 4.18 2.56 3.05 NM_008564 
 
  
The result of biological pathway analysis of cluster 1 is presented in 
Figure 3.1.3, which shows that c-MYC activation in early time point has already 
triggered complicated gene regulations and most of the regulated genes were located 
in cytoplasm or nucleus.  
Mxi1 (MAX interactor 1), Rad51 (RAD51 homolog (RecA homolog, E. coli; 
S. cerevisiae)), Atr (ataxia telangiectasia and Rad3 related) and Ccne1 (cyclin E1) 
were up-regulated genes located in nucleus. Mcm2 (minichromosome maintenance 
complex component 2), Mcm4 (minichromosome maintenance complex component 
4) and Mcm7 (minichromosome maintenance complex component 7) were also 
up-regulated as a result of MYC activation.  
Ccnb1 (cyclin B1), Ccna2 (cyclin A2) and Chek1 (CHK1 checkpoint homolog 
(S. pombe)), located in cytoplasm, are important cell cycle related genes and were 
up-regulated as well. Genes, i.e. Pdk1 (pyruvate dehydrogenase kinase, isoenzyme 1), 
Ptrh2 (peptidyl-tRNA hydrolase 2) and Hspd1 (heat shock protein 1 (chaperonin)) 
located in mitochondrion were also up-regulated. 
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Figure 3.1.3. Biological pathways of up-regulated genes. (A) Biological pathways, (B) legends of 
pathway and (C) heatmap of expression level (of log2 normalisation). 
A complicated gene regulatory network was triggered by c-MYC activation. Using a text-mining 
method (see Section 2.3.4), differentially expressed genes and their related functions are discovered. 
Because c-MYC activated a complicated gene network, a RAR compressed file, which contains the 
information in Figure 3.1.3, was generated and can be downloaded from 
https://files.warwick.ac.uk/yi-fangwang/files/thesis/pure_myc.rar. After the file is decompressed, a 
file named upregulated_gene_network.html, which is a navigable html page of Figure 3.1.3 (A) with 
hyperlink functions, can be found. 
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In the down-regulated cluster, cluster 2, no statistically significant biological 
process GO terms could be defined. The result of pathway analysis for cluster 2 is 
shown in Figure 3.1.4. Cdkn2b (cyclin-dependent kinase inhibitor 2B (p15, inhibits 
CDK4)), Kdr (kinase insert domain receptor, which is a type III receptor tyrosine 
kinase) and Figf (c-fos induced growth factor (vascular endothelial growth factor D)) 
were down-regulated through the experimental period after c-MYC activation.  
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Figure 3.1.4. Biological pathways of down-regulated genes. Legends see Figure 3.1.3. 
 
A full list of statistically significant differentially expressed transcripts is given 
in Appendix C. 
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3.1.2. Effect of exenatide and c-MYC during the early activation 
of c-MYC 
In this section, the effects of two different conditions will be studied; 
condition 1 (M
+
/E
+
 vs M
+
/E
-
): the effect of exenatide under c-MYC activation, and 
condition 2 (M
-
/E
+
 vs M
-
/E
-
): the effects of exenatide without c-MYC activation. In 
condition 1, 43 transcripts in the MYC-activated transgenic mouse system exhibited 
significant changes in response to the exenatide treatment whereas 39 transcripts 
were significantly up- or down-regulated in condition 2. A full list of statistically 
significant differentially expressed transcripts under condition 1 and condition 2 is 
provided in Appendix F. 
The statistically significant GO terms for condition 1 and condition 2 are 
presented in Table 3.1.2 and Table 3.1.3. Because of the stringency of the statistical 
analysis, only a few significant GO terms could be determined in condition 1 and 
condition 2. In condition 1, the significant GO terms were osteoblast fate 
commitment and embryonic pattern specification, whereas in condition 2, the 
significant GO terms were regulation of glycogen biosynthetic process, regulation of 
glucan biosynthetic process, positive regulation of glycogen biosynthetic process and 
regulation of polysaccharide biosynthetic process.  
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Table 3.1.2. GO terms of condition 1. 
GO ACCESSION GO Term 
corrected 
p-value 
Count in 
Selection 
% Count in 
Selection 
Count in 
Total 
% Count in 
Total 
GO:0002051 osteoblast fate commitment 9.44E-02 2 66.66 5 0.0290 
GO:0009880 embryonic pattern specification 9.44E-02 3 100 28 0.1626 
 
Table 3.1.3. GO terms of condition 2.  
GO ACCESSION GO Term 
corrected 
p-value 
Count in 
Selection 
% Count in 
Selection 
Count in 
Total 
% Count in 
Total 
GO:0005979 
regulation of glycogen biosynthetic 
process 
4.05E-02 2 100 5 
0.0290 
GO:0010962 
regulation of glucan biosynthetic 
process 
4.05E-02 2 100 5 
0.0290 
GO:0045725 
positive regulation of glycogen 
biosynthetic process 
4.05E-02 2 100 5 
0.0290 
GO:0032885 
regulation of polysaccharide 
biosynthetic process 
4.05E-02 2 100 5 
0.0290 
 
The pathway analysis results of condition 1 and condition 2 are shown in 
Figure 3.1.5 and Figure 3.1.6. In condition 1, Vegfa (vascular endothelial growth 
factor A), which was down-regulated, was shown as a hub gene to regulate several 
biological functions, such as endothelial cell migration, endothelial cell proliferation, 
ossification, apoptosis, endocytosys, positive regulation of mitosis, cell division, cell 
growth, neurogenesis, and transcription. Smad5 (MAD homolog 5 (Drosophila)), 
Hsph1 (heat shock 105kDa/110kDa protein 1) and Hdac9 (histone deacetylase 9) 
were also down-regulated. Fabp7 (fatty acid binding protein 7, brain), Zbtb16 (zinc 
finger and BTB domain containing 16), Nr1h4 (nuclear receptor subfamily 1, group 
H, member 4), Ccrn4l (CCR4 carbon catabolite repression 4-like (S. cerevisiae)) 
were up-regulated. 
In condition 2, Wnt4 (wingless-related MMTV integration site 4), Vldlr (very 
low density lipoprotein receptor), Gna13 (guanine nucleotide binding protein, alpha 
13), Lyve1 (lymphatic vessel endothelial hyaluronan receptor 1), Ccrn4l, Fkbp5 
(FK506 binding protein 5) and Btg3 (B-cell translocation gene 3) were up-regulated, 
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whereas Hdac9, Terf2 (telomeric repeat binding factor 2), Vdr (vitamin D receptor) 
and Cited2 (Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal 
domain, 2) were down-regulated. 
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Figure 3.1.5. Biological pathways of condition 1. 
Biological pathways of condition 1 (M
+
/E
+
 vs M
+
/E
-
): the effect of exenatide under c-MYC activation. 
Legends see Figure 3.1.3. 
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Figure 3.1.6. Biological pathways of condition 2. 
Biological pathways of condition 2 (M
-
/E
+
 vs M
-
/E
-
): the effect of exenatide without c-MYC 
activation. Legends see Figure 3.1.3. 
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3.2 Hypoglycaemia in early c-MYC activation 
In most plns-c-MycER
TAM
 transgenic mouse studies, the main focus is on 
glucotoxicity (Cheung et al., 2010; Pascal et al., 2008), carcinogenesis (Pelengaris et 
al., 2004; Pelengaris and Khan, 2001; Pelengaris et al., 2002b), and the provenance 
of the new -cells (Cano et al., 2008); invariably concentrating on the late stage of 
c-MYC activation in the plns-c-MycER
TAM
 transgenic mouse. By contrast, this 
section presents in vivo data on the early effects of c-MYC in this transgenic animal 
system. The dynamics of glucose is presented in Section 3.2.1 and further results of 
the energy expenditure are shown in Section 3.2.2. In Section 3.2.3, the insulin levels 
of specific corresponding time points of glucose levels are presented. The application 
of exenatide in early c-MYC activation is presented in Section 3.2.4. Finally, -cell 
mass quantification and -cell numbers are presented in Section 3.2.5. 
 
3.2.1. Hypoglycaemia starts within 16 hours of c-MYC activation 
Glucose dynamics in vivo is presented in this section. The glucose dynamics of 
different TL experiments which record the blood glucose level every 4 or 8 hours 
continuously within 36 hours treatment of WT (wild-type littermates treated with 
peanut oil), MYC-OFF (plns-c-MycER
TAM
 mice treated with peanut oil) and 
MYC-ON (plns-c-MycER
TAM
 mice treated with 4-OHT) is shown in Figure 3.2.1.  
For more details of TL experiments, see Figure 2.1.1 in Section 2.1.3. Different TL 
experiments results were combined together in this figure according to different 
treatment groups to generate a continuous glucose profile, i.e. experimental results of 
WT from TL1, TL2 and TL3 were combined as Figure 3.2.1 (A); experimental 
results of MYC-OFF from TL1, TL2 and TL3 were combined as Figure 3.2.1 (B); 
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and experimental results of MYC-ON from TL1, TL2 and TL3 were combined as 
Figure 3.2.1 (C). The average glucose levels across all time points were stable for 
WT and MF, which were 7.8 ± 0.75 mmol/l (mean ± sample standard deviation (SD)) 
and 3.3 ± 0.53 mmol/l, respectively. In the MYC-ON group, the glucose level 
remained close to the average level, which was 3.6 ± 0.92 mmol/l, until 16 hours of 
c-MYC activation. A significant decline of the glucose level occurred and endured 
until 24 hours. Figure 3.2.1 (C) also shows that the decreased glucose level became 
hyperglycaemic at 32 hours but returned to euglycaemic at 36 hours.  
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Figure 3.2.1. Glucose dynamics of c-MYC activation within 36 hours. Glucose level for (A) WT, (B) 
MYC-OFF, and (C) MYC-ON.  
The experimental design is described in Figure 2.1.1 in Section 2.1.3. Different TL experiments were 
combined according to different treatment groups (n=3) to make a continuous blood glucose profile of 
c-MYC activation/control over 36 hours. (A) represents the blood glucose level of WT from TL1, 
TL2 and TL3, (B) is the glucose level of MYC-OFF from TL1, TL2 and TL3 and (C) represents the 
blood glucose level of MYC-ON from TL1, TL2 and TL3. The error bars represent the sample 
standard deviation (SD). 
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Apart from the possible c-MYC effect, glucose dynamics is coordinated through 
various metabolic and endocrine regulatory processes. Food intake contributes 
directly to glucose influx and will be discussed in Section 3.2.2, whereas insulin 
regulates blood glucose level via its endocrine actions, and will be considered in 
Section 3.2.3. 
 
3.2.2. Altered energetic balance does not completely account for 
hypoglycaemia 
Food intake and faeces production were evaluated throughout the TL 
experiments. Mice body weights were also recorded every 4 or 8 hours. The energy 
expenditure and food intake in vivo is presented in Figure 3.2.2. The energy usage 
throughout all TLs from 0 to 28 hours is presented in Figure 3.2.2 (A). There was no 
difference within MYC-ON and MYC-OFF groups but a statistical difference (paired 
t-test, p-value< 0.05) was detected between WT (0.0943 ± 0.0152 (g/hr); mean ± SD) 
and MYC-ON (0.0742 ±  0.0102 (g/hr)). The energy usage of WT 
(0.1235 ± 0.0220 (g/hr)), MYC-OFF (0.1014 ±  0.0463 (g/hr)) and MYC-ON 
(0.0773 ± 0.0129 (g/hr)) during hypoglycaemia is shown in Figure 3.2.2 (B), which 
shows a statistically significant difference (paired t-test, p-value<0.01) in energy 
usage between WT and MYC-ON across the hypoglycaemic period, which was 8 to 
20 hours. Food intake and faeces production during the experimental period and 
hypoglycaemic period are also presented in Figure 3.2.2 (C), (D), (G), and (H), 
which show a significant decrease of food intake in MYC-ON mice during 
experimental and hypoglycaemic periods compared to their WT and MYC-OFF 
littermates. A significant difference is observed in the change of body weight (w) 
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during the experimental period (Figure 3.2.2 (E)) between MYC-ON and MYC-OFF 
group whereas no significant difference is shown during hypoglycaemia 
(Figure 3.2.2 (F)). 
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Figure 3.2.2. Energy expenditure dynamics. 
Energy usage (A), food intake (C), change of body weight (w) (E), and faeces production (G) during 
the experimental period (n=9), and energy usage (B), food intake (D), w (F), and faeces production 
(H) during the hypoglycaemic period (n=6). The error bars represent the SD. * significant difference 
according to the paired t-test (p<0.05) and ** (p<0.01). 
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3.2.3. Hypoglycaemia results from hyperinsulinaemia 
The analysis of the in vivo glucose dynamics in Section 3.2.1 confirms the 
existence of hyperglycaemia during 16-24 hours after c-MYC activation. Different 
scenarios can be hypothesised to explain this phenomenon: (i) increased insulin 
secretion or release from dying cells; (ii) rapid -cell proliferation; and (iii) increased 
insulin sensitivity. The first two hypotheses can be addressed by testing the insulin 
levels and immuno-staining with specific antibodies (such as Ki-67 as a maker for 
proliferation and Caspase-3 as a marker for apoptosis). Figure 3.2.3 shows the fed 
blood glucose level and serum insulin level at -4, 8, 12, 16, 20, 28, 32, and 36 hours. 
The insulin level is similar in the WT and MYC-OFF treatments whereas MYC-OFF 
has a lower glucose level. Figure 3.2.3 (C) and Figure 3.2.3 (F) present the glucose 
level and its corresponding insulin level at different time points in MYC-ON mice. 
At 16 to 20 hours, MYC-ON mice were hypoglycaemic with an acute insulin release, 
which confirmed that hypoglycaemia occurred within 16 hours accompanied by a 
surge of insulin release in MYC-ON mice. 
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Figure 3.2.3. Early c-MYC activation causes hyperinsulinaemic hypoglycaemia (HH).  
Glucose level for (A) WT, (B) MYC-OFF, and (C) MYC-ON mice and insulin level for (D) WT, (E) 
MYC-OFF, and (F) MYC-ON mice at initial time point and 8, 12, 16, 20, 28, 32, and 36 hours after 
the first injection of 4-OHT or the same volume of vehicle. n=3 and the error bars represent the SD. 
 
In order to show that hypoglycaemia and hyperinsulinaemia at 16 hours were 
genuine, a further negative control group was presented in Figure 3.2.4. WT mice 
were treated with 4-OHT (WT-4-OHT) and the glucose and insulin levels were 
tested at 8 and 16 hours after the injection. Both glucose and insulin levels of 
WT-4-OHT (see Figure 3.2.4 (A) and Figure 3.2.4 (B)) were within the average 
levels comparing to the WT group (see Figure 3.2.3 (A) and Figure 3.2.3 (D)). 
Therefore, the administration of 4-OHT did not affect the whole blood glucose and 
serum insulin levels in the plns-c-MycER
TAM
 transgenic mouse WT littermates. 
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Figure 3.2.4. Administration of 4-OHT does not affect WT glucose and insulin levels.  
WT type littermates of plns-c-MycER
TAM
 mouse were treated with 4-OHT (WT-4-OHT). The glucose 
levels (A) and insulin levels (B) were tested at 8 and 16 hours after the treatment. n=3 and the error 
bars represent the SD. 
 
3.2.4. Effects of exenatide 
Exenatide is frequently employed in the treatment of T2DM, perhaps because 
it is well-known for having fewer side effects than other glucose-lowering agents, for 
example it will not cause hypoglycaemia. The plns-c-MycER
TAM
 transgenic mouse 
system is a well-established conditional -cell ablation animal model, which causes 
high glucose levels, without other confounding factors. This section presents the 
effect of exenatide on the glucose level of this transgenic model at early time points, 
in which plns-c-MycER
TAM
 transgenic mice were experiencing hypoglycaemia. 
Figure 3.2.5 shows the glucose level of exenatide treatment in 
plns-c-MycER
TAM
 transgenic mice after 16 hours of c-MYC activation. It is clear that 
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glucose levels were significantly lower in the exenatide treated mice than in the 
untreated ones, which suggests that exenatide might further lower the glucose level 
in this transgenic mouse, even without c-MYC activation.  
 
 
Figure 3.2.5. Exenatide treatment causes a decrease of glucose levels in MYC-OFF and does not 
correct c-MYC induced hypoglycaemia. 
Glucose levels of MYC-OFF and MYC-ON at 16 hours treated with exenatide or water vehicle is 
presented. n=3 and the error bars represent the SD. *, significant difference according to the paired 
t-test (p<0.05). 
 
A further negative control of WT littermates treated with exenatide (EW) or 
the same volume of vehicle (WW) is presented in Figure 3.2.6 and a decrease (paired 
t-test, p-value<0.05) of glucose levels was observed in the EW group whereas there 
was no statistically detectable change of glucose levels in the WW group. 
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Figure 3.2.6. Treatment of exenatide lowers glucose levels in WT. 
Glucose levels of WT treated with water vehicle (WW) or exenatide (EW). Fed glucose levels were 
measured before the SC injection (before treatment) and 2 hours after (after treatment). n=3 and the 
error bars represent the SD. *, significant difference according to the paired t-test (p<0.05). 
 
3.2.5. Regulation of -cells 
Proliferation of -cells after c-MYC activation is shown in Figure 3.2.7, in 
which representative figures of the experiment are presented, by means of 
immunofluorescence staining of Ki-67 and insulin in MYC-ON transgenic mice. The 
Ki-67 fluorescent staining was regarded as a marker for proliferation whereas the 
insulin fluorescent staining identified where the β-cells were. However, apoptosis 
was not observed from an early stage, such as 16 hours, of c-MYC activation 
because IHC staining of caspase-3 did not present any detectable fluorescent signals 
(data not shown).  
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Figure 3.2.7. -cell proliferation in early c-MYC activation. 
After 16 hours of c-MYC activation, the proliferation of -cells was detected by immunofluorescence 
staining of Ki-67 (green) and Insulin (red). (A)-(D) presents the staining result of WT and (E)-(H) 
presents the staining result of MYC-ON. The blue staining refers to DAPI, which stains the nuclei. 
Images were captured by confocal microscopy with x400. 
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As shown in Figure 3.2.3, the MYC-OFF (plns-c-MycER
TAM
 mice treated with 
peanut oil) and WT (WT littermates treated with peanut oil) groups had similar 
serum insulin levels but the blood glucose level in the MYC-OFF group was lower 
than the WT group, even without the activation of c-MYC. It might be inferred that 
the transgenic mouse system has a residual level of c-MYC activation at a small but 
steady level even without the administration of 4-OHT; this is called ‗leakiness‘. To 
investigate this possibility, -cell mass quantification was carried out. The results are 
presented in Figure 3.2.8 at 8 and 16 hours after the first injection of 4-OHT or the 
same volume of vehicle. It is evident that plns-c-MycER
TAM
 mice had a bigger -cell 
mass (3.45 ± 0.29 mg; mean ± SD) compared to their WT littermates 
(1.30 ±  0.14 mg), even when they had not received any 4-OHT treatment (see upper 
left panel of Figure 3.2.8).  In the WT group, the β-cell masses for WT and 
WT-4-OHT were 1.93 ± 0.20 (mg) and 2.09 ± 0.80 (mg) at 8 hours, and 
1.70 ± 0.17 (mg) and 1.56 ± 0.25 (mg) at 16 hours, and there was no significant 
change because of the 4-OHT treatment. In the MYC group, the treatment did 
change the β-cell mass at 8 hours which was 3.31 ± 0.63 (mg) for MYC-OFF and 
4.55 ± 0.38 (mg) for MYC-ON, whereas no significant difference was observed at 
16 hours between MYC-OFF (3.15 ± 0.60 mg) and MYC-ON (3.59 ±0.97 mg) 
groups. 
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Figure 3.2.8. -cell mass of plns-c-MycERTAM mice or their WT littermates at 8 and 16 hours after the 
first injection of 4-OHT or peanut oil. Upper left panel, the -cell mass of the control group of 
plns-c-MycER
TAM
 mice or WT. n=3 and the error bars represent the SD. *, (p<0.05). 
 
Phenotype data, i.e., body weight and pancreas weight, on two experimental 
objects were lost, viz., WT-4-OHT2 at 8 hours (08WT-4-OHT2) and MYC-ON2 at 
8 hours (08MYC-ON2). Apart from those two data points, the mean pancreas 
weights of the WT-4-OHT group and the MYC-ON group were calculated and used 
as 08WT-4-OHT2 and 08MYC-ON2‘s pancreas weights to compute their -cell 
mass. The details of mouse body weight and pancreas weight of each treatment 
group at 8 and 16 hours is given in Table 3.2.1. 
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Table 3.2.1. Body weight and pancreas weight at 8 and 16 hours. n=3 in each group; all data represent 
a mean ± SD. 
 8hr 16hr 
 body weight (g) pancreas weight (mg) body weight (g) pancreas weight (mg) 
WT 24.27±3.36  219.67±6.51  27.17±0.76  277.33±10.12  
WT-4-OHT 27.85±1.85  220.50±19.50  27.90±0.70  266.67±22.94  
MYC-OFF 23.73±1.36  234.67±24.85  23.80±1.06  232.33±16.77  
MYC-ON 27.50±0.10  250.50±0.50  26.07±0.85  243.00±27.87  
 
A surge of insulin secretion can be observed after 16 hours of c-MYC 
activation. In order to estimate the -cell volume, the -cell size at 16 hours was 
evaluated; results are presented in Figure 3.2.9. In the MYC-ON group, the -cell 
size (1.48±0.21 (μm2); mean ± SD) is statistically significantly larger than that in 
WT (0.90±0.05 (μm2)) or WT-4-OHT (0.87±0.19 (μm2)) group. Although the 
statistical analysis did not show the significant difference between WT and 
MYC-OFF (1.09±0.06 (μm2)) groups, there was a trend for the transgenic mice to 
have larger -cells even in the absence of activation of c-MYC. However, this thesis 
indicates that -cell size was increased in the MYC-ON group. 
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Figure 3.2.9. -cell size of plns-c-MycERTAM mice or their WT littermates at 16 hours after the first 
injection of 4-OHT or peanut oil. n=3 and the error bars represent the sample standard deviation (SD). 
**, p<0.01. 
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3.3 Mathematical model 
3.3.1. Analysis without neogenesis of -cells 
To analyse the dynamics without -cells neogenesis, the parameter NGˆ  is set 
to zero.  If the given parameter values obtained from the literature are accepted, the 
resulting -cell dynamics is very slow, which can be considered as indirect evidence 
that neogenesis is an important factor in fast adaption, i.e. hours/days instead of 
months or years. 
Using the method given in Appendix B, the system was rendered 
dimensionless, but retaining the dimension of time. The method also comprises the 
determination of the maximum absolute rates (the  s) and ranking of scaled 
variables according to these rates. For instance, if 10 g is chosen as the reference 
value for glucose and 44 mU as the reference value for insulin, then the rank is found 
as follows ( s all in min-1; Q is already dimensionless): 
refGGx /1   refp IIx /2   refi IIx /3   refIx /14   refIx /25   refIx /36   
Qx 7  
8.41   11.02   066.03   028.04   028.05   028.06   
7
7 107.8
  
A time-scale separation at 7  is apparent, with small parameter 
  00125.0min 6024min107.8 17  T ; a unit of slow time   thus 
corresponding to 800 days. 
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In Appendix B, the dynamics in slow time for ]1[7x  is derived by using 
Eqn  (A 13), whereas the variables ]1[6
]1[
1  , , xx   are to be obtained as functions of 
]1[
7x  
on the basis of the slow-manifold condition, which corresponds to the stationary 
forced cycle in fast time when ]1[7x  is held at a fixed value. These relations can be 
obtained numerically, and results are shown in Figure 3.3.1. In this system the 
reference cycle corresponds to a fairly high glycaemic load. At these high loads, the 
dynamics of the -cell mass has two fixed points, i.e. a lower unstable one and a 
higher stable one. Topp et al. (2000) regards this kind of unstable fixed point as a 
―pathological fixed point,‖ which means that if x7 becomes lower than this 
equilibrium value, a destructive involution of -cell mass will occur. The loss of 
-cells leads to further hyperglycaemia and lower insulinaemia, which leads to 
further -cell losses, so that this pathological fixed point will then decay to zero. 
This process may underlie non-autoimmune diabetes mellitus, as described by 
Imagawa et al. (2000). 
When the glycaemic loads increase, these two points move together and collide. 
At a higher glycaemic loads, the globally attracting point is the trivial equilibrium 
Q=0, that is, zero -cell mass. When -cell death rate is increased at high glycaemic 
loads, the stable equilibrium value is decreased. It is due to the higher glucose 
toxicity (Efanova et al., 1998), and the increased susceptibility to apoptosis at higher 
insulin levels (Johnson and Alejandro, 2008); the latter authors describe this 
situation as a ―sweet spot‖ for insulin in the high pico-molar range, and the high 
insulin level corresponds to order 1 levels in the scaled system. 
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Figure 3.3.1. Dynamics of -cell mass on the slow time scale. Top: relative daily change of -cell 
mass, for various glycaemic loads (black curves, from top to bottom: 1, 2, 2.5 and 3 times the 
reference input; grey curves, from top to the bottom: 0.5 and 0 times the reference input). Middle: 
fixed point of the -cell dynamics as a function of the relative glycaemic load (solid line: stable 
branch; dashed line: unstable branch). Bottom: fast-time scale glucose stationary cycle characteristics 
(dotted line: average value; bottom and top of filled region: minimum and maximum values). 
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Figure 3.3.2 shows a comparison of the dynamics under the situations of 
overfeeding and underfeeding. The dynamics was according to the approximation 
(which is simple and 1-dimensional) are shown, together with the solutions 
according to the dynamics of the original, 7-dimensional, system. The results are 
virtually indistinguishable. This means that the long-term dynamics is well-captured 
by the approximation. The full system was numerically integrated in fast time by 
using an explicit Runge-Kutta method of order 2(1), which is the Mathematica 
default method (Sofroniou and Spaletta, 2004). The slow system was evaluated using 
Euler-forward with a step size of one day, giving virtually the same result at less than 
a thousandth of the computational cost (run time; excluding the one-time cost of 
establishing the dynamics of x7, which costs about 1% of the full-system‘s run time). 
 
Figure 3.3.2. Simulations of overfeeding (left) and (underfeeding) right. On day 1,000, the glycaemic 
load is changed to 2.5 (left) or 0.1 (right) normal; on day 11,000 the load is restored to the normal 
value. Dotted line: 
 1
1x (glucose); dot-dashed line: 
 1
2x  (plasma insulin); dashed line: 
 1
7x  (-cell 
mass). Thin lines show the results of a direct simulation of the 7-dimensional system. (―Relative 
value‖ refers to scaling by refG  and refI , as explained in the text; Q=x7=1 corresponds to the 
stationary value of -cell mass if the standard-cycle glycaemic load were administered at a constant 
rate; stationary values can be read off from Figure 3.3.1.) 
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It is tempting to treat the glycaemic load as a constant that represents the 
average of the daily cycle when a mathematical model for the long-term -cell mass 
dynamics is formulated. Topp et al. (2000) and Winter et al. (2006) adopted this 
assumption. However, the dynamics of ]1[7x  in slow time   do in fact depend 
critically on the ―temporal fine structure‖ of glucose uptake on the fast time scale t , 
through the integration in Eqn (A 13). If glucose uptake is replaced by its short-term 
average, such dependence is neglected. If one considers the case where the 
glycaemic load is taken up as a constant infusion (set to zero for the first 30 minutes 
after midnight, to execute a 24-hour cycle) instead of a daily 3-meal cycle, this 
neglect is apparent.  Figure 3.3.3 shows the relative daily change of -cell mass 
dynamics with various glucose inputs on a slow time scale. This long-term dynamics 
of the -cell mass is notably different, i.e. the ―pathological fixed point‖ remains 
very close to zero and the system achieves near-perfect regulation of the average 
glucose level even at a hyperglycaemic load that is 4 times higher than normal. 
Comparison with the case AI  (data not shown) indicates that without 
compromising insulin‘s ability to regulate, the decrease of insulin‘s capability in 
inhibiting apoptosis is responsible for keeping the -cell mass in check. If AI , 
even with the normalisation of glucose levels is already reached at x7-values, the 
fixed point of x7 still increases quickly with the load. 
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Figure 3.3.3. Dynamics of -cell mass on the slow time scale: relative daily change of -cell mass, for 
various glycaemic loads, given as a constant infusion (black curves, from left to right: 1, 2, 2.5, and 
3 times the reference input; grey curves, from left to right: 0 and 0.5 times the reference input). 
 
3.3.2. Extended model with neogenesis of -cells 
The dynamics shown in Figure 3.3.2 is very slow. An example of such slow 
dynamics is shown in Figure 3.3.4. When 80% of the -cell mass is ablated, it takes 
50 years to recover. It means that the subject will be suffering from the -cell 
deficiency for life, and the baseline turn-over dynamics of -cells is too sluggish to 
respond properly to such challenges. However, in reality, as shown in the literature, 
recovery from such damage is accomplished within a few weeks‘ time (Bouwens and 
Rooman, 2005). There are many different theories of the -cell regeneration, as 
described in Section 2.4.4, including the idea that these the slowly proliferating 
-cell pool may be supplied by a faster proliferating progenitor cell (De Leon et al., 
2003) or the differentiated -cells themselves (Ackermann Misfeldt et al., 2008) 
whereas it has also been suggested -cells themselves are capable of rapid 
proliferation (Dor et al., 2004; Lee et al., 2006; Nir et al., 2007).  
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Figure 3.3.4. Dynamics of -cell mass on the slow time scale: recovery to normal values after 
addition or destruction of -cells at time t = 0. (―Relative value" has the meaning explained in the 
caption for Figure 3.3.2.) 
 
Neogenesis of -cells from the progenitor cells was introduced as described in 
Section 2.4.4 and the result is shown in Figure 3.3.5. When the model is extended 
with neogenesis, the recovery from ablated -cell mass is faster and closer to the 
value that is quoted in the literature (Bouwens and Rooman, 2005). The slow-time 
approximation after combining the neogenesis is still working properly, apart from 
the fact that the time-scale separation is now up to two orders of magnitude worse 
because of the fast -cell expansion that occurs when the -cell mass ablation is too 
severe. The relationship between 7x
d
d

 and 7x  still stays qualitatively equal, despite 
the fact that the lower, unstable fixed point is now very low and the positive rate of 
change that prevails when 7x  lies in between the fixed points is now several orders 
of magnitude larger. 
As shown in the bottom panel of Figure 3.3.5, if the -cell ablation is too 
critical, recovery will take disproportionally longer, i.e. when more than 80% of 
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-cells are destroyed, recovery takes the best part of a year, which implies the 
subject is diabetic for a number of months until recovery occurs. 
 
 
Figure 3.3.5. Model with neogenesis: recovery to normal values after addition or destruction of 
-cells at time t = 0. Gray curves: direct simulation; circles: approximation according to slow-time 
approximation. Top panel: recovery over a month; bottom panel: recovery over a year. ("Relative 
value" has the meaning explained in the caption for Figure 3.3.2, but the normal stationary value is 
now different since the dynamics includes neogenesis.) 
 
In T1DM, patients are suffering from an absolute -cell mass losses because 
the autoimmune system destroys the pancreatic -cells directly (Bach, 1994; 
Eisenbarth, 1986). The simulation in Figure 3.3.5 suggests that there is a critical 
level of depletion at which recovery becomes very slow. If the progenitor cells do 
not express the insulin-derived antigen, or do so in sufficiently low levels to escape 
immune attack, the progression to T1DM is a matter of the neogenic suppletion rate 
being unable to compensate for the losses, leading to a net regression of -cell mass 
until the critical ablation level is reached. However, if progenitor cells are also 
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susceptible to immune attack, the rate of recovery will be further compromised and 
the rate at which the -cell mass descends to the critical level may be accelerated. 
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Chapter 4. General Discussion 
The oncogene c-Myc controls multiple cellular functions. In the switchable 
plns-c-MycER
TAM
 transgenic mouse model, activation of c-MYC leads to acute cell 
proliferation in -cells which is subsequently overwhelmed by apoptosis, results of 
which is hyperglycaemia, a main characteristic in diabetes. However, withdrawal of 
4-OHT leads to restoration of -cell mass in this transgenic animal model, which has 
been used to study -cell regeneration and source of new -cells. This thesis uses 
this transgenic animal model to study the early effects of c-MYC activation on 
-cells, and the discussion will be presented in this chapter. 
 
4.1 In silico analysis 
The targets of c-MYC are about 600 genes which regulate more than 15% of 
the expression of the genome. In view of the complexity of the c-MYC regulatory 
network, this thesis employed Affymetrix GeneChips to study the effects of early 
c-MYC activation and the treatment of exenatide. 
 
4.1.1. Early effects of c-MYC activation 
In the M
+
/E
-
 vs M
-
/E
-
 study, significantly differentially expressed genes were 
separated into two different clusters by k-means. Cluster 1 contained most of the 
up-regulated genes whereas cluster 2 consisted of the down-regulated genes. With 
regards to cluster 1, it is perhaps not surprising that many of the genes were related 
to the cell cycle because the early c-MYC activation triggers proliferation in the 
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plns-c-MycER
TAM
 transgenic mouse (Pelengaris et al., 2002b). As shown in 
Figure 3.1.3, c-MYC activation in early time point has already triggered complicated 
gene regulations and most of the regulated genes were located in the cytoplasm or 
nucleus. 
Mxi-1, Rad51, Atr and Ccne1 were up-regulated genes located in the nucleus. 
Mxi-1 encodes MXI1 or MAD2 (also called MXD2), which is regarded as a tumour 
suppressor that competes with the bHLH protein, MAX, with MYC (Ayer et al., 
1995; Grandori et al., 2000; Schreiber-Agus et al., 1995; Wechsler et al., 1996). 
Ccne1 encodes an important regulator in the cell cycle of the G1/S transition, 
cyclin E1, which activates with CDK2 and enables the hyperphosphorylation of RB 
(Geng et al., 1996; Lew et al., 1991; Zariwala et al., 1998). This pathway is also one 
of the well-known MYC-activated proliferation pathways. The Rad51 gene encodes 
RAD51, which is expressed in proliferating cells, especially in the S or S/G2 phase 
but the expression level is low in the G0/G1 (Chen et al., 1997; Xia et al., 1997; 
Yamamoto et al., 1996). RAD51 has also been reported in the DNA repair 
mechanisms by forming nucleoprotein filaments on single-stranded DNA (Baumann 
et al., 1996; Stark et al., 2002). Phosphoinositide 3-kinase related kinases (PIKKs), 
ATM, ATR, and DNA-PK are key factors involved in the DNA damage repair 
mechanism to maintain the genomic integrity by mediating cell cycle arrest in G1, S, 
or G2 phases (Bakkenist and Kastan, 2004; Bartek et al., 2004; Lukas et al., 2004; 
Shiloh, 2003). ATR kinase phosphorylates CHK1 in response to single strand DNA 
breaks (Abraham, 2001). Mini-chromosome maintenance (MCM) deficient genes 
Mcm2, Mcm4, and Mcm7 were also up-regulated because of MYC activation. MCM 
proteins are important in DNA replication-licensing by binding to origins of DNA 
replication before the S phase and at early G1 phase to unwind the template DNA 
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ahead of the replication fork (Bailis and Forsburg, 2004; Labib and Diffley, 2001; 
Lei, 2005). An overexpression/deregulation of MCM proteins has been observed in 
premalignant lesions and cancers (Bailis and Forsburg, 2004; Blow and Gillespie, 
2008). 
Ccnb1, Ccna2, and Chek1, located in cytoplasm, are important cell cycle 
related genes and were up-regulated as well. Cyclin B1 is one of the key regulators 
of cell cycle: it binds to CDC2 and activates downstream transcripts, and 
subsequently progresses the cell cycle from the G2 to the M phase (Jackman et al., 
2003; Jin et al., 1998; Pines and Hunter, 1991). Ccna2 encodes cyclin A2, which is 
another important protein in cell cycle in G1/S and G2/M transitions (Gong and 
Ferrell, 2010). The Chek1 gene encodes CHEK1, which is one of the subtypes of 
checkpoint kinases (Chks) and is activated by phosphorylation (Sanchez et al., 1997) 
and subsequently arrests the cell cycle in late S or G2 phases (Mailand et al., 2000; 
Peng et al., 1997). The genes Pdk1 (pyruvate dehydrogenase kinase, isoenzyme 1), 
Ptrh2 (peptidyl-tRNA hydrolase 2) and Hspd1 (heat shock protein 1 (chaperonin)) 
located in mitochondrion were also up-regulated. 
In cluster 2, as shown in Figure 1.3.4, Cdkn2b, Kdr and Figf were 
down-regulated through the experimental period after c-MYC activation. Cdkn2b is 
located on chromosome 9p21, next to Cdkn2a (encodes p16), and encodes a 
cyclin-dependent kinase inhibitor 2B (p15), which inhibits CDK4 (Sherr, 2004; 
Tycko, 2000). The cell proliferation after c-MYC activation can be confirmed by 
observing the inhibition of Cdkn2b in these array data. The suppression of this cell-
cycle inhibitory gene by MYC through the interaction with MIZ1 has also been 
discussed (Seoane et al., 2001; Staller et al., 2001). Kdr encodes two receptors for 
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vascular endothelial growth factor (VEGF), which is a major growth factor for 
endothelial cells (Liu and Ellis, 1998). Genes relating to mitochondria biogenesis 
were also observed in this analysis. Other array studies have also suggested the 
implication of c-MYC in the metabolic regulatory network (Li et al., 2005; Robson 
et al., 2011). 
 
4.1.2. Dynamic changes in islet-specific gene expression during 
exendatide treatment in vivo 
Early effects of exanatide treatment on c-MYC activation in mice, i.e. 
condition 1 (M
+
/E
+
 vs M
+
/E
-
) have been examined. The dynamic effects of exanatide 
treatment on islet gene expression in non-diabetic mice in vivo without activation of 
c-MYC in β-cells have also been presented, i.e. condition 2 (M-/E+ vs M-/E-). In 
condition 1, genes related to development were suppressed, such as Vegfa and 
Smad5. Suppression of Hsph1 and Hdac9 was also observed. Vegfa was shown as a 
hub gene to regulate multi-biological functions, such as endothelial cell migration, 
endothelial cell proliferation, ossification, apoptosis, endocytosis, positive regulation 
of mitosis, cell division, cell growth, neurogenesis, and transcription (Ferrara, 1999). 
During endocrine pancreatic islet development, inductive signals are produced by the 
blood vessel endothelium, such as VEGF (Lammert et al., 2001). After the endocrine 
pancreatic cells have been formed, they start to generate a certain level of VEGFs. 
Lammert et al. (2003) used the VEGF-A deleted transgenic pdx1-cre x VEGFloxP 
mice to demonstrate the loss of capillary network formation inside islets, thus 
effecting the optimized blood glucose regulation. The down-regulated Kdr in M
+
/E
-
 
vs M
-
/E
-
 group, also indicated a suppression of VEGF. Smad5 protein product has 
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been identified as a key component in transforming growth factor- (TGF-) 
signalling, which regulates cell proliferation, differentiation, recognition, apoptosis, 
and specification of developmental fate by binding to and bringing together type I 
and type II receptor serine/threonine kinases (Attisano and Wrana, 2002; Shi and 
Massague, 2003). SMAD proteins can be divided into three subgroups according to 
their functions: SMAD5 is the receptor-specific to SMAD proteins (R-SMAD), 
which are direct targets for the activated type I serine/threonine kinase receptors 
(Lutz and Knaus, 2002; Moustakas et al., 2001). In vitro and in vivo studies pointed 
out that SMAD5 is essential in developmental processes (Chang et al., 1999; Chang 
et al., 2001). Hsph1 encodes HSP (heat shock protein)105, which is one of the 
common HSPs in mammals (Ishihara et al., 1999).  It enhances apoptosis in response 
to oxidative stress (Yamagishi et al., 2002) or endoplasmic reticulum (ER) stress 
through caspase-3-dependent signallings in vitro (Meares et al., 2008). Hdac9 is 
required for HDACs, which represses transcriptional activities by catalyzing histone 
hypoacetylation, in the homologous recombination process (Kotian et al., 2011). 
In condition 2 (M
-
/E
+
 vs M
-
/E
-
), genes involved in growth-regulatory and 
metabolic pathways, such as Vdr and Vldlr, were differentially expressed. Wnt4 has 
been related to adipocyte differentiation (Nishizuka et al., 2008). Gna13, Lyve1, and 
Ccrn4l were up-regulated. Fkbp5, which is a co-chaperone of hsp90 and regulates 
glucocorticoid receptor (GR) sensitivity (Schiene-Fischer and Yu, 2001), was 
up-regulated. Btg3 is a member of the antiproliferative BTG (B-cell translocation 
gene)/TOB (transducer of ErbB2 gene) family (Matsuda et al., 2001). It carries out 
its antiproliferactive action by inhibiting the transcriptional factor E2F1 (Ou et al., 
2007).  
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Terf2, which encodes a telomere specific protein, TERF2, plays an important 
role in maintaining telomere length and structure (Chen et al., 2008; de Lange, 2002), 
was suppressed. Also, epigenetic genes, such as Hdac9, were found to be 
down-regulated. The protein encoded by Cited2 is a CBP/p300-binding transcription 
co-activator without typical DNA binding domains (Dunwoodie et al., 1998; Shioda 
et al., 1997). Cited2 has been suggested to have an important role in cell growth, 
malignant transformation, and hypoxia (Bhattacharya et al., 1999; Yin et al., 2002). 
In different cell types, apart from hypoxia, other biological stimuli can induce the 
expression of Cited2, such as IL-1a, -2, -4, -6, -9 and -11, granulocyte/macrophage 
colony-stimulating factor, interferon-g, platelet-derived growth factor, insulin, serum, 
and lipopolysaccharide (Bhattacharya et al., 1999; Sun et al., 1998). The analysis 
shows Cited2 was down-regulated. Based on microarray experiments in different cell 
lines, Cited2 was suppressed by TGF- (Chen et al., 2001; Kang et al., 2003; Luo et 
al., 2005). 
 
4.2 Effects of c-MYC activation in vivo 
This thesis presents the early effects of c-MYC activation to investigate the 
relationship between -cell proliferation and glucose homeostasis by manipulating 
the switchable plns-c-MycER
TAM
 transgenic mouse model. A transient 
hypoglycaemia has been confirmed in early c-MYC activation, which is presented in 
Figure 3.2.1. Figure 3.2.1 (C) shows hypoglycaemia after c-MYC activation at 
16 hours and it also exhibits a decrease in the glucose level back to euglycaemia at 
36 hours. This is most likely due to glucose counterregulation. After transient 
hypoglycaemia, the MYC-ON (plns-c-MycER
TAM
 mice treated with 4-OHT) group 
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became hyperglycaemic at 32 hours. This can be regarded as a rebound after 
hypoglycaemia because under stressful situations, the secretion of other hormones, 
for instance adrenaline, cortisol, and growth hormone, will be increased to maintain 
glucose concentration (Gerich, 1993). However, another explanation could be that 
the data were derived from a different group of mice, i.e. glucose levels at -4, 8, 20, 
and 32 hours were recorded in TL2 whereas glucose levels at 0, 12, 24, and 36 hours 
were recorded in TL1. Thus, there were two different groups of MYC-ON mice, and 
those in TL2 were experiencing hyperglycaemia at 32 hours whereas mice in TL1 
were just at the onset of high glucose levels.  
To further investigate the factors causing low glucose level in the early c-MYC 
activation, the energy expenditure and insulin level of objects were evaluated. The 
energy usage of WT (WT littermates treated with peanut oil), MYC-OFF 
(plns-c-MycER
TAM
 mice treated with peanut oil) and MYC-ON groups is presented in 
Figure 3.2.2.  A statistically detectable difference of energy usage was observed 
between WT and MYC-ON group throughout the whole experimental period, which 
was 28 hours. From the experiment shown in Section 3.2.1, the glucose levels of 
MYC-OFF and MYC-ON groups were lower than WT group (see Figure 3.2.1). If 
the energy usage during the experimental period accounts for the objects‘ glucose 
level, a difference of energy usage will be observed between the WT and MYC-OFF 
group as well because the glucose level of MYC-OFF was lower than WT. 
Furthermore, the energy usage of objects during the hypoglycaemic period, which 
was 8 to 20 hours, showed no significant difference within those three groups of 
mice. The results from Figure 3.2.2 (A) and Figure 3.2.2 (B) imply that the energy 
balance does not directly affect the glucose level although a trend of reducing energy 
usage was observed in MYC-ON group.  
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However, energy usage (by using food intake, faeces production and body 
weight) was simplified here: urine was not measured. Measurement of urine 
secretion is difficult because the urine will be absorbed by the litter quickly. If the 
litter has been removed and a grid floor is applied, the amount of urine production is 
still difficult to measure because it will have evaporated. Moreover, the measurement 
of urine might incur a systematic error because the polyuria in diabetic animals may 
lead to a decrease of body weight, which incurs errors in the energy expenditure. For 
future work, an indirect calorimetry system can be used so that energy expenditure 
and respiratory exchange can be obtained precisely (Arch et al., 2006).  
A physiological parameter, insulin level, was also measured and is shown in 
Figure 3.2.3, which confirms that c-MYC-induced hypoglycaemia resulted from 
hyperinsulinaemia because insulin secretion is based on GSIS and is expected to be 
near zero when hypoglycaemia happens. However, in Figure 3.2.3 (C) and (F) at 16 
and 20 hours, MYC-ON mice were hypoglycaemic with an acute insulin release, 
which points out an inappropriate insulin secretion because -cells were not able to 
turn off the insulin secretion under low glucose level (Schwartz et al., 1987). This 
experiment also confirmed c-MYC activation causes hyperinsulinaemic 
hypoglycaemia (HH) within 16 hours in MYC-ON mice. In normal situation, 
hyperinsulinaemia results in hypoglycaemia, which incurs hyperphagia because 
hypoglycaemia per se triggers hunger and increase food ingestion (Lotter and Woods, 
1977). However, this seems not to be the case because the MYC-ON mice did not 
have higher food ingestion during hypoglycaemia comparing to their WT or 
MYC-OFF littermates, as shown in Figure 3.2.2 (D). There are numerous factors that 
influence food intake, and one of the peripherally arising signals that is produced 
during the meal is the satiety signal from hormones, such as pancreatic islet 
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hormones (glucagon, amylin and insulin) and leptin from adipose tissue (Woods et 
al., 1998). However, insulin might reduce food intake after binding specific insulin 
receptor on hypothalamic neurons (Booth, 1968; Plum et al., 2005; Woods et al., 
1979 ). 
Hypoglycaemia caused by c-MYC activation may be caused by: (i) increased 
insulin secretion or release from dying cells; (ii) rapid -cell proliferation; and (iii) 
increased insulin sensitivity. This thesis further investigated the -cells‘ regulation 
by means of immuno-staining. The immunofluorescence staining of Ki-67 (see 
Figure 3.2.7) indicates that -cells were proliferating during the c-MYC-induced 
hypoglycaemia whereas no detectable fluorescent signals of Caspase-3 staining infer 
no apoptotic cells or a low number of apoptotic cells. Findings from the 
immnofluorescence staining suggest that the hypothesis of the passive release of 
insulin from apoptopic -cells seems an unlikely explanation of c-MYC-induced 
transient hypoglycaemia. 
In order to understand how c-MYC activation triggers hyperinsulinaemia, the 
-cell mass and volume were further evaluated in this thesis. As shown in 
Figure 3.2.3, the MYC-OFF and WT groups had similar serum insulin levels but the 
blood glucose level in the MYC-OFF group was lower than the WT group, even 
without the activation of c-MYC. It might be inferred that the transgenic mouse 
system has a residual level of c-MYC activation at a small but steady level even 
without the administration of 4-OHT; this is called ‗leakiness‘. This thesis has shown 
that the -cell mass of the MYC group was bigger than their WT littermates, which 
might explain why the MYC group had a lower glucose level to start with comparing 
to their WT littermates, although a bigger -cell mass does not directly relate to 
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higher insulin levels, which cause lower glucose levels. However, the -cell size 
result shows that after 16 hours of c-MYC activation, MYC-ON had a bigger -cell 
size, whereas there was no difference between MYC-ON and MYC-OFF. Apart 
from the bigger -cell size and mass, c-MYC activation might affect the insulin 
secretion signalling that caused dysfunction of insulin secretion. It should be noted 
that the increase of -cell size or a bigger -cell mass does not necessarily contribute 
to the increase of insulin level because normal -cells should be able to control the 
release of insulin to maintain glucose homeostasis. 
As regards to the insulin sensitivity measurement in this study, I did not have 
enough time to finish the quantifying of insulin action. A glucose tolerance test 
(OGTT) can be applied in future work to assess the insulin resistance in 
c-MYC-induced hypoglycaemic objects. 
The effect of exenatide on glucose homeostasis during hypoglycaemia has also 
been studied in this thesis. As shown in Figure 3.2.5, the exenatide treatment 
decreased the glucose level in both MYC-ON and MYC-OFF groups. During the 
c-MYC-induced hypoglycaemia, exenatide treatment decreased the glucose levels in 
the MYC-ON group, although there was no statistically detectable difference. 
However, the exenatide treatment did not prevent the c-MYC-induced 
hypoglycaemia either. An additional experiment was carried out on a further control 
group to observe the effect of exenatide on WT, and the glucose levels are presented 
in Figure 3.2.6, which shows a decreased glucose level after exenatide treatment. 
This finding is in conflict with the observation from literature, which suggests that 
exenatide can lower glucose level without causing hypoglycaemia.  
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4.3 Mathematical model 
The glycaemic homeostasis feedback loop operates on the ultradian time scale, 
whereas the adaptive changes in -cell mass happen on a days-to-months time scale. 
Therefore, the interplay between the blood glucose homeostasis feedback loop and 
the adaptive changes in -cell mass is a typical feature of endocrinological and 
neuroendocrinological regulation, where a slower adaptive feedback loop is 
superimposed on a faster feedback loop. The latter feedback loop is directly involved 
with a physiological system, whereas the former one regulates the level of activity in 
some manner, e.g. by controlling rates of transcription, translation, electrical activity 
(secretion), or number of endocrine cells (Brook and Marshall, 2001). Moreover, the 
dynamics of such systems usually exhibits a strongly non-linear character (Keener 
and Sneyd, 1998), which means that small variations in the precise time course of the 
fast processes (the temporal fine structure) can have a profound effect on the rates of 
change of the slow processes as was shown in Section 3.3.1. Time-scale separation 
can be a powerful tool to isolate a low-dimensional dynamical system modelling the 
slow adaptation process, which is relatively easy to analyse and visualise. A 
7-dimensional model was reduced to 1-dimensional dynamics, which is 
straightforward to analyse; indeed, as Figure 3.3.1 shows, in qualitative terms the 
system is much like logistic growth with an Allee effect. 
When Eqn (A 13) is evaluated, the causal relationships may be obscured. For 
example, in the present model, the rate of change of the -cell mass is dependent, in 
the direct, mechanistic sense of the word, on glucose and insulin, as the model‘s 
equations make specific. However, the time courses of glucose and insulin depend 
on the prevailing -cell mass, together with the input in , and as a result, in slow 
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time, the rate of change of the -cell mass depends on the -cell mass itself plus the 
input waveform, i.e., the rate of change in slow time is a functional of the input 
)(tin , as is clear from the integration over the fast-time scale cycle in Eqn (A13). In 
this way, the temporal fine structure is taken into account, in analogy to similar 
spatial homogenisation procedures (Holmes, 1995; Keener and Sneyd, 1998). 
This thesis assumes that rapid -cell mass compensation is driven by 
proliferation, based on the observation that -cells can be driven into cell cycle by 
activation of c-MYC (Pelengaris et al., 2002b) and data on recovery from partial 
pancreatomy (De Leon et al., 2003; Leahy et al., 1988; Pearson et al., 1977) and 
hyperglycaemic challenge, reviewed by Bouwens and Rooman (2005). However, 
another possibility is that -cells respond by adjusting the amount of 
hormone-producing machinery per cell (and thus, incidentally, cell volume) and that 
data concerning short-term changes in numbers of -cells are distorted by the fact 
that temporarily depleted cells (degranulated cells) are spuriously not counted as 
-cells. The relative importance of such non-proliferative adaptation, which possibly 
depends on the time scales and extend of challenge at hand, remains to be elucidated 
in detail; whereas hypertrophy was held to be the main mechanism for increases in 
-cell mass in human until the last decade (Nielsen et al., 1999; Weir et al., 2001), 
recent years have been a change in emphasis towards proliferation and neogenesis 
(Bouwens and Rooman, 2005; Lingohr et al., 2002; Pelengaris et al., 2002b). 
In the model considered here, all but one of the state variables was fast. The 
Sturis-Tolic model can be extended with further slow variables. One such variable 
might be the insulin sensitivity of the body‘s tissues, which plays a major role in the 
aetiology of T2DM (Salway, 1999). However, it seems obvious that a more precise 
132 
 
characterisation of neogenesis is essential to make progress: in particular, the 
maximum rate at which this pool can proliferate, as well as the rates at which it is 
restored (which may depend on the sources: -cells are transdifferentiated pancreatic 
cells) are likely to be critical to the ability of neogenesis to furnish the amount of 
new -cells required. The pathological fixed point, first noted and defined by Topp 
et al. (2000), becomes a prominent factor only when neogenesis is impaired, and, 
moreover, this pathological fixed point has a value that is dependent on the diet time 
course of the rate at which glucose is administered to the system. Whereas 
mathematical modelling can never replace the experiments that elucidate these 
processes, it can help to characterise the functional consequences of these findings 
along the lines outlined in this thesis. 
 A more robust model can be further built by combing experimental data 
obtaining from this thesis, such -cell mass, -cell number, and -cell size. -cell 
hypertrophy happens in the pre-diabetic stage of T2DM to compensate the demand 
of physiological changes. However, there is at present no mathematical model that 
considers the -cell size, to simulate the -cell regulation in diabetes. 
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Conclusion 
 -cells are able to adapt to different physiological conditions dynamically by 
changing their mass or function to maintain blood glucose levels in a narrow range. 
This thesis applied the plns-c-MycER
TAM
 transgenic mice to study the -cell 
physiology and glucose homeostasis in short term c-MYC activation by means of 
in vivo experiments, in silico microarray analysis, and a mathematical model. This 
thesis confirmed that the transient hypoglycaemia in the plns-c-MycER
TAM
 transgenic 
mice results from hyperinsulinaemia. Other factors, i.e. food intake and energy 
expenditure, which affect glucose levels were tested and discussed in this thesis. 
 This thesis investigated relationships between -cell physiology and glucose 
homeostasis by evaluating the -cell proliferation, apoptosis, mass and size. 
Proliferation and apoptosis in -cells in short term c-MYC activation were examined 
by using immunofluorescence staining of Ki-67 and Caspase-3. This thesis 
confirmed that in the plns-c-MycER
TAM
 transgenic mice, during the transient 
hypoglycaemia, -cells were proliferating and there was no detectable apoptosis. 
This finding concludes that the hyperinsulinaemia was not the result of passive 
release of insulin from apoptopic -cells. -cell mass and -cell size were evaluated 
by this thesis. Before the start of experiments, the transgenic mice had lower glucose 
levels compared to their WT littermates. Although the transgenic mice also had a 
higher -cell mass to start with comparing to their WT littermates, this is not directly 
linked with the higher insulin levels in the transgenic mice, which caused lower 
glucose levels. This might be explained by the slight leakiness of c-MYC which 
means the transgenic mouse system has a residual level of c-MYC activation at a 
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small but steady level even without the administration of 4-OHT. The -cell size 
evaluation result shows the transgenic mice had a larger -cell size compared to their 
WT littermates 16 hours after 4-OHT injection, although a bigger -cell size does 
not necessarily contribute to the increased insulin levels. 
The GLP-1 analogue, exenatide, has been widely used in controlling the glucose 
levels of diabetic patients because it is reported to lower the glucose levels without 
causing hypoglycaemia. However, in this in vivo experiment, the exenatide treatment 
of plns-c-MycER
TAM
 transgenic mice and their WT littermates incurs hypoglycaemia 
as well. Furthermore, the treatment of exenatide did not prevent the transient 
hypoglycaemia in 4-OHT administrated transgenic mice. This finding conflicts with 
the current studies and is worthy of further investigation of -cell physiology. 
In addition to in vivo experiments, this thesis applied in silico data to discuss the 
transient hypoglycaemia. Microarray analysis suggests that c-MYC activation 
triggers complicated gene regulatory networks, and most of these genes are 
up-regulated. The treatment of exenatide in the plns-c-MycER
TAM
 transgenic mice 
during the early c-MYC activation was also presented in this thesis. The study of 
exenatide treatment array analysis was shown and revealed the metabolically related 
genes. 
Finally, a theoretical mathematical model of glucose, insulin, and -cell 
dynamics was built and separated into a fast and slow system. The interplay between 
blood glucose and insulin levels behaves as a fast feedback loop. -cell mass 
changes in response to this endocinological regulation with a slower adaptive 
feedback loop, which is superimposed on a faster feedback loop. This thesis also 
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assumes that the rapid -cell mass compensation is driven by proliferation because 
of the activation of c-MYC. However, other non-proliferative adaptation factors 
remain to be investigated.  
It is proposed that further work should focus on: 
1) Combining experimental data with mathematical models; 
2) Using RT-PCR to confirm interested genes obtained from microarray 
analysis; 
3) A more detailed monitoring of energy usage, over a longer timescale; 
4) A glucose tolerance test to quantify the insulin sensitivity; 
5) A detailed analysis of -cell physiology of the exenatide treated mice. 
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Appendix A. Principles of the microarray experiments and 
microarray data analysis 
 
After the completion of genome sequencing of key model organisms and 
humans (Lander et al., 2001; Venter et al., 2001), the application of genomics has 
brought researchers from a single cellular function study to a molecular level. 
However, functional genomics is as important as it ever was, because sequences of 
DNA, hundreds of millions of bases long do not give information about what the 
genes do until further investigation. Many tools can be used for this purpose and 
microarray analysis is one of these high-throughput methods (Lockhart and Winzeler, 
2000). Researchers can observe the change of gene expression of a group of cells or 
a specific tissue on a small chip, which contains thousands of mRNA transcripts 
(also called the transcriptome), in a single experiment at a given time (Hayashizaki 
and Kawai, 2004). This section will describe the principles of microarray 
experiments (Section A.1) and microarray analysis procedure (Section A.2). 
 
A.1. Microarray experiments 
The first microarray platform was designed about 20 years ago (Pease et al., 
1994; Southern et al., 1992). More complicated array systems were developed with 
known or unknown transcripts that can be synthesized on a single chip and the gene 
expression levels can be analysed. cDNA (two-colour) microarray (Duggan et al., 
1999; Schena et al., 1995) and oligonuclotide (one-colour) microarray (Lipshutz et 
al., 1999; Lockhart et al., 1996) are two popular array chips of parallel hybridization 
assays. The main idea of these microarrays is to use the designed DNA probes on a 
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chip to measure, through hybridisation, the abundance of mRNA transcriptions from 
an experiment or a sample. Thousands of genes can be studied in parallel. The 
principles of these two assays are presented in Figure A.1.  In Figure A.1 (A), the 
basic idea of the two-colour microarray is presented, whereas an outline of the 
one-colour microarray is shown in Figure A.1 (B). The first step of both assays is 
extracting poly A mRNA from samples obtained from control (healthy) or treatment 
(disease) groups. The complementary DNA (cDNA) or cRNA will be generated 
subsequently in two-colour or one-colour microarray and labelled with fluorescent 
molecules, i.e. Cy3 (green) and Cy5 (red), or biotin nucleotides. The result 
interpretation for two-colour microarray is using the hybridization ratio of Cy3/Cy5 
to show the relative measurement, for example, if control is labelled by Cy3 and 
treatment is labelled by Cy5, a red fluorescence scanning result of a specific 
transcript indicates that the transcript of interest is up-regulated because of the 
treatment, whereas a green signal suggests the opposite. A yellow signal shows that 
the amounts of mRNA from two samples are the same. In one-colour microarray, the 
scanning result relates to the abundance of corresponding mRNA transcripts. 
162 
 
 
Figure A.1. Principle of DNA microarrays.  
(A) Outline of two-colour microarray. In the two-colour microarray assay, mRNA is extracted from 
two different samples, e.g. sample A stands for control/healthy whereas sample B stands for 
treatment/disease. This mRNA is subsequently annealed into single-strand of complementary DNA 
(cDNA), and labelled with one of the suitable fluorescent molecules, e.g. Cy3 (green) and Cy5 (red). 
The relative transcript abundance is estimated from the Cy5/Cy3 ratio using confocal fluorescence 
scanning and image processing after this fluorescent-labelled cDNA from two different samples are 
hybridized to a single array. If the amounts of mRNA from two samples are the same, the scanning 
result is yellow. A red scanning result indicates that the amount of mRNA in the Cy5 labelled sample 
is higher than that of the Cy3 labelled one whereas a green scanning result suggests the opposite. (B) 
Outline of one-colour microarray. The principles of one-colour microarray assay are similar to those 
of the two-colour assay but the former measures the absolute intensity after hybridization. Therefore, 
two separate chips are required for a single experiment to represent two different samples, e.g. 
control/healthy and treatment/disease. The one-colour microarray procedure starts with extracting 
mRNA from the sample and subsequently synthesizing double stranded cDNA from this mRNA. 
After the biotin-labelled nucleotides are incorporated, this complementary RNA (cRNA) is 
fragmented and hybridized to a chip. A staining step is followed by a wash step, and the cRNA 
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fragments are conjugated with streptavidin fluorescent dye. An absolute intensity is obtained after the 
scanning step. Comparison between different samples, e.g. treated vs untreated or disease vs healthy, 
is measured by assaying the intensity of probes across chips. 
 
Affymetrix (Santa Clara, CA) is a company that manufactures oligonucleotide 
microarrays, also called GeneChips. This high-density oligonucleotide expression 
array uses the length of 25 base pairs oligonucleotides to form a ‗probe‘. Because 
only a short region of target transcript will be formed by a probe, in order to ensure 
the gene specificity, around 11-20 probe pairs compose a ‗probe set‘, which is used 
to present a transcript. In each probe pair, not only the interested mRNA, but also a 
perfect match (PM) and a mismatch probe (MM), which is designed to measure the 
non-specific binding by replacing the 13
th
 base of the PM probe, will be presented 
(Lipshutz et al., 1999; Lockhart et al., 1996). This thesis uses the Affymetrix 
GeneChip to analyse gene expression because it can assay the absolute gene 
expression value, instead of the relative value, which is obtained from a two-colour 
array assay. 
164 
 
 
A.2. Microarray data analysis 
The intensity of scanning result is obtained from the fluorescent molecule after 
hybridisation onto Affymetrix GeneChips. It is assumed that the intensity of 
fluorescence is in proportion to the amount of cRNA that has bound to the 
corresponding probes on the array. Therefore, subtraction of fluorescence signals 
from the scanned image, which is stored in a file with suffix DAT by Affymetrix 
platform, is the first step to analyze microarray data by evaluating the pixels in each 
single probe, and this information will be stored in another file with suffix CEL 
(Arteaga-Salas et al., 2008). 
After the image processing step, the intensities of PM and MM are recorded in 
the CEL file. In order to remove the background from non-specific bindings, the 
probe-level summarisation is processed. The summarisation step produces a single 
value to represent a probe set after summarising the probe level values. A 
normalisation step is followed to remove the systematic errors across different array 
experiments to ensure different probe sets and arrays are comparable. Some of the 
common algorithms for data summarisation and normalisation are: Microarray Suite 
(MAS) 4.0 (Affymetrix, 1999), MAS 5.0 (Affymetrix, 2003), the model-based 
expression index (MBEI; Li and Wong, 2001), the robust multi-array analysis (RMA; 
Irizarry et al., 2003), and the GeneChip robust multi-array analysis (GC-RMA; Wu 
et al., 2004). MAS 4.0 and MAS 5.0 assume the average difference (AD) intensity 
value of a probe pair between PM and MM is linear with its corresponding RNA 
amount. In a given probe set, arrays i=1,…,I and probe pairs j=1,…,J , MAS 4.0 
models the AD by using JjMMPM ijiijij ,,1 ,   . The expression i  
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denotes the mean expression of the target probe set on array i with an probe-level 
error 
ji
 , which is assumed to have equal variance. MAS 5.0 further adjusts this 
model by using Tukey biweight (Hoaglin et al., 2000) and log transformation 
(Hubbell et al., 2002) to reduce the noise from the subtraction of PM, such as the 
negative numbers that might result after subtraction MM from PM. These data 
summarisation still may not be able to remove the noise, especially at low intensity 
(Irizarry et al., 2003); Li and Wong (2001) took the probe-specific affinity into 
account and introduced MBEI. 
Apart from those MM subtractive models, Irizarry et al. (2003) suggested a 
model, RMA, using the PM only to do the estimation. Non-specific binding is 
adjusted by introducing an additive background model. However, this global 
background adjustment model has a problem of a large false negative rate (Wu et al., 
2004), especially at low expression level probes. GC-RMA is proposed by Wu et al. 
(2004), and considers the probe-specific GC content to weigh the MM and adjust the 
background. 
To ensure the hybridisation of cRNA to the arrays has been sufficient. Several 
quality control steps can be carried out, e.g. rRNA ratio (28S/18S) and RNA 
integrity numbers (RIN) are used for RNA intactness assessment (Schroeder et al., 
2006). RNA is degraded by ubiquitous RNase enzymes, and the RIN, which is 
scored from 1 to 10 where 10 refers to an intact RNA whereas 1 refers to the 
opposite, is used as a criterion to judge mRNA quality.  
Gene curation is the next step in selecting differentially expressed genes. After a list 
of genes has been selected, the next step is to interpret these differentially regulated 
genes in terms of biological phenomena. Gene Ontology (GO) was proposed to 
annotate biological data, such as sequences, genes or gene products, with controlled 
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and structured vocabularies (Harris et al., 2004). Several tools have been proposed to 
use an automatic ontological analysis to help the functional analysis of high 
throughput experiments, such as Onto-Express, GoMiner, DAVID, EASEonline, 
GeneMerge, FuncAssociate, GOTM, FatiGO, CLENCH, GOstat, GOToolBOX, 
GoSurfer, Ontology Traverser, and eGOn (Khatri and Draghici, 2005). The 
ontological analysis can be performed by various statistical models, such as the 
hypergeometric (Cho et al., 2001b), the binomial, the χ2 (chi-square), and the 
Fisher‘s exact test (Khatri and Draghici, 2005). Using a standard hypergeometric 
distribution, the probability of a random subset of x genes drawn from the total set of 
N genes will have y or more entities containing a given GO term can be estimated. 
However, if the threshold for statistical significance in a given experiment is α=0.05, 
we can expect to find a false positive for every 1 out of 20 tests. Thus thousands of 
genes may incur hundreds of false positive results. In order to correct the false 
positive rate, multiple testing corrections can be applied to adjust p-values derived 
from multiple statistical tests (Dudoit et al., 2003). 
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Appendix B. Method to analyze time scale physiological 
interactions in endocrine regulation systems 
The dynamics of a physiologically endocrine regulation system can be 
presented in the following equation: 
), ,( uxfx 
dt
d
       (A1) 
where x is the output of the system, u is the external input, and f is the system‘s 
dynamics. Output variables in x and input variables u are assumed to be 
non-dimensionalised, so the time t is the only unit bearing quantity in this system. 
The input u(t) is assumed to be a period function of time with period T. In this thesis, 
the system was decomposed into two distinct systems of lower dynamic dimension 
and these two systems may be studied independently of one another. The idea is to 
construct the slow dynamic that is specific to the fast-scale regime as a map, so that 
the characters of the dynamic affect the dynamics at the slow time scale can be kept. 
In a physiological system, it is natural to have constrains on the rate of changes. 
Therefore, for each of the n state variables, the dynamics of xi satisfies a finite 
positive number ξi 
,) ,(  iif ux       (A2) 
as x and u are the presentation of physiological associating values. Without loss of 
generality, the state variables can be ordered so that 
.021  n        (A3) 
Scaling of the fi with respect to the corresponding ξ results in 
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), ,(* uxfξx 
dt
d
      (A4) 
where ξ is a diagonal matrix with the ξi on its main diagonal and fi
*
 is a 
dimensionless quantity which satisfies 1* f . This thesis is going to discuss some 
of the variables are ―rapid‖, i.e. oscillate on a time scale of order T, and others are 
―slow‖. So it is considered that nT  
1
1  and assumed that there exists an 
n such that ξiT is a small parameter for ni  . Eqn (A5) represents the 
separation of time scales. 
)),(())(),(()( ]1[]0[ tttt  xxx       (A5) 
where x
[0]
 refers to the fast component depending on a fast time φ and a slow time τ, 
whereas x
[1]
 refers to the slow component depending on the slow time τ only. 
Eqn (A6) and (A7) define these two times. 
,






T
t
T
t
        (A6) 
,






T
t
T        (A7) 
where  x  denotes the largest integer smaller than or equal to x. The input is 
decomposed into Eqn (A8). 
)).(())(),(()( ]1[]0[ tttt  uuu       (A8) 
Eqn (A9) follows the fast dynamics so that the integration of this equation is from 
φ=0 to φ=1- subject to initial condition x[0]=0 at φ=0. 
).,;,( ]1[]1[]0[]0[]0[ uxuxfξx *


T

     (A9) 
Then define the following differential for T  and ni   , , : 
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
)/(
0
]1[]1[]0[]0[]1[ .),;,(*),(
T
ii duxuxfTdx

   (A10) 
Dividing Eqn (A10) by η and specifying for T  , this becomes: 

1
0
]1[]1[]0[]0[*
]1[
,),;,(
),(





duxuxf
ξT
dx ii    (A11) 
for ni   , ,1  . In the limit 0T , the following expressions are exact: 
1,- , 1,for     ),;,( ]1[]1[]0[]0[*
]0[
νifTx
d
d
ii  uxux

  (A12) 
, ,  ,for     ),;,(
1
0
]1[]1[]0[]0[]1[ nνidx
d
d i
i   

 
uxux   (A13) 
where for i , it has 0]0[ ix  and the operator )/(   has been replaced by 
without impunity since φ is restricted to the interval [0, 1]. If ) , ,( ]1[]1[]1[ nxxx   then 
for i , it follows that )( ]1[]1[  xXx ii , where ))( , ),((
]1[
1
]1[
1   xXxX   is a 
parametrical representation of the slow manifold of the dynamics of the system. This 
slow manifold satisfies the condition that ) ,1() ,0( ]0[]0[  ii xx   for all  1 ,1  i , 
which means that the fast variables move through a forced limit cycle of period T. 
The slow manifold can be varying in slow time τ. 
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Appendix C. Differentially expressed transcripts in M
+
/E
-
 vs 
M
-
/E
-
 
 
The full differentially expressed transcripts list of M
+
/E
-
 vs M
-
/E
-
 is given in this 
appendix. 
Probe Set ID Gene Symbol 
Corrected 
p-value 
Fold change ratio (Treatment/Control) at different time points 
Ref_seq_id 
4 8 16 32 
1419238_at Abca7 3.81E-03 -1.61  -2.71  -1.25  -2.80  NM_013850 
1450721_at Acp1 3.43E-03 1.27  1.39  2.05  1.31  
NM_001110239 /// 
NM_021330 
1435605_at Actr3b 2.29E-03 3.44  2.70  1.71  2.93  NM_001004365 
1435923_at Ado 8.22E-03 1.91  1.61  1.64  2.05  NM_001005419 
1418372_at Adsl 6.36E-03 1.88  2.79  1.64  2.24  NM_009634 
1434287_at Agpat5 1.64E-03 3.27  2.41  2.67  2.05  NM_026792 
1424712_at Ahctf1 7.59E-03 2.80  1.37  1.10  2.95  NM_026375 
1451459_at Ahctf1 8.00E-03 3.51  1.45  1.95  2.98  NM_026375 
1441320_a_at AI413194 4.52E-03 -1.15  -2.39  -1.92  -2.75   
1434266_at AI847670 3.20E-03 2.18  2.67  2.18  2.09  NM_177869 
1448450_at 
Ak2 /// 
LOC100047005 
1.28E-03 2.74  2.98  1.17  1.81  
NM_001033966 /// 
NM_016895 /// 
XM_001477790 
1450387_s_at 
Ak3l1 /// 
LOC100047616 
1.76E-03 4.00  4.81  -1.11  4.98  
NM_009647 /// 
XM_001478522 
1433669_at Akap8 8.65E-03 2.76  2.04  -1.15  1.50  NM_019774 
1437133_x_at Akr1b3 2.40E-03 2.50  2.50  -1.07  2.11  NM_009658 
1456590_x_at Akr1b3 7.09E-04 2.41  1.96  1.38  2.62  NM_009658 
1434721_at Ankle2 1.95E-03 -1.82  -2.20  -2.34  -2.38  NM_027922 
1437217_at Ankrd6 2.13E-03 9.13  2.55  1.39  8.49  
NM_001012450 /// 
NM_001012451 /// 
NM_080471 
1434555_at Anp32a 4.79E-03 2.21  1.59  1.01  1.57  NM_009672 
1451703_s_at Aprt 4.63E-03 1.62  1.74  2.23  2.18  NM_009698 
1425914_a_at Armcx1 1.49E-03 -2.93  -4.29  -1.44  -3.65  NM_030066 
1422609_at Arpp19 4.60E-03 1.96  2.89  1.94  2.44  
NM_001142655 /// 
NM_021548 
1422461_at Atad3a 7.46E-04 3.29  2.38  1.93  2.69  NM_179203 
1437343_x_at Atad3a 6.05E-04 4.70  3.90  1.57  2.23  NM_179203 
1438178_x_at Atad3a 3.87E-04 3.97  4.07  1.24  2.35  NM_179203 
1427197_at Atr 6.05E-04 2.57  4.41  1.58  2.96  NM_019864 
1433663_s_at AU014645 6.74E-03 2.52  1.34  1.40  1.64  NM_001033201 
1424546_at BC003965 8.70E-03 3.18  1.27  1.25  1.46  
XM_128528 /// 
XM_914663 
1451541_at Bcs1l 8.55E-03 1.98  2.00  3.68  2.03  NM_025784 
1438961_s_at Blmh 6.64E-03 2.27  3.85  -1.00  1.47  NM_178645 
1447679_s_at Bms1 6.69E-04 1.89  2.05  1.08  1.37  NM_194339 
1434543_a_at Bola2 1.53E-03 1.70  2.97  2.01  1.33  NM_175103 
1434545_x_at Bola2 2.64E-03 1.57  2.42  2.71  1.71  NM_175103 
1423264_at Bop1 7.70E-03 2.86  3.94  2.50  4.55  NM_013481 
1419046_at Brp16 3.68E-03 2.87  3.13  1.59  2.55  NM_021555 
1456738_s_at Brp16 1.52E-03 3.17  3.67  -1.01  2.34  NM_021555 
1450742_at Bysl 5.04E-03 2.17  2.94  1.58  1.81  NM_016859 
1423456_at Bzw2 7.56E-04 6.42  2.83  3.88  6.86  NM_025840 
1439027_at C330023M02Rik 2.64E-03 2.26  2.45  -1.07  1.65  NM_172722 
1440910_at C77370 5.87E-03 3.97  3.37  1.29  2.50  NM_001077354 
1424533_a_at Ccdc137 1.38E-03 4.77  2.21  -1.13  3.01  NM_152807 
1459840_s_at Ccdc28b 1.62E-03 -2.76  -2.25  -2.25  -3.47  NM_025455 
1417910_at Ccna2 9.67E-04 -1.08  4.82  11.07  3.21  NM_009828 
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1448205_at Ccnb1 2.37E-03 1.09  3.82  9.56  3.63  NM_172301 
1416492_at Ccne1 1.76E-03 2.10  4.16  5.80  1.28  NM_007633 
1441910_x_at Ccne1 2.08E-03 1.93  8.88  1.74  1.60  NM_007633 
1422535_at Ccne2 4.52E-03 2.17  8.20  6.32  5.70  
NM_001037134 /// 
NM_009830 
1417131_at Cdc25a 4.22E-03 2.55  2.19  1.49  3.07  NM_007658 
1417132_at Cdc25a 7.24E-03 2.29  2.07  1.24  1.76  NM_007658 
1452040_a_at Cdca3 5.88E-03 -1.08  1.05  5.51  1.10  NM_013538 
1416802_a_at Cdca5 5.65E-03 -1.42  22.18  21.74  8.58  NM_026410 
1449152_at Cdkn2b 1.34E-04 -2.39  -2.21  -1.56  -2.39  NM_007670 
1424143_a_at Cdt1 6.36E-03 5.79  24.94  11.12  6.83  NM_026014 
1418264_at Cenpk 5.88E-03 1.14  7.33  15.96  3.49  
NM_021790 /// 
NM_181061 
1436034_at Cep68 3.62E-03 2.73  2.38  -1.22  2.49  NM_172260 
1456325_at Cep68 7.28E-03 1.75  1.81  -1.14  2.30  NM_172260 
1417233_at Chchd4 5.35E-03 1.81  2.04  1.50  2.29  NM_133928 
1449708_s_at Chek1 5.87E-03 2.69  6.39  4.48  4.69  NM_007691 
1423884_at Cirh1a 7.56E-04 2.95  1.98  1.69  4.26  NM_011574 
1416698_a_at Cks1b 9.27E-04 1.52  3.58  3.15  2.45  NM_016904 
1417457_at Cks2 7.14E-03 -1.24  3.77  8.09  6.65  NM_025415 
1434866_x_at Cpt1a 3.38E-03 -1.60  -2.59  -2.42  -1.45  NM_013495 
1415948_at Creg1 3.87E-03 2.13  2.39  1.48  1.79  NM_011804 
1435800_a_at Csda 1.04E-03 2.51  2.14  1.37  2.72  
NM_011733 /// 
NM_139117 
1451012_a_at Csda 3.59E-03 4.95  2.28  2.39  5.30  
NM_011733 /// 
NM_139117 
1448809_at Cse1l 2.72E-03 1.98  2.93  2.48  2.24  NM_023565 
1419645_at Cstf2 3.85E-03 2.09  1.94  1.54  2.45  NM_133196 
1416563_at Ctps 2.89E-04 2.66  3.35  1.97  2.17  NM_016748 
1422484_at Cycs 5.16E-03 1.29  2.15  1.54  2.02  NM_007808 
1417071_s_at Cyp4v3 6.30E-04 -1.12  -3.00  -2.28  -2.50  NM_133969 
1454659_at Dctd 5.58E-05 4.60  3.06  2.33  4.08  NM_178788 
1448271_a_at Ddx21 7.73E-03 1.91  1.83  -1.03  2.00  NM_019553 
1448619_at Dhcr7 5.69E-03 2.57  3.10  1.13  1.51  NM_007856 
1428267_at Dhx40 6.36E-03 -2.04  -2.19  1.64  -2.12  NM_026191 
1426609_at Dis3 4.06E-03 3.54  2.58  1.90  4.32  NM_028315 
1426265_x_at Dlat 8.21E-03 1.03  2.28  1.69  2.60  NM_145614 
1417182_at Dnaja2 8.55E-03 2.10  2.02  1.50  1.44  NM_019794 
1433880_at Dnajc11 2.94E-03 3.00  2.17  1.34  2.54  NM_172704 
1428087_at Dnm1l 5.35E-03 1.82  1.75  1.21  3.76  
NM_001025947 /// 
NM_152816 
1459973_x_at Dpp4 6.36E-03 -1.21  -1.98  -2.71  -4.33  
NM_001159543 /// 
NM_010074 
1423767_at Dpy30 8.15E-03 1.17  1.94  2.18  2.00  
NM_001146222 /// 
NM_001146223 /// 
NM_001146224 /// 
NM_024428 
1436301_at Dstyk 6.89E-03 -1.50  -3.23  -1.04  -3.14  NM_172516 
1424697_at Dtwd1 2.29E-03 3.51  1.62  1.74  2.57  NM_026981 
1435734_x_at Dus1l 2.64E-03 3.03  2.54  -1.08  1.25  NM_026824 
1424229_at Dyrk3 1.62E-03 1.80  1.21  4.53  2.77  NM_145508 
1454963_at E430028B21Rik 7.70E-03 2.85  3.28  1.30  3.07  NM_178668 
1440338_at E430028B21Rik 9.02E-03 1.97  1.38  1.11  2.02  NM_178668 
1449044_at Eef1e1 7.46E-04 3.26  2.75  5.25  8.83  NM_025380 
1437829_s_at Eef2k 2.13E-03 3.26  3.26  -1.52  2.42  NM_007908 
1456107_x_at Eftud2 1.20E-03 2.24  3.14  1.02  1.96  
NM_001109995 /// 
NM_011431 
1416021_a_at EG620603 /// Fabp5 5.04E-03 3.64  2.87  1.81  4.34  
NM_010634 /// 
XR_031387 
1424343_a_at Eif1a 7.91E-03 1.28  1.63  2.21  1.51  NM_010120 
1424344_s_at Eif1a 7.09E-04 1.92  3.30  1.35  1.84  NM_010120 
1426394_at Eif3j 5.78E-03 1.93  1.85  1.74  2.69  NM_144545 
1426395_s_at Eif3j 2.73E-03 1.58  1.85  1.56  2.85  NM_144545 
1423220_at Eif4e 4.57E-04 2.86  2.75  1.54  2.11  
NM_007917 /// 
XM_001004193 
1450908_at Eif4e 2.73E-03 1.95  2.84  2.07  4.23  
NM_007917 /// 
XM_001004193 
1435803_a_at Eif4e2 8.87E-03 1.50  2.15  1.40  1.62  
NM_001039169 /// 
NM_001039170 /// 
NM_023314 
1434976_x_at Eif4ebp1 1.65E-03 3.47  3.78  1.25  2.12  NM_007918 
1428477_at Elac2 5.54E-03 3.18  1.32  1.12  2.14  NM_023479 
1417403_at Elovl6 6.94E-05 3.10  4.60  2.47  5.50  NM_130450 
1417404_at Elovl6 5.41E-05 3.49  3.28  2.74  2.99  NM_130450 
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1421097_at Endog 1.07E-03 2.79  3.90  1.74  2.44  NM_007931 
1438317_a_at Endog 1.03E-03 2.79  3.74  1.27  1.68  NM_007931 
1450380_at Epdr1 3.87E-04 2.47  2.35  2.89  5.04  NM_134065 
1420024_s_at Etf1 3.06E-03 2.16  2.73  1.16  1.66  NM_144866 
1452012_a_at Exosc1 1.62E-03 2.72  2.68  1.18  2.60  NM_025644 
1435544_at Exosc6 2.81E-03 3.18  5.31  1.36  3.43  NM_028274 
1435076_at Fam57a 5.60E-05 2.91  2.42  1.66  2.80  NM_027773 
1423828_at Fasn 4.63E-03 2.62  3.52  1.98  2.28  NM_007988 
1435369_at Fastkd5 5.07E-03 2.16  3.19  1.73  2.37  
NM_001146084 /// 
NM_198176 
1419577_at Fig4 6.60E-05 4.28  3.52  1.35  6.03  NM_133999 
1438953_at Figf /// LOC100047108 2.64E-03 -1.01  -2.51  -1.01  -1.01  
NM_010216 /// 
XM_001477393 
1438167_x_at Flcn 4.66E-03 -2.11  -2.58  -1.08  -2.06  NM_146018 
1422801_at G3bp1 2.70E-03 1.62  2.00  1.30  1.78  NM_013716 
1441911_x_at Gart 5.42E-03 1.97  2.37  1.29  2.31  NM_010256 
1432164_a_at Gcsh 1.51E-03 2.24  1.65  1.43  1.57  NM_026572 
1424300_at Gemin6 1.62E-03 1.78  2.20  5.22  2.23  NM_026053 
1451400_at Gemin8 5.69E-03 2.02  1.95  1.78  2.04  NM_146238 
1435245_at Gls2 1.87E-05 9.89  6.97  5.23  5.61  NM_001033264 
1428784_at Gmip 9.02E-03 9.99  5.18  -1.47  10.74  NM_198101 
1439489_at Gpr120 6.95E-04 4.97  2.28  2.11  3.21  NM_181748 
1455841_s_at Grwd1 3.75E-03 3.56  2.42  -1.15  2.12  NM_153419 
1448704_s_at H47 7.54E-03 -1.74  -1.29  1.01  -2.29  NM_024439 
1438510_a_at Hars 6.89E-03 1.53  2.02  1.16  1.48  NM_008214 
1428823_at Hddc2 2.23E-03 1.94  2.01  1.54  1.53  NM_027168 
1419964_s_at Hdgf 2.48E-03 1.66  1.82  2.07  2.08  NM_008231 
1436050_x_at Hes6 8.87E-03 3.11  2.26  -1.02  3.01  NM_019479 
1416101_a_at Hist1h1c 5.63E-03 -1.78  -3.16  -1.17  -1.80  NM_015786 
1434736_at Hlf 1.51E-03 3.37  3.66  -1.15  3.49  NM_172563 
1416184_s_at Hmga1 5.16E-03 2.73  3.09  1.99  3.98  
NM_001025427 /// 
NM_001039356 /// 
NM_016660 
1450156_a_at Hmmr 3.39E-05 -1.11  1.02  8.41  -1.06  NM_013552 
1438988_x_at Hn1 2.89E-04 4.29  3.72  1.13  2.77  NM_008258 
1448180_a_at Hn1 3.42E-03 5.35  5.96  2.57  4.82  NM_008258 
1431349_at Hnrnpab 4.26E-03 2.10  1.89  1.93  1.34  
NM_001048061 /// 
NM_010448 
1455120_at Hpdl 1.84E-03 2.86  2.23  1.04  4.30  NM_146256 
1450047_at Hs6st2 7.82E-03 1.20  1.54  2.44  3.25  
NM_001077202 /// 
NM_015819 
1434642_at Hsd17b11 6.95E-04 -1.83  -2.09  -1.54  -2.02  NM_053262 
1416968_a_at Hsd3b7 1.62E-03 2.57  3.12  1.19  2.93  
NM_001040684 /// 
NM_133943 
1426351_at Hspd1 7.32E-03 1.31  1.84  2.45  2.63  NM_010477 
1426705_s_at Iars 6.21E-03 1.62  1.28  2.01  1.42  NM_172015 
1435140_at Ide 5.16E-04 2.21  2.09  1.83  1.80  NM_031156 
1422501_s_at Idh3a 8.09E-03 1.54  1.66  1.87  2.22  NM_029573 
1432016_a_at Idh3a 2.73E-03 1.38  1.66  2.11  2.96  NM_029573 
1451775_s_at Il13ra1 8.35E-03 1.96  -1.03  1.38  2.66  NM_133990 
1453784_at Ilkap 7.09E-04 1.15  1.13  2.20  1.27  NM_023343 
1426213_at Imp4 2.37E-03 2.77  2.90  2.16  2.94  NM_178601 
1426858_at 
Inhbb /// 
LOC100046802 
7.70E-03 -1.01  -1.01  4.05  -1.06  
NM_008381 /// 
XM_001476835 
1456200_at Ipmk 2.29E-03 3.31  1.16  1.66  1.53  NM_027184 
1426946_at Ipo5 6.33E-03 2.68  2.61  2.78  4.82  NM_023579 
1450084_s_at Ivns1abp 6.16E-03 2.06  1.98  1.47  1.42  
NM_001039511 /// 
NM_001039512 /// 
NM_054102 
1460676_at Josd1 1.31E-04 3.70  2.97  1.66  3.08  NM_028792 
1457587_at Kcnq5 3.85E-03 4.60  4.82  -1.05  7.23  
NM_001160139 /// 
NM_023872 
1434154_at Kctd13 5.42E-03 1.39  1.26  1.10  2.56  NM_172747 
1449379_at Kdr 7.70E-03 -2.26  -1.82  -2.72  -2.20  NM_010612 
1450386_at Kpna3 5.28E-03 1.35  3.25  2.04  1.80  NM_008466 
1448526_at Kpnb1 8.89E-03 1.36  2.41  1.84  1.25  NM_008379 
1455434_a_at Ktn1 1.94E-03 3.37  1.51  2.11  3.28  NM_008477 
1438633_x_at Lasp1 1.41E-03 -2.71  -2.55  -1.34  -1.53  NM_010688 
1438634_x_at Lasp1 1.41E-03 -2.83  -2.38  -1.56  -2.14  NM_010688 
1455470_x_at Lasp1 8.22E-03 -3.22  -2.40  -1.37  -1.48  NM_010688 
1456309_x_at Lasp1 9.21E-03 -2.52  -1.41  -1.32  -1.49  NM_010688 
1438977_x_at LOC100045999 /// Ran 4.91E-03 1.50  1.34  1.51  2.07  
NM_009391 /// 
XM_001475422 
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1452226_at 
LOC100047340 /// 
Rcc2 
5.88E-03 2.87  2.62  -1.02  8.23  
NM_173867 /// 
XM_001477942 
1433842_at Lrrfip1 2.73E-03 4.45  4.11  1.01  4.45  
NM_001111311 /// 
NM_001111312 /// 
NM_008515 
1432431_s_at Macrod2 7.18E-03 1.33  1.70  2.15  2.30  
NM_001013802 /// 
NM_028387 
1415928_a_at Map1lc3b 3.31E-04 -1.72  -2.15  -1.16  -1.36  NM_026160 
1452798_s_at Mapk1ip1 8.57E-03 -1.74  -2.06  -1.25  -1.24  
NM_001045483 /// 
NM_027115 
1433576_at Mat2a 5.42E-03 3.21  2.98  -1.44  2.05  NM_145569 
1438386_x_at Mat2a 2.93E-03 2.17  1.81  -1.24  1.79  NM_145569 
1438630_x_at Mat2a 6.95E-04 2.49  2.50  -1.22  1.87  NM_145569 
1438976_x_at Mat2a 5.16E-04 2.58  2.64  -1.25  1.85  NM_145569 
1456702_x_at Mat2a 1.62E-03 2.57  2.07  -1.19  1.93  NM_145569 
1434079_s_at Mcm2 1.66E-03 1.84  4.18  2.56  3.05  NM_008564 
1436708_x_at Mcm4 4.85E-03 2.10  8.25  1.43  2.69  NM_008565 
1436808_x_at Mcm5 7.63E-03 4.34  28.35  2.00  9.02  NM_008566 
1438320_s_at Mcm7 1.62E-03 2.81  5.93  3.11  3.61  NM_008568 
1439269_x_at Mcm7 1.45E-03 2.40  7.40  2.73  3.72  NM_008568 
1429911_at Mcph1 8.65E-03 2.71  2.60  1.67  2.24  NM_173189 
1460050_x_at Mettl13 3.87E-04 3.17  1.97  -1.02  2.38  NM_144877 
1455529_at Mex3a 7.39E-03 1.51  2.64  1.02  1.45  NM_001029890 
1424001_at Mki67ip 3.52E-03 2.23  1.80  1.72  2.80  NM_026472 
1416313_at Mllt11 5.14E-03 2.32  3.06  2.46  3.38  NM_019914 
1435232_x_at Mrpl15 2.31E-03 2.20  1.97  1.67  2.90  NM_025300 
1416349_at Mrpl34 2.73E-03 2.39  2.00  1.99  3.07  NM_053162 
1449194_at Mrps25 1.84E-03 1.77  2.56  1.26  1.55  NM_025578 
1433878_at Mrps26 1.76E-03 1.97  2.01  2.54  1.81  NM_207207 
1427158_at Mrps30 7.09E-04 2.13  1.91  1.25  2.80  NM_021556 
1424425_a_at Mtap 1.04E-04 3.17  3.38  1.26  2.74  NM_024433 
1424426_at Mtap 1.10E-03 6.30  5.80  1.24  3.51  NM_024433 
1451346_at Mtap 1.62E-03 3.05  2.91  1.33  3.78  NM_024433 
1456653_a_at Mthfd1l 2.47E-03 3.16  1.45  1.62  4.59  NM_172308 
1434278_at Mtm1 3.83E-04 5.67  9.10  3.98  8.94  NM_019926 
1452110_at Mtrr 8.02E-04 4.28  5.67  1.77  2.59  NM_172480 
1450376_at Mxi1 2.93E-03 2.36  1.42  2.52  4.78  
NM_001008542 /// 
NM_001008543 /// 
NM_010847 
1449072_a_at N6amt2 1.15E-03 1.28  2.13  1.98  1.74  NM_026526 
1452192_at Naf1 5.58E-05 5.70  4.67  1.65  4.73  
XR_032374 /// 
XR_032626 
1420477_at Nap1l1 4.44E-03 1.90  1.68  2.20  1.68  
NM_001146707 /// 
NM_015781 
1436707_x_at Ncaph 6.21E-03 -2.35  7.60  20.88  3.76  NM_144818 
1415772_at Ncl 1.86E-04 2.70  3.47  1.38  1.76  NM_010880 
1433205_at Ndfip2 6.96E-03 1.09  -2.50  -1.03  -1.03  NM_029561 
1427997_at Ndufaf4 3.69E-04 2.33  2.26  1.12  2.39  NM_026742 
1416972_at Nhp2l1 7.56E-04 2.31  2.37  1.70  1.88  NM_011482 
1416973_at Nhp2l1 2.91E-03 1.91  2.11  2.05  1.76  NM_011482 
1437238_x_at Nmd3 1.41E-04 2.24  1.84  2.06  3.77  NM_133787 
1430530_s_at Nmral1 4.04E-03 2.36  4.58  4.56  3.57  NM_026393 
1438095_x_at Noc4l 9.67E-03 2.86  3.35  1.25  2.49  NM_153570 
1443794_x_at Noc4l 7.54E-03 2.76  2.38  1.20  2.38  NM_153570 
1428870_at Nolc1 2.12E-03 4.89  3.42  2.01  4.16  
NM_001039351 /// 
NM_001039352 /// 
NM_001039353 /// 
NM_053086 
1424620_at Nop16 8.86E-04 3.20  2.31  1.95  6.32  NM_178605 
1424019_at Nop2 3.46E-03 1.90  2.39  1.27  2.52  NM_138747 
1426533_at Nop56 3.88E-03 2.06  4.74  1.66  3.90  NM_024193 
1455035_s_at Nop56 1.34E-04 3.19  3.14  2.89  2.52  NM_024193 
1423850_at Nsun2 5.88E-03 3.12  1.72  5.57  3.32  NM_145354 
1434216_a_at Nudt19 1.18E-03 3.20  2.58  1.42  3.00  NM_033080 
1448651_at Nudt5 5.88E-03 1.55  1.88  2.37  3.16  NM_016918 
1450111_a_at Nudt8 7.18E-03 1.75  1.95  2.13  2.47  NM_025529 
1438951_x_at Nup54 1.62E-03 1.87  3.51  1.27  1.65  NM_183392 
1416073_a_at Nup85 7.09E-04 3.33  6.81  4.49  5.34  NM_001002929 
1437520_a_at Nup85 1.11E-04 3.13  6.64  1.61  2.42  NM_001002929 
1449017_at Nutf2 4.31E-03 1.51  1.50  2.04  1.30  NM_026532 
1427364_a_at Odc1 1.27E-03 1.99  2.93  1.29  1.78  NM_013614 
1418225_at Orc2l 3.06E-03 2.28  2.01  1.33  2.31  
NM_001025378 /// 
NM_008765 
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1417037_at Orc6l 9.78E-03 2.17  2.22  1.98  2.66  NM_019716 
1420142_s_at Pa2g4 4.79E-03 2.30  6.21  1.33  1.57  NM_011119 
1450854_at Pa2g4 1.66E-03 2.34  4.59  2.06  1.97  NM_011119 
1423564_a_at Paics 5.16E-03 1.57  1.38  2.40  2.45  NM_025939 
1423766_at Pak1ip1 2.18E-03 2.40  1.45  1.35  2.02  NM_026550 
1421989_s_at Papss2 3.47E-03 -2.29  -5.58  -1.02  -4.27  NM_011864 
1434510_at Papss2 8.17E-03 -1.85  -9.15  1.17  -3.70  NM_011864 
1448627_s_at Pbk 2.40E-03 -1.30  4.18  18.83  3.28  NM_023209 
1424081_at Pcgf6 8.02E-05 2.35  2.28  2.40  2.42  NM_027654 
1426981_at Pcsk6 6.62E-04 2.59  1.94  5.45  4.84  
XM_355911 /// 
XM_886136 /// 
XM_905687 /// 
XM_919493 
1423747_a_at Pdk1 8.82E-06 4.74  4.40  2.45  5.13  NM_172665 
1423748_at Pdk1 7.09E-04 5.64  6.35  4.16  6.23  NM_172665 
1435836_at Pdk1 7.08E-04 3.28  2.66  1.76  3.01  NM_172665 
1428309_s_at Pdrg1 6.72E-03 2.15  3.12  1.37  1.82  NM_178939 
1427929_a_at Pdxk 2.59E-03 2.38  1.89  1.05  1.43  NM_172134 
1435440_at Pdzd8 7.09E-04 3.28  1.94  1.12  2.45  NM_001033222 
1435562_at Pdzd8 7.09E-04 4.33  5.99  1.71  2.21  NM_001033222 
1439088_at Pdzd8 2.91E-03 2.34  2.27  1.22  2.81  NM_001033222 
1425042_s_at Pelp1 6.36E-03 1.74  2.36  1.20  1.79  NM_029231 
1455496_at Pfas 3.80E-03 4.32  3.65  2.65  7.32  
NM_001159519 /// 
XM_111232 /// 
XM_908501 
1426554_a_at Pgam1 5.16E-04 1.77  1.83  1.72  2.16  NM_023418 
1428080_at Pgam5 8.12E-04 2.43  2.68  2.01  3.78  NM_028273 
1452919_a_at Pgp 3.31E-03 1.90  2.37  1.63  1.79  NM_025954 
1416202_at Phb2 2.09E-03 3.12  2.51  2.62  2.94  NM_007531 
1438938_x_at Phb2 5.96E-07 2.94  2.89  1.43  2.52  NM_007531 
1455713_x_at Phb2 5.58E-05 3.12  4.18  2.01  2.10  NM_007531 
1454862_at Phldb2 5.63E-03 -1.65  -1.75  -1.44  -2.63  NM_153412 
1452676_a_at Pnpt1 1.91E-03 2.27  2.88  1.53  2.71  NM_027869 
1448277_at Pold2 8.55E-03 3.10  4.32  3.17  3.41  NM_008894 
1416126_at Polr1b 3.30E-03 4.49  1.78  1.60  3.95  NM_009086 
1435057_x_at Polr1e 8.77E-04 2.74  2.00  -1.02  2.58  NM_022811 
1449155_at Polr3g 1.11E-04 4.71  3.09  1.76  5.99  NM_001081176 
1424227_at Polr3h 6.69E-04 2.84  3.86  2.00  2.77  NM_030229 
1439266_a_at Polr3k 1.65E-03 1.57  2.42  1.86  1.56  NM_025901 
1452831_s_at Ppat 5.87E-03 2.65  3.69  1.49  1.55  
XM_001002879 /// 
XM_001002886 /// 
XM_896000 /// 
XM_924520 /// 
XM_973937 /// 
XM_973973 
1418369_at Prim1 4.37E-03 1.37  4.55  6.60  3.36  NM_008921 
1449061_a_at Prim1 1.11E-04 1.50  4.82  4.72  3.25  NM_008921 
1428783_at Prkar2a 3.87E-04 3.29  3.24  1.31  2.76  NM_008924 
1452915_at Prkar2a 2.98E-03 2.85  3.11  1.47  2.36  NM_008924 
1417425_at Prkrip1 6.69E-04 1.88  2.67  1.31  1.78  NM_025774 
1416844_at Prmt2 6.02E-04 -1.94  -2.95  -1.06  -1.72  
NM_001077638 /// 
NM_133182 
1437234_x_at Prmt2 1.28E-03 -3.13  -4.03  -1.51  -2.69  
NM_001077638 /// 
NM_133182 
1454789_x_at Prpf6 3.66E-03 -1.24  -1.45  -1.69  -2.60  NM_133701 
1451064_a_at Psat1 1.03E-03 5.57  11.92  4.08  8.53  NM_177420 
1454607_s_at Psat1 8.33E-04 3.53  4.98  3.91  6.60  NM_177420 
1428853_at Ptch1 8.35E-03 2.18  1.56  1.24  1.65  NM_008957 
1450344_a_at Ptger3 6.21E-03 10.97  5.48  -1.36  10.49  NM_011196 
1451845_a_at Ptrh2 6.36E-03 1.70  1.20  2.24  3.97  
NM_001098810 /// 
NM_175004 
1428800_a_at Pus7l 8.46E-04 3.41  3.84  -1.10  3.54  NM_172437 
1460447_at Pus7l 4.72E-04 2.73  5.25  1.29  2.75  NM_172437 
1424193_at Pwp2 5.14E-03 2.68  3.03  -1.33  2.31  NM_029546 
1433947_at Rab37 7.56E-04 -2.49  -6.53  -1.33  -7.12  NM_021411 
1418281_at Rad51 8.22E-03 1.09  4.62  9.60  1.58  NM_011234 
1417938_at Rad51ap1 3.22E-03 1.29  7.28  6.77  7.52  NM_009013 
1460551_at Ran 1.80E-03 2.00  2.13  2.21  2.83  NM_009391 
1423749_s_at Rangap1 8.09E-03 1.80  1.75  2.34  2.04  
NM_001146174 /// 
NM_011241 
1448740_at Rangrf 2.80E-03 2.13  1.69  1.77  2.04  NM_021329 
1427344_s_at Rasd2 8.35E-03 7.09  5.34  1.72  5.75  
NM_029182 /// 
XM_204287 /// 
XM_905295 
1439622_at Rassf4 7.70E-03 -2.18  -3.70  -1.85  -1.88  NM_178045 
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1444009_at Rassf4 7.62E-03 -2.02  -1.31  -1.75  -2.42  NM_178045 
1452091_a_at Rbm28 1.38E-03 2.88  2.27  1.28  4.10  
NM_026650 /// 
NM_133925 
1438161_s_at Rfc4 4.47E-03 1.16  10.82  3.13  4.65  NM_145480 
1451516_at Rhebl1 3.06E-03 4.53  2.87  1.94  2.79  NM_026967 
1447818_x_at Rhebl1 1.33E-04 3.43  4.73  1.24  1.83  NM_026967 
1419460_at Rpp14 2.17E-04 2.94  3.09  2.00  2.42  
NM_025938 /// 
XM_001471720 
1419461_at Rpp14 8.33E-04 2.72  3.61  2.10  3.68  
NM_025938 /// 
XM_001471720 
1424792_at Rpp40 4.32E-03 3.19  2.43  1.12  3.05  NM_145938 
1455174_at Rps19bp1 3.75E-03 1.80  2.50  1.44  2.43  NM_175109 
1423254_x_at Rps27l 3.39E-03 1.27  1.78  2.58  2.41  NM_026467 
1450925_a_at Rps27l 5.35E-03 1.27  1.74  2.12  2.29  NM_026467 
1415878_at Rrm1 2.81E-03 1.09  6.36  6.77  2.32  NM_009103 
1456117_at Rrp1b 2.12E-03 3.71  5.12  -1.19  4.06  NM_028244 
1456383_at Rsl1d1 3.98E-03 2.50  2.38  1.17  3.56  NM_025546 
1452649_at Rtn4 2.81E-03 -1.83  -2.23  1.12  -1.67  
NM_024226 /// 
NM_194051 /// 
NM_194052 /// 
NM_194053 /// 
NM_194054 
1437991_x_at Rusc1 6.44E-04 -2.03  -1.94  -2.46  -5.23  
NM_001083807 /// 
NM_001083808 /// 
NM_028188 
1437279_x_at Sdc1 4.60E-03 1.69  6.31  -1.12  5.00  NM_011519 
1426853_at Set 1.33E-04 2.37  3.52  -1.02  1.46  NM_023871 
1428797_at Setd6 1.78E-03 1.89  2.27  2.94  2.52  NM_001035123 
1424619_at Sf3b4 7.62E-03 1.44  1.40  -1.20  2.06  NM_153053 
1428100_at Sfrs1 7.56E-04 3.47  2.65  -1.25  2.85  
NM_001078167 /// 
NM_173374 
1416151_at Sfrs3 7.56E-04 2.34  2.21  1.81  1.81  NM_013663 
1437370_at Sgol2 1.20E-03 1.02  1.11  3.87  1.14  NM_199007 
1425178_s_at Shmt1 6.60E-03 1.16  3.00  1.03  1.52  NM_009171 
1415802_at Slc16a1 2.12E-03 10.37  9.98  1.60  6.76  NM_009196 
1420138_at Slc19a1 4.26E-03 4.38  4.25  1.53  3.02  NM_031196 
1448132_at Slc19a1 7.56E-04 4.97  2.86  2.00  6.22  NM_031196 
1424211_at Slc25a33 9.45E-03 2.82  2.26  -1.22  1.98  NM_027460 
1447748_x_at Slc29a2 4.72E-03 2.62  1.51  -1.06  1.32  NM_007854 
1434015_at Slc2a6 5.16E-04 3.55  6.09  2.11  2.66  NM_172659 
1436164_at Slc30a1 7.09E-04 2.06  1.35  3.12  2.23  NM_009579 
1417042_at Slc37a4 7.45E-03 2.71  2.00  3.72  2.41  NM_008063 
1433751_at Slc39a10 1.84E-03 2.65  3.37  -1.13  8.51  NM_172653 
1426712_at Slc6a15 3.06E-03 6.94  3.06  1.44  7.96  
NM_175328 /// 
XR_035425 /// 
XR_035434 
1454991_at Slc7a1 3.82E-03 3.93  2.12  1.94  3.05  NM_007513 
1448321_at Smoc1 4.31E-03 3.63  3.58  3.09  3.63  
NM_001146217 /// 
NM_022316 
1417300_at Smpdl3b 5.96E-07 5.08  8.81  5.39  15.15  NM_133888 
1451722_s_at Smyd5 2.06E-03 4.46  2.41  1.22  4.93  NM_144918 
1455552_at Snapc4 3.17E-03 3.44  2.17  1.18  3.95  NM_172339 
1452680_at Snrpd2 8.55E-03 1.30  1.26  2.02  1.55  NM_026943 
1438844_x_at Spata5 3.46E-03 1.69  2.00  1.09  2.00  NM_021343 
1431087_at Spc24 7.45E-03 -1.42  2.99  14.46  1.42  NM_026282 
1454962_at Spire1 6.61E-03 2.56  2.01  1.98  8.95  
NM_176832 /// 
NM_194355 
1454042_a_at Srpk1 5.88E-03 1.96  2.22  1.30  1.71  NM_016795 
1417725_a_at Sssca1 6.60E-05 6.78  5.85  1.52  4.73  NM_020491 
1420928_at St6gal1 9.27E-04 -1.76  -1.90  -1.41  -2.70  NM_145933 
1418074_at St6galnac4 1.34E-04 4.77  5.72  1.02  4.16  NM_011373 
1418075_at St6galnac4 5.97E-03 4.39  4.14  2.36  5.06  NM_011373 
1415849_s_at Stmn1 7.45E-03 -1.57  3.11  4.91  1.87  NM_019641 
1419912_s_at Strap 2.41E-03 2.28  1.93  1.74  1.94  NM_011499 
1418089_at Stx8 9.27E-04 2.41  2.28  2.02  2.43  NM_018768 
1429711_at Styx 7.87E-04 3.95  4.27  1.02  2.34  NM_019637 
1428546_at Syncrip 2.37E-03 2.96  1.62  1.65  1.97  
NM_019666 /// 
NM_019796 
1423483_s_at Taf1c 6.05E-04 4.02  2.78  -1.22  1.76  NM_021441 
1435302_at Taf4b 1.45E-03 4.07  2.74  1.20  4.97  
NM_001100449 /// 
XM_128905 /// 
XM_911701 
1451509_at Taf9 2.31E-03 1.68  1.86  2.11  1.32  
NM_001015889 /// 
NM_027139 /// 
NM_027592 
1436856_x_at Tars2 5.16E-03 2.02  3.52  1.13  1.33  NM_027931 
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1423809_at Tcf19 8.55E-03 -1.52  9.76  14.09  3.90  NM_025674 
1423989_at Tecpr1 3.80E-03 -1.53  -1.85  -1.36  -2.90  NM_027410 
1460378_a_at Tes 8.13E-04 -2.47  -2.01  -1.37  -2.21  
NM_011570 /// 
NM_207176 
1423441_at Tfb2m 6.99E-03 2.05  1.20  2.25  2.13  NM_008249 
1423241_a_at Tfdp1 3.80E-03 3.48  1.93  3.10  3.13  NM_009361 
1448907_at Thop1 7.91E-03 2.79  2.98  6.56  10.90  NM_022653 
1438769_a_at Thyn1 7.09E-04 2.78  4.00  2.79  3.59  NM_144543 
1416485_at Timm23 4.13E-03 1.89  1.88  1.55  2.10  NM_016897 
1416345_at Timm8a1 2.13E-04 4.30  5.75  2.03  4.26  NM_013898 
1430084_at Tlcd1 6.36E-03 2.13  4.48  1.58  2.37  NM_026708 
1419655_at Tle3 9.24E-03 -1.20  -1.58  -1.69  -2.76  
NM_001083927 /// 
NM_001083928 /// 
NM_009389 
1433895_at Tmem127 2.40E-03 -2.21  -1.88  -1.91  -2.06  NM_175145 
1428074_at Tmem158 1.24E-05 6.46  7.47  1.48  8.08  NM_001002267 
1424191_a_at Tmem41a 4.32E-03 2.50  1.48  1.49  2.53  NM_025693 
1433735_a_at Tmem64 1.20E-03 3.07  4.11  -1.54  4.60  NM_181401 
1454709_at Tmem64 2.89E-04 2.67  3.37  -1.29  3.59  NM_181401 
1416376_at Tmem97 7.70E-03 1.96  1.27  1.69  2.82  NM_133706 
1426302_at Tmprss4 5.28E-03 -1.62  -6.11  -1.47  -2.97  NM_145403 
1423081_a_at Tomm20 5.88E-03 1.65  2.67  2.35  1.99  NM_024214 
1415733_a_at Tomm5 1.65E-04 2.92  3.40  2.12  3.30  
NM_001099675 /// 
NM_001134646 /// 
XM_001474120 /// 
XM_898905 /// 
XM_906738 /// 
XM_920041 
1460370_at Top1mt 6.60E-05 5.54  3.97  2.24  6.53  NM_028404 
1454694_a_at Top2a 6.36E-03 -1.65  3.58  13.89  3.46  NM_011623 
1421998_at Tor3a 4.77E-03 -1.63  -2.50  -1.35  -2.87  NM_023141 
1448276_at Tspan4 7.08E-04 6.09  14.25  1.96  12.06  NM_053082 
1451351_at Ttc13 5.88E-03 2.22  3.30  1.16  2.18  NM_145607 
1436833_x_at Ttll1 6.36E-03 -2.56  -2.09  1.05  -4.49  NM_178869 
1417373_a_at Tuba4a 8.31E-03 1.61  2.21  1.82  1.13  NM_009447 
1427347_s_at Tubb2a 7.44E-03 -2.10  -2.04  -1.04  -1.44  NM_009450 
1447780_x_at Tufm 1.62E-03 1.59  2.28  1.54  1.81  NM_172745 
1433698_a_at Txnl4a 4.63E-03 2.24  1.65  1.58  2.75  
NM_001038608 /// 
NM_001042408 /// 
NM_025299 /// 
NM_178604 
1428689_at Tysnd1 7.56E-04 3.45  1.74  1.96  2.79  
XM_125636 /// 
XM_905996 
1441856_x_at Tysnd1 8.96E-05 2.99  1.99  1.40  2.00  
XM_125636 /// 
XM_905996 
1424281_at Ubap2 6.71E-03 2.00  1.61  1.43  2.21  NM_026872 
1417188_s_at Ube2k 3.20E-03 1.76  3.55  3.41  2.78  NM_016786 
1425753_a_at Ung 3.87E-04 10.07  21.53  -2.41  3.55  
NM_001040691 /// 
NM_011677 
1455829_at Usp14 2.57E-03 2.50  3.26  1.10  1.90  
NM_001038589 /// 
NM_021522 
1437007_x_at Usp39 3.31E-03 2.48  2.65  -1.08  2.16  NM_138592 
1434125_at Utp15 5.68E-03 2.03  1.51  1.40  2.20  NM_178918 
1454846_at Utp15 7.52E-03 1.81  1.73  -1.22  2.18  NM_178918 
1435114_at Wdhd1 6.60E-03 5.61  4.97  4.95  5.08  NM_172598 
1433746_at Wdr3 7.87E-04 2.30  2.24  -1.16  1.92  NM_175552 
1423735_a_at Wdr36 8.35E-03 2.62  1.67  1.37  2.42  
NM_001110015 /// 
NM_001110016 /// 
NM_144863 
1426496_at Wdr55 1.48E-03 2.03  3.91  2.37  2.65  NM_026464 
1428677_at Wdr73 6.69E-04 2.64  2.42  1.28  2.11  
XM_001479473 /// 
XM_001479496 
1451649_a_at Wdr75 1.28E-03 1.79  1.55  1.02  2.35  NM_028599 
1453433_at Wdr89 4.70E-03 2.90  1.86  1.30  1.38  
NM_028203 /// 
XM_001001795 /// 
XM_001476702 /// 
XM_001476717 /// 
XM_001479426 
1418442_at Xpo1 4.02E-04 2.14  3.02  1.92  2.40  
NM_001035226 /// 
NM_134014 
1418443_at Xpo1 2.57E-03 2.08  2.48  2.27  2.63  
NM_001035226 /// 
NM_134014 
1439442_x_at Yars2 7.66E-04 3.32  2.15  1.47  3.11  NM_198246 
1434501_at Ypel4 2.79E-03 -1.63  -1.60  -1.18  -4.43  NM_001005342 
1451196_at Ypel5 3.74E-04 -2.37  -2.73  -1.86  -3.22  NM_027166 
1428779_at Zbtb41 1.10E-03 2.75  2.45  2.64  2.57  NM_172643 
1418495_at Zc3h8 6.51E-04 2.91  3.24  1.09  2.32  NM_020594 
1439057_x_at Zdhhc6 9.27E-04 1.79  2.27  1.49  2.12  NM_001033573 /// 
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NM_025883 
1454787_at Zdhhc9 3.87E-04 3.33  1.69  1.00  3.93  NM_172465 
1447403_a_at Zmynd19 8.08E-03 3.32  2.31  -1.08  3.67  NM_026021 
1454967_at  9.77E-03 -2.46  -2.25  -1.28  -1.68   
1433813_at  1.05E-03 1.93  8.95  3.29  1.71   
1440205_at  6.94E-05 8.80  5.96  1.52  4.23   
1456396_at  1.46E-03 2.02  1.54  1.63  1.65   
1457132_at  9.46E-03 -2.50  -3.09  -1.16  -5.25   
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Appendix D. Significant gene ontology (GO) terms in 
c-MYC early activation 
 
In this appendix, the significant gene ontology (GO) terms in c-MYC early 
activation are presented. Significant GO terms of cluster 1 were found to be 167 and 
were split into three categories according to their functions, i.e. cellular process, 
metabolic process and cellular component organization or biogenesis, which are 
shown in Table C.1, Table C.2, and Table C.3. 
 
Table D.1. Significant GO terms relating to cellular process. 
GO ACCESSION GO Term p-value 
corrected p-
value 
Count in 
Selection 
% Count in 
Selection 
Count 
in Total 
% Count 
in Total 
GO:0006564 L-serine biosynthetic process 6.20E-24 9.84E-20 14 5.51  15 0.09  
GO:0006563 L-serine metabolic process 2.70E-23 1.43E-19 15 5.91  19 0.11  
GO:0006566 threonine metabolic process 2.40E-21 9.52E-18 13 5.12  15 0.09  
GO:0006544 glycine metabolic process 3.19E-21 1.01E-17 14 5.51  23 0.13  
GO:0006541 glutamine metabolic process 1.51E-20 3.00E-17 16 6.30  30 0.17  
GO:0009070 
serine family amino acid biosynthetic 
process 
1.47E-20 3.00E-17 14 5.51  20 0.12  
GO:0009448 
gamma-aminobutyric acid metabolic 
process 
1.26E-20 3.00E-17 13 5.12  16 0.09  
GO:0019530 taurine metabolic process 1.86E-19 3.29E-16 13 5.12  18 0.10  
GO:0009069 
serine family amino acid metabolic 
process 
2.15E-19 3.41E-16 15 5.91  34 0.20  
GO:0034641 
cellular nitrogen compound metabolic 
process 
3.97E-19 5.73E-16 110 43.31  3658 21.24  
GO:0016070 RNA metabolic process 3.45E-17 4.21E-14 45 17.72  754 4.38  
GO:0006396|GO:0006394 RNA processing 1.13E-15 1.28E-12 39 15.35  477 2.77  
GO:0009064 
glutamine family amino acid metabolic 
process 
2.04E-15 2.16E-12 16 6.30  55 0.32  
GO:0009066 
aspartate family amino acid metabolic 
process 
5.98E-15 5.94E-12 13 5.12  32 0.19  
GO:0021782 glial cell development 2.42E-14 2.26E-11 13 5.12  35 0.20  
GO:0008652 cellular amino acid biosynthetic process 1.08E-13 9.53E-11 14 5.51  58 0.34  
GO:0034660 ncRNA metabolic process 2.93E-13 2.45E-10 22 8.66  236 1.37  
GO:0006520 cellular amino acid metabolic process 3.81E-13 3.02E-10 18 7.09  219 1.27  
GO:0022613 ribonucleoprotein complex biogenesis 1.40E-12 1.01E-09 18 7.09  157 0.91  
GO:0044106 cellular amine metabolic process 1.54E-12 1.06E-09 18 7.09  296 1.72  
GO:0034470 ncRNA processing 2.05E-12 1.36E-09 22 8.66  178 1.03  
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GO:0071843 
cellular component biogenesis at 
cellular level 
2.30E-12 1.46E-09 18 7.09  161 0.93  
GO:0006139|GO:0055134 
nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 
2.53E-12 1.54E-09 93 36.61  3405 19.77  
GO:0042254|GO:0007046 ribosome biogenesis 3.86E-12 2.27E-09 18 7.09  131 0.76  
GO:0009309 amine biosynthetic process 1.38E-11 7.57E-09 14 5.51  93 0.54  
GO:0006519 
cellular amino acid and derivative 
metabolic process 
1.93E-11 1.02E-08 18 7.09  261 1.52  
GO:0006575 
cellular amino acid derivative 
metabolic process 
2.60E-11 1.33E-08 13 5.12  69 0.40  
GO:0044237 cellular metabolic process 4.46E-11 2.21E-08 122 48.03  6993 40.60  
GO:0010001|GO:0007404|
GO:0043360 
glial cell differentiation 6.98E-11 3.17E-08 13 5.12  61 0.35  
GO:0022402 cell cycle process 7.65E-11 3.37E-08 13 5.12  450 2.61  
GO:0042063 gliogenesis 2.97E-10 1.21E-07 13 5.12  68 0.39  
GO:0044271 
cellular nitrogen compound 
biosynthetic process 
6.90E-10 2.67E-07 20 7.87  333 1.93  
GO:0006260|GO:0055133 DNA replication 9.24E-10 3.41E-07 17 6.69  140 0.81  
GO:0090304 nucleic acid metabolic process 1.60E-09 5.77E-07 81 31.89  2791 16.20  
GO:0006364|GO:0006365 rRNA processing 2.56E-09 8.66E-07 14 5.51  96 0.56  
GO:0016072 rRNA metabolic process 2.95E-09 9.75E-07 14 5.51  97 0.56  
GO:0007049 cell cycle 3.17E-09 1.03E-06 35 13.78  734 4.26  
GO:0016053 organic acid biosynthetic process 3.32E-09 1.03E-06 14 5.51  152 0.88  
GO:0046394 carboxylic acid biosynthetic process 3.32E-09 1.03E-06 14 5.51  152 0.88  
GO:0006261|GO:0006262|
GO:0006263 
DNA-dependent DNA replication 1.39E-08 3.94E-06 8 3.15  36 0.21  
GO:0006790 sulfur compound metabolic process 2.78E-08 7.48E-06 13 5.12  115 0.67  
GO:0006259|GO:0055132 DNA metabolic process 3.66E-08 9.36E-06 18 7.09  403 2.34  
GO:0019752 carboxylic acid metabolic process 3.61E-08 9.36E-06 18 7.09  518 3.01  
GO:0043436 oxoacid metabolic process 3.61E-08 9.36E-06 18 7.09  518 3.01  
GO:0006082 organic acid metabolic process 4.10E-08 1.03E-05 18 7.09  521 3.02  
GO:0042180 cellular ketone metabolic process 5.74E-08 1.42E-05 18 7.09  529 3.07  
GO:0006270|GO:0042024 
DNA-dependent DNA replication 
initiation 
5.92E-08 1.45E-05 6 2.36  13 0.08  
GO:0004017 adenylate kinase activity 8.90E-07 1.86E-04 5 1.97  11 0.06  
GO:0006268 DNA unwinding involved in replication 2.41E-06 4.77E-04 5 1.97  13 0.08  
GO:0006399 tRNA metabolic process 3.60E-06 7.05E-04 8 3.15  125 0.73  
GO:0032508 DNA duplex unwinding 5.44E-06 0.001041 5 1.97  15 0.09  
GO:0006189 'de novo' IMP biosynthetic process 6.29E-06 1.19E-03 3 1.18  3 0.02  
GO:0051301 cell division 8.28E-06 0.001528 17 6.69  290 1.68  
GO:0006913|GO:0000063 nucleocytoplasmic transport 1.12E-05 2.04E-03 10 3.94  117 0.68  
GO:0051169 nuclear transport 1.32E-05 0.002286 10 3.94  119 0.69  
GO:0019201 nucleotide kinase activity 1.48E-05 0.002505 5 1.97  18 0.10  
GO:0044249 cellular biosynthetic process 1.63E-05 0.00273 62 24.41  3487 20.24  
GO:0006188 IMP biosynthetic process 2.48E-05 3.79E-03 3 1.18  4 0.02  
GO:0046040 IMP metabolic process 2.48E-05 0.003788 3 1.18  4 0.02  
GO:0071841 
cellular component organization or 
biogenesis at cellular level 
3.65E-05 0.005412 22 8.66  1548 8.99  
GO:0006606 protein import into nucleus 3.97E-05 5.84E-03 8 3.15  69 0.40  
GO:0008033 tRNA processing 5.42E-05 0.007677 8 3.15  72 0.42  
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GO:0051170 nuclear import 5.99E-05 0.00841 8 3.15  73 0.42  
GO:0009113 purine base biosynthetic process 6.12E-05 0.008522 2 0.79  5 0.03  
GO:0008380|GO:0006395 RNA splicing 6.73E-05 0.009045 14 5.51  221 1.28  
GO:0006397 mRNA processing 7.10E-05 9.47E-03 15 5.91  280 1.63  
GO:0034504 protein localization to nucleus 7.28E-05 0.009559 8 3.15  75 0.44  
GO:0016071 mRNA metabolic process 8.58E-05 0.010986 15 5.91  315 1.83  
GO:0009127 
purine nucleoside monophosphate 
biosynthetic process 
9.98E-05 0.012372 3 1.18  14 0.08  
GO:0009168 
purine ribonucleoside monophosphate 
biosynthetic process 
9.98E-05 0.012372 3 1.18  14 0.08  
GO:0031175 neuron projection development 1.24E-04 0.015215 13 5.12  234 1.36  
GO:0000059 protein import into nucleus, docking 1.34E-04 1.62E-02 4 1.57  15 0.09  
GO:0006605 protein targeting 1.68E-04 1.97E-02 10 3.94  157 0.91  
GO:0009126 
purine nucleoside monophosphate 
metabolic process 
1.76E-04 0.020409 3 1.18  16 0.09  
GO:0009167 
purine ribonucleoside monophosphate 
metabolic process 
1.76E-04 0.020409 3 1.18  16 0.09  
GO:0046939 nucleotide phosphorylation 2.06E-04 0.023312 5 1.97  30 0.17  
GO:0033365 protein localization to organelle 3.28E-04 0.035466 8 3.15  117 0.68  
GO:0071103 DNA conformation change 3.70E-04 0.03792 5 1.97  172 1.00  
GO:0003899|GO:0000129 
DNA-directed RNA polymerase 
activity 
4.34E-04 4.36E-02 5 1.97  35 0.20  
GO:0044260|GO:0034960 
cellular macromolecule metabolic 
process 
4.75E-04 0.047455 81 31.89  5089 29.54  
GO:0046112 nucleobase biosynthetic process 4.87E-04 0.04826 2 0.79  9 0.05  
GO:0009156 
ribonucleoside monophosphate 
biosynthetic process 
5.39E-04 0.053084 3 1.18  21 0.12  
GO:0000278 mitotic cell cycle 6.40E-04 6.27E-02 1 0.39  275 1.60  
GO:0006144 purine base metabolic process 6.86E-04 6.67E-02 2 0.79  10 0.06  
GO:0048666 neuron development 7.01E-04 0.067812 14 5.51  310 1.80  
GO:0009161 
ribonucleoside monophosphate 
metabolic process 
7.74E-04 0.073541 3 1.18  23 0.13  
GO:0055086 
nucleobase, nucleoside and nucleotide 
metabolic process 
7.71E-04 0.073541 11 4.33  672 3.90  
GO:0019205 
nucleobase, nucleoside, nucleotide 
kinase activity 
8.16E-04 0.076653 5 1.97  40 0.23  
GO:0032392 DNA geometric change 8.16E-04 0.076653 5 1.97  40 0.23  
 
 
Table D.2. metabolic process 
GO ACCESSION GO Term p-value 
corrected 
p-value 
Count in 
Selection 
% Count 
in 
selection 
Count 
in 
Total 
% 
Count in 
Total 
GO:0006564 
L-serine biosynthetic 
process 
6.20E-24 9.84E-20 14 5.51  15 0.09  
GO:0004617 
phosphoglycerate 
dehydrogenase activity 
2.36E-23 1.43E-19 13 5.12  13 0.08  
GO:0006563 
L-serine metabolic 
process 
2.70E-23 1.43E-19 15 5.91  19 0.11  
GO:0006566 
threonine metabolic 
process 
2.40E-21 9.52E-18 13 5.12  15 0.09  
GO:0006544 
glycine metabolic 
process 
3.19E-21 1.01E-17 14 5.51  23 0.13  
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GO:0006541 
glutamine metabolic 
process 
1.51E-20 3.00E-17 16 6.30  30 0.17  
GO:0009070 
serine family amino acid 
biosynthetic process 
1.47E-20 3.00E-17 14 5.51  20 0.12  
GO:0009448 
gamma-aminobutyric 
acid metabolic process 
1.26E-20 3.00E-17 13 5.12  16 0.09  
GO:0009069 
serine family amino acid 
metabolic process 
2.15E-19 3.41E-16 15 5.91  34 0.20  
GO:0034641 
cellular nitrogen 
compound metabolic 
process 
3.97E-19 5.73E-16 110 43.31  3658 21.24  
GO:0006807 
nitrogen compound 
metabolic process 
3.49E-18 4.62E-15 110 43.31  3746 21.75  
GO:0016070 RNA metabolic process 3.45E-17 4.21E-14 45 17.72  754 4.38  
GO:0006396|GO:0006394 RNA processing 1.13E-15 1.28E-12 39 15.35  477 2.77  
GO:0009064 
glutamine family amino 
acid metabolic process 
2.04E-15 2.16E-12 16 6.30  55 0.32  
GO:0009066 
aspartate family amino 
acid metabolic process 
5.98E-15 5.94E-12 13 5.12  32 0.19  
GO:0008652 
cellular amino acid 
biosynthetic process 
1.08E-13 9.53E-11 14 5.51  58 0.34  
GO:0034660 
ncRNA metabolic 
process 
2.93E-13 2.45E-10 22 8.66  236 1.37  
GO:0006520 
cellular amino acid 
metabolic process 
3.81E-13 3.02E-10 18 7.09  219 1.27  
GO:0044106 
cellular amine metabolic 
process 
1.54E-12 1.06E-09 18 7.09  296 1.72  
GO:0034470 ncRNA processing 2.05E-12 1.36E-09 22 8.66  178 1.03  
GO:0006139|GO:0055134 
nucleobase, nucleoside, 
nucleotide and nucleic 
acid metabolic process 
2.53E-12 1.54E-09 93 36.61  3405 19.77  
GO:0009309 
amine biosynthetic 
process 
1.38E-11 7.57E-09 14 5.51  93 0.54  
GO:0016616 
oxidoreductase activity, 
acting on the CH-OH 
group of donors, NAD 
or NADP as acceptor 
5.98E-11 2.88E-08 14 5.51  118 0.69  
GO:0016614 
oxidoreductase activity, 
acting on CH-OH group 
of donors 
2.86E-10 1.19E-07 14 5.51  130 0.75  
GO:0009308 amine metabolic process 3.44E-10 1.36E-07 18 7.09  372 2.16  
GO:0006260|GO:0055133 DNA replication 9.24E-10 3.41E-07 17 6.69  140 0.81  
GO:0090304 
nucleic acid metabolic 
process 
1.60E-09 5.77E-07 81 31.89  2791 16.20  
GO:0006364|GO:0006365 rRNA processing 2.56E-09 8.66E-07 14 5.51  96 0.56  
GO:0016072 rRNA metabolic process 2.95E-09 9.75E-07 14 5.51  97 0.56  
GO:0008152 metabolic process 1.14E-08 3.34E-06 149 58.66  8720 50.62  
GO:0006261|GO:0006262|GO:0006263 
DNA-dependent DNA 
replication 
1.39E-08 3.94E-06 8 3.15  36 0.21  
GO:0006259|GO:0055132 DNA metabolic process 3.66E-08 9.36E-06 18 7.09  403 2.34  
GO:0006270|GO:0042024 
DNA-dependent DNA 
replication initiation 
5.92E-08 1.45E-05 6 2.36  13 0.08  
GO:0004017 adenylate kinase activity 8.90E-07 1.86E-04 5 1.97  11 0.06  
GO:0003824 catalytic activity 1.58E-06 3.16E-04 79 31.10  5311 30.83  
GO:0006268 
DNA unwinding 
involved in replication 
2.41E-06 4.77E-04 5 1.97  13 0.08  
GO:0006399 tRNA metabolic process 3.60E-06 7.05E-04 8 3.15  125 0.73  
GO:0006189 
'de novo' IMP 
6.29E-06 1.19E-03 3 1.18  3 0.02  
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biosynthetic process 
GO:0019201 
nucleotide kinase 
activity 
1.48E-05 0.002505 5 1.97  18 0.10  
GO:0006188 
IMP biosynthetic 
process 
2.48E-05 3.79E-03 3 1.18  4 0.02  
GO:0046040 IMP metabolic process 2.48E-05 0.003788 3 1.18  4 0.02  
GO:0008033 tRNA processing 5.42E-05 0.007677 8 3.15  72 0.42  
GO:0009113 
purine base biosynthetic 
process 
6.12E-05 0.008522 2 0.79  5 0.03  
GO:0008380|GO:0006395 RNA splicing 6.73E-05 0.009045 14 5.51  221 1.28  
GO:0006397 mRNA processing 7.10E-05 9.47E-03 15 5.91  280 1.63  
GO:0016071 
mRNA metabolic 
process 
8.58E-05 0.010986 15 5.91  315 1.83  
GO:0009127 
purine nucleoside 
monophosphate 
biosynthetic process 
9.98E-05 0.012372 3 1.18  14 0.08  
GO:0009168 
purine ribonucleoside 
monophosphate 
biosynthetic process 
9.98E-05 0.012372 3 1.18  14 0.08  
GO:0009126 
purine nucleoside 
monophosphate 
metabolic process 
1.76E-04 0.020409 3 1.18  16 0.09  
GO:0009167 
purine ribonucleoside 
monophosphate 
metabolic process 
1.76E-04 0.020409 3 1.18  16 0.09  
GO:0016740 transferase activity 2.06E-04 0.023312 48 18.90  1744 10.12  
GO:0046939 
nucleotide 
phosphorylation 
2.06E-04 0.023312 5 1.97  30 0.17  
GO:0016776 
phosphotransferase 
activity, phosphate 
group as acceptor 
2.82E-04 0.031508 5 1.97  32 0.19  
GO:0003899|GO:0000129 
DNA-directed RNA 
polymerase activity 
4.34E-04 4.36E-02 5 1.97  35 0.20  
GO:0034062 
RNA polymerase 
activity 
4.34E-04 0.043624 5 1.97  35 0.20  
GO:0046112 
nucleobase biosynthetic 
process 
4.87E-04 0.04826 2 0.79  9 0.05  
GO:0009156 
ribonucleoside 
monophosphate 
biosynthetic process 
5.39E-04 0.053084 3 1.18  21 0.12  
GO:0006144 
purine base metabolic 
process 
6.86E-04 6.67E-02 2 0.79  10 0.06  
GO:0009161 
ribonucleoside 
monophosphate 
metabolic process 
7.74E-04 0.073541 3 1.18  23 0.13  
GO:0055086 
nucleobase, nucleoside 
and nucleotide metabolic 
process 
7.71E-04 0.073541 11 4.33  672 3.90  
GO:0019205 
nucleobase, nucleoside, 
nucleotide kinase 
activity 
8.16E-04 0.076653 5 1.97  40 0.23  
 
Table D.3. Significant GO terms relating to cellular component organization or biogenesis. 
GO ACCESSION GO Term p-value 
corrected p-
value 
Count in 
Selection 
% Count 
in 
Selection 
Count 
in 
Total 
% Count 
in Total 
GO:0022613 
ribonucleoprotein complex 
biogenesis 
1.40E-12 1.01E-09 18 7.09  157 0.91  
GO:0071843 
cellular component biogenesis at 
2.30E-12 1.46E-09 18 7.09  161 0.93  
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cellular level 
GO:0042254|GO:0007046 ribosome biogenesis 3.86E-12 2.27E-09 18 7.09  131 0.76  
GO:0006364|GO:0006365 rRNA processing 2.56E-09 8.66E-07 14 5.51  96 0.56  
GO:0044085 cellular component biogenesis 2.51E-07 5.53E-05 22 8.66  695 4.03  
GO:0071840 
cellular component organization or 
biogenesis 
4.61E-06 8.93E-04 35 13.78  2224 12.91  
GO:0071841 
cellular component organization or 
biogenesis at cellular level 
3.65E-05 5.41E-03 22 8.66  1548 8.99  
GO:0031175 neuron projection development 1.24E-04 1.52E-02 13 5.12  234 1.36  
GO:0000059 
protein import into nucleus, 
docking 
1.34E-04 1.62E-02 4 1.57  15 0.09  
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Appendix E. Significant biological processes in cluster 1 
 
I. Cellular process 
Genes relating to cell cycle, cell cycle process, cell division and DNA conformation change 
Probe Set ID Gene Symbol 
Fold change ratio (Treatment/Control) at different time points 
Ref_seq_id 
4 8 16 32 
1433669_at Akap8 2.76  2.04  -1.15  1.5 NM_019774 
1417910_at Ccna2 -1.08  4.82  11.07  3.21 NM_009828 
1448205_at Ccnb1 1.09  3.82  9.56  3.63 NM_172301 
1416492_at Ccne1 2.10  4.16  5.80  1.28 NM_007633 
1441910_x_at Ccne1 1.93  8.88  1.74  1.6 NM_007633 
1422535_at Ccne2 2.17  8.20  6.32  5.7 
NM_001037134 /// 
NM_009830 
1417131_at Cdc25a 2.55  2.19  1.49  3.07 NM_007658 
1417132_at Cdc25a 2.29  2.07  1.24  1.76 NM_007658 
1452040_a_at Cdca3 -1.08  1.05  5.51  1.1 NM_013538 
1416802_a_at Cdca5 -1.42  22.18  21.74  8.58 NM_026410 
1424143_a_at Cdt1 5.79  24.94  11.12  6.83 NM_026014 
1449708_s_at Chek1 2.69  6.39  4.48  4.69 NM_007691 
1416698_a_at Cks1b 1.52  3.58  3.15  2.45 NM_016904 
1417457_at Cks2 -1.24  3.77  8.09  6.65 NM_025415 
1434079_s_at Mcm2 1.84  4.18  2.56  3.05 NM_008564 
1436708_x_at Mcm4 2.10  8.25  1.43  2.69 NM_008565 
1436808_x_at Mcm5 4.34  28.35  2.00  9.02 NM_008566 
1438320_s_at Mcm7 2.81  5.93  3.11  3.61 NM_008568 
1439269_x_at Mcm7 2.40  7.40  2.73  3.72 NM_008568 
1420477_at Nap1l1 1.90  1.68  2.20  1.68 
NM_001146707 /// 
NM_015781 
1436707_x_at Ncaph -2.35  7.60  20.88  3.76 NM_144818 
1416073_a_at Nup85 3.33  6.81  4.49  5.34 NM_001002929 
1437520_a_at Nup85 3.13  6.64  1.61  2.42 NM_001002929 
1418281_at Rad51 1.09  4.62  9.60  1.58 NM_011234 
1426853_at Set 2.37  3.52  -1.02  1.46 NM_023871 
1437370_at Sgol2 1.02  1.11  3.87  1.14 NM_199007 
1431087_at Spc24 -1.42  2.99  14.46  1.42 NM_026282 
1415849_s_at Stmn1 -1.57  3.11  4.91  1.87 NM_019641 
1423241_a_at Tfdp1 3.48 1.93 3.1 3.13 NM_009361 
1460370_at Top1mt 5.54 3.97 2.24 6.53 NM_028404 
1454694_a_at Top2a -1.65 3.58 13.89 3.46 NM_011623 
1433698_a_at Txnl4a 2.24 1.65 1.58 2.75 
NM_001038608 /// 
NM_001042408 /// 
NM_025299 /// 
NM_178604 
 
II. Metabolic process 
Genes relating to cellular metabolic process 
Probe Set ID Gene Symbol 
Fold change ratio (Treatment/Control) at different time points Ref_seq_id 
4 8 16 32 
1450721_at Acp1 1.27  1.39  2.05  1.31  
NM_001110239 /// 
NM_021330 
1418372_at Adsl 1.88  2.79  1.64  2.24  NM_009634 
1434287_at Agpat5 3.27  2.41  2.67  2.05  NM_026792 
1424712_at Ahctf1 2.80  1.37  1.10  2.95  NM_026375 
1451459_at Ahctf1 3.51  1.45  1.95  2.98  NM_026375 
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1448450_at 
Ak2 /// 
LOC100047005 
2.74  2.98  1.17  1.81  
NM_001033966 /// 
NM_016895 /// 
XM_001477790 
1450387_s_at 
Ak3l1 /// 
LOC100047616 
4.00  4.81  -1.11  4.98  
NM_009647 /// 
XM_001478522 
1433669_at Akap8 2.76  2.04  -1.15  1.50  NM_019774 
1434555_at Anp32a 2.21  1.59  1.01  1.57  NM_009672 
1451703_s_at Aprt 1.62  1.74  2.23  2.18  NM_009698 
1427197_at Atr 2.57  4.41  1.58  2.96  NM_019864 
1433663_s_at AU014645 2.52  1.34  1.40  1.64  NM_001033201 
1423264_at Bop1 2.86  3.94  2.50  4.55  NM_013481 
1440910_at C77370 3.97  3.37  1.29  2.50  NM_001077354 
1448205_at Ccnb1 1.09  3.82  9.56  3.63  NM_172301 
1416492_at Ccne1 2.10  4.16  5.80  1.28  NM_007633 
1441910_x_at Ccne1 1.93  8.88  1.74  1.60  NM_007633 
1422535_at Ccne2 2.17  8.20  6.32  5.70  
NM_001037134 /// 
NM_009830 
1417131_at Cdc25a 2.55  2.19  1.49  3.07  NM_007658 
1417132_at Cdc25a 2.29  2.07  1.24  1.76  NM_007658 
1452040_a_at Cdca3 -1.08  1.05  5.51  1.10  NM_013538 
1424143_a_at Cdt1 5.79  24.94  11.12  6.83  NM_026014 
1449708_s_at Chek1 2.69  6.39  4.48  4.69  NM_007691 
1417457_at Cks2 -1.24  3.77  8.09  6.65  NM_025415 
1435800_a_at Csda 2.51  2.14  1.37  2.72  
NM_011733 /// 
NM_139117 
1451012_a_at Csda 4.95  2.28  2.39  5.30  
NM_011733 /// 
NM_139117 
1419645_at Cstf2 2.09  1.94  1.54  2.45  NM_133196 
1416563_at Ctps 2.66  3.35  1.97  2.17  NM_016748 
1422484_at Cycs 1.29  2.15  1.54  2.02  NM_007808 
1454659_at Dctd 4.60  3.06  2.33  4.08  NM_178788 
1448271_a_at Ddx21 1.91  1.83  -1.03  2.00  NM_019553 
1426609_at Dis3 3.54  2.58  1.90  4.32  NM_028315 
1426265_x_at Dlat 1.03  2.28  1.69  2.60  NM_145614 
1417182_at Dnaja2 2.10  2.02  1.50  1.44  NM_019794 
1428087_at Dnm1l 1.82  1.75  1.21  3.76  
NM_001025947 /// 
NM_152816 
1435734_x_at Dus1l 3.03  2.54  -1.08  1.25  NM_026824 
1424229_at Dyrk3 1.80  1.21  4.53  2.77  NM_145508 
1449044_at Eef1e1 3.26  2.75  5.25  8.83  NM_025380 
1437829_s_at Eef2k 3.26  3.26  -1.52  2.42  NM_007908 
1456107_x_at Eftud2 2.24  3.14  1.02  1.96  
NM_001109995 /// 
NM_011431 
1424343_a_at Eif1a 1.28  1.63  2.21  1.51  NM_010120 
1424344_s_at Eif1a 1.92  3.30  1.35  1.84  NM_010120 
1426394_at Eif3j 1.93  1.85  1.74  2.69  NM_144545 
1426395_s_at Eif3j 1.58  1.85  1.56  2.85  NM_144545 
1423220_at Eif4e 2.86  2.75  1.54  2.11  
NM_007917 /// 
XM_001004193 
1450908_at Eif4e 1.95  2.84  2.07  4.23  
NM_007917 /// 
XM_001004193 
1435803_a_at Eif4e2 1.50  2.15  1.40  1.62  
NM_001039169 /// 
NM_001039170 /// 
NM_023314 
1428477_at Elac2 3.18  1.32  1.12  2.14  NM_023479 
1417403_at Elovl6 3.10  4.60  2.47  5.50  NM_130450 
1417404_at Elovl6 3.49  3.28  2.74  2.99  NM_130450 
1421097_at Endog 2.79  3.90  1.74  2.44  NM_007931 
1438317_a_at Endog 2.79  3.74  1.27  1.68  NM_007931 
1420024_s_at Etf1 2.16  2.73  1.16  1.66  NM_144866 
1452012_a_at Exosc1 2.72  2.68  1.18  2.60  NM_025644 
1435544_at Exosc6 3.18  5.31  1.36  3.43  NM_028274 
1423828_at Fasn 2.62  3.52  1.98  2.28  NM_007988 
1435369_at Fastkd5 2.16  3.19  1.73  2.37  
NM_001146084 /// 
NM_198176 
1419577_at Fig4 4.28  3.52  1.35  6.03  NM_133999 
1441911_x_at Gart 1.97  2.37  1.29  2.31  NM_010256 
1432164_a_at Gcsh 2.24  1.65  1.43  1.57  NM_026572 
1424300_at Gemin6 1.78  2.20  5.22  2.23  NM_026053 
1451400_at Gemin8 2.02  1.95  1.78  2.04  NM_146238 
1435245_at Gls2 9.89  6.97  5.23  5.61  NM_001033264 
1438510_a_at Hars 1.53  2.02  1.16  1.48  NM_008214 
1419964_s_at Hdgf 1.66  1.82  2.07  2.08  NM_008231 
1436050_x_at Hes6 3.11  2.26  -1.02  3.01  NM_019479 
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1434736_at Hlf 3.37  3.66  -1.15  3.49  NM_172563 
1416184_s_at Hmga1 2.73  3.09  1.99  3.98  
NM_001025427 /// 
NM_001039356 /// 
NM_016660 
1431349_at Hnrnpab 2.10  1.89  1.93  1.34  
NM_001048061 /// 
NM_010448 
1455120_at Hpdl 2.86  2.23  1.04  4.30  NM_146256 
1416968_a_at Hsd3b7 2.57  3.12  1.19  2.93  
NM_001040684 /// 
NM_133943 
1426351_at Hspd1 1.31  1.84  2.45  2.63  NM_010477 
1426705_s_at Iars 1.62  1.28  2.01  1.42  NM_172015 
1422501_s_at Idh3a 1.54  1.66  1.87  2.22  NM_029573 
1432016_a_at Idh3a 1.38  1.66  2.11  2.96  NM_029573 
1453784_at Ilkap 1.15  1.13  2.20  1.27  NM_023343 
1426213_at Imp4 2.77  2.90  2.16  2.94  NM_178601 
1456200_at Ipmk 3.31  1.16  1.66  1.53  NM_027184 
1434154_at Kctd13 1.39  1.26  1.10  2.56  NM_172747 
1433842_at Lrrfip1 4.45  4.11  1.01  4.45  
NM_001111311 /// 
NM_001111312 /// 
NM_008515 
1433576_at Mat2a 3.21  2.98  -1.44  2.05  NM_145569 
1438386_x_at Mat2a 2.17  1.81  -1.24  1.79  NM_145569 
1438630_x_at Mat2a 2.49  2.50  -1.22  1.87  NM_145569 
1438976_x_at Mat2a 2.58  2.64  -1.25  1.85  NM_145569 
1456702_x_at Mat2a 2.57  2.07  -1.19  1.93  NM_145569 
1434079_s_at Mcm2 1.84  4.18  2.56  3.05  NM_008564 
1436708_x_at Mcm4 2.10  8.25  1.43  2.69  NM_008565 
1436808_x_at Mcm5 4.34  28.35  2.00  9.02  NM_008566 
1438320_s_at Mcm7 2.81  5.93  3.11  3.61  NM_008568 
1439269_x_at Mcm7 2.40  7.40  2.73  3.72  NM_008568 
1460050_x_at Mettl13 3.17  1.97  -1.02  2.38  NM_144877 
1435232_x_at Mrpl15 2.20  1.97  1.67  2.90  NM_025300 
1416349_at Mrpl34 2.39  2.00  1.99  3.07  NM_053162 
1427158_at Mrps30 2.13  1.91  1.25  2.80  NM_021556 
1424425_a_at Mtap 3.17  3.38  1.26  2.74  NM_024433 
1424426_at Mtap 6.30  5.80  1.24  3.51  NM_024433 
1451346_at Mtap 3.05  2.91  1.33  3.78  NM_024433 
1456653_a_at Mthfd1l 3.16  1.45  1.62  4.59  NM_172308 
1434278_at Mtm1 5.67  9.10  3.98  8.94  NM_019926 
1452110_at Mtrr 4.28  5.67  1.77  2.59  NM_172480 
1450376_at Mxi1 2.36  1.42  2.52  4.78  
NM_001008542 /// 
NM_001008543 /// 
NM_010847 
1449072_a_at N6amt2 1.28  2.13  1.98  1.74  NM_026526 
1452192_at Naf1 5.70  4.67  1.65  4.73  
XR_032374 /// 
XR_032626 
1416972_at Nhp2l1 2.31  2.37  1.70  1.88  NM_011482 
1416973_at Nhp2l1 1.91  2.11  2.05  1.76  NM_011482 
1424019_at Nop2 1.90  2.39  1.27  2.52  NM_138747 
1423850_at Nsun2 3.12  1.72  5.57  3.32  NM_145354 
1448651_at Nudt5 1.55  1.88  2.37  3.16  NM_016918 
1427364_a_at Odc1 1.99  2.93  1.29  1.78  NM_013614 
1418225_at Orc2l 2.28  2.01  1.33  2.31  
NM_001025378 /// 
NM_008765 
1417037_at Orc6l 2.17  2.22  1.98  2.66  NM_019716 
1420142_s_at Pa2g4 2.30  6.21  1.33  1.57  NM_011119 
1450854_at Pa2g4 2.34  4.59  2.06  1.97  NM_011119 
1423564_a_at Paics 1.57  1.38  2.40  2.45  NM_025939 
1448627_s_at Pbk -1.30  4.18  18.83  3.28  NM_023209 
1424081_at Pcgf6 2.35  2.28  2.40  2.42  NM_027654 
1423747_a_at Pdk1 4.74  4.40  2.45  5.13  NM_172665 
1423748_at Pdk1 5.64  6.35  4.16  6.23  NM_172665 
1435836_at Pdk1 3.28  2.66  1.76  3.01  NM_172665 
1428309_s_at Pdrg1 2.15  3.12  1.37  1.82  NM_178939 
1427929_a_at Pdxk 2.38  1.89  1.05  1.43  NM_172134 
1425042_s_at Pelp1 1.74  2.36  1.20  1.79  NM_029231 
1455496_at Pfas 4.32  3.65  2.65  7.32  
NM_001159519 /// 
XM_111232 /// 
XM_908501 
1426554_a_at Pgam1 1.77  1.83  1.72  2.16  NM_023418 
1452919_a_at Pgp 1.90  2.37  1.63  1.79  NM_025954 
1416202_at Phb2 3.12  2.51  2.62  2.94  NM_007531 
1438938_x_at Phb2 2.94  2.89  1.43  2.52  NM_007531 
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1455713_x_at Phb2 3.12  4.18  2.01  2.10  NM_007531 
1452676_a_at Pnpt1 2.27  2.88  1.53  2.71  NM_027869 
1448277_at Pold2 3.10  4.32  3.17  3.41  NM_008894 
1416126_at Polr1b 4.49  1.78  1.60  3.95  NM_009086 
1435057_x_at Polr1e 2.74  2.00  -1.02  2.58  NM_022811 
1449155_at Polr3g 4.71  3.09  1.76  5.99  NM_001081176 
1424227_at Polr3h 2.84  3.86  2.00  2.77  NM_030229 
1439266_a_at Polr3k 1.57  2.42  1.86  1.56  NM_025901 
1452831_s_at Ppat 2.65  3.69  1.49  1.55  
XM_001002879 /// 
XM_001002886 /// 
XM_896000 /// 
XM_924520 /// 
XM_973937 /// 
XM_973973 
1418369_at Prim1 1.37  4.55  6.60  3.36  NM_008921 
1449061_a_at Prim1 1.50  4.82  4.72  3.25  NM_008921 
1428783_at Prkar2a 3.29  3.24  1.31  2.76  NM_008924 
1452915_at Prkar2a 2.85  3.11  1.47  2.36  NM_008924 
1451064_a_at Psat1 5.57  11.92  4.08  8.53  NM_177420 
1454607_s_at Psat1 3.53  4.98  3.91  6.60  NM_177420 
1451845_a_at Ptrh2 1.70  1.20  2.24  3.97  
NM_001098810 /// 
NM_175004 
1428800_a_at Pus7l 3.41  3.84  -1.10  3.54  NM_172437 
1460447_at Pus7l 2.73  5.25  1.29  2.75  NM_172437 
1418281_at Rad51 1.09  4.62  9.60  1.58  NM_011234 
1417938_at Rad51ap1 1.29  7.28  6.77  7.52  NM_009013 
1460551_at Ran 2.00  2.13  2.21  2.83  NM_009391 
1452091_a_at Rbm28 2.88  2.27  1.28  4.10  
NM_026650 /// 
NM_133925 
1438161_s_at Rfc4 1.16  10.82  3.13  4.65  NM_145480 
1419460_at Rpp14 2.94  3.09  2.00  2.42  
NM_025938 /// 
XM_001471720 
1419461_at Rpp14 2.72  3.61  2.10  3.68  
NM_025938 /// 
XM_001471720 
1424792_at Rpp40 3.19  2.43  1.12  3.05  NM_145938 
1423254_x_at Rps27l 1.27  1.78  2.58  2.41  NM_026467 
1450925_a_at Rps27l 1.27  1.74  2.12  2.29  NM_026467 
1415878_at Rrm1 1.09  6.36  6.77  2.32  NM_009103 
1456117_at Rrp1b 3.71  5.12  -1.19  4.06  NM_028244 
1456383_at Rsl1d1 2.50  2.38  1.17  3.56  NM_025546 
1424619_at Sf3b4 1.44  1.40  -1.20  2.06  NM_153053 
1428100_at Sfrs1 3.47  2.65  -1.25  2.85  
NM_001078167 /// 
NM_173374 
1416151_at Sfrs3 2.34  2.21  1.81  1.81  NM_013663 
1425178_s_at Shmt1 1.16  3.00  1.03  1.52  NM_009171 
1417042_at Slc37a4 2.71  2.00  3.72  2.41  NM_008063 
1417300_at Smpdl3b 5.08  8.81  5.39  15.15  NM_133888 
1455552_at Snapc4 3.44  2.17  1.18  3.95  NM_172339 
1452680_at Snrpd2 1.30  1.26  2.02  1.55  NM_026943 
1454042_a_at Srpk1 1.96  2.22  1.30  1.71  NM_016795 
1418074_at St6galnac4 4.77  5.72  1.02  4.16  NM_011373 
1418075_at St6galnac4 4.39  4.14  2.36  5.06  NM_011373 
1419912_s_at Strap 2.28  1.93  1.74  1.94  NM_011499 
1429711_at Styx 3.95  4.27  1.02  2.34  NM_019637 
1428546_at Syncrip 2.96  1.62  1.65  1.97  
NM_019666 /// 
NM_019796 
1423483_s_at Taf1c 4.02  2.78  -1.22  1.76  NM_021441 
1435302_at Taf4b 4.07  2.74  1.20  4.97  
NM_001100449 /// 
XM_128905 /// 
XM_911701 
1451509_at Taf9 1.68  1.86  2.11  1.32  
NM_001015889 /// 
NM_027139 /// 
NM_027592 
1436856_x_at Tars2 2.02  3.52  1.13  1.33  NM_027931 
1423441_at Tfb2m 2.05  1.20  2.25  2.13  NM_008249 
1423241_a_at Tfdp1 3.48  1.93  3.10  3.13  NM_009361 
1448907_at Thop1 2.79  2.98  6.56  10.90  NM_022653 
1460370_at Top1mt 5.54  3.97  2.24  6.53  NM_028404 
1454694_a_at Top2a -1.65  3.58  13.89  3.46  NM_011623 
1417373_a_at Tuba4a 1.61  2.21  1.82  1.13  NM_009447 
1447780_x_at Tufm 1.59  2.28  1.54  1.81  NM_172745 
1433698_a_at Txnl4a 2.24  1.65  1.58  2.75  
NM_001038608 /// 
NM_001042408 /// 
NM_025299 /// 
NM_178604 
1417188_s_at Ube2k 1.76  3.55  3.41  2.78  NM_016786 
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1425753_a_at Ung 10.07  21.53  -2.41  3.55  
NM_001040691 /// 
NM_011677 
1455829_at Usp14 2.50  3.26  1.10  1.90  
NM_001038589 /// 
NM_021522 
1437007_x_at Usp39 2.48  2.65  -1.08  2.16  NM_138592 
1434125_at Utp15 2.03  1.51  1.40  2.20  NM_178918 
1454846_at Utp15 1.81  1.73  -1.22  2.18  NM_178918 
1433746_at Wdr3 2.30  2.24  -1.16  1.92  NM_175552 
1423735_a_at Wdr36 2.62  1.67  1.37  2.42  
NM_001110015 /// 
NM_001110016 /// 
NM_144863 
1426496_at Wdr55 2.03  3.91  2.37  2.65  NM_026464 
1439442_x_at Yars2 3.32  2.15  1.47  3.11  NM_198246 
1428779_at Zbtb41 2.75  2.45  2.64  2.57  NM_172643 
 
III. Cellular component organization or biogenesis 
Genes relating to cellular component organization or biogenesis 
Probe Set ID Gene Symbol 
Fold change ratio (Treatment/Control) at different time points 
Ref_seq_id 
4 8 16 32 
1433669_at Akap8 2.76 2.04 -1.15 1.5 NM_019774 
1447679_s_at Bms1 1.89 2.05 1.08 1.37 NM_194339 
1423264_at Bop1 2.86 3.94 2.5 4.55 NM_013481 
1450742_at Bysl 2.17 2.94 1.58 1.81 NM_016859 
1417910_at Ccna2 -1.08 4.82 11.07 3.21 NM_009828 
1448205_at Ccnb1 1.09 3.82 9.56 3.63 NM_172301 
1417131_at Cdc25a 2.55 2.19 1.49 3.07 NM_007658 
1417132_at Cdc25a 2.29 2.07 1.24 1.76 NM_007658 
1452040_a_at Cdca3 -1.08 1.05 5.51 1.1 NM_013538 
1416802_a_at Cdca5 -1.42 22.18 21.74 8.58 NM_026410 
1448809_at Cse1l 1.98 2.93 2.48 2.24 NM_023565 
1426609_at Dis3 3.54 2.58 1.9 4.32 NM_028315 
1421097_at Endog 2.79 3.9 1.74 2.44 NM_007931 
1438317_a_at Endog 2.79 3.74 1.27 1.68 NM_007931 
1420024_s_at Etf1 2.16 2.73 1.16 1.66 NM_144866 
1452012_a_at Exosc1 2.72 2.68 1.18 2.6 NM_025644 
1435544_at Exosc6 3.18 5.31 1.36 3.43 NM_028274 
1419577_at Fig4 4.28 3.52 1.35 6.03 NM_133999 
1424300_at Gemin6 1.78 2.2 5.22 2.23 NM_026053 
1451400_at Gemin8 2.02 1.95 1.78 2.04 NM_146238 
1426213_at Imp4 2.77 2.9 2.16 2.94 NM_178601 
1426946_at Ipo5 2.68 2.61 2.78 4.82 NM_023579 
1448526_at Kpnb1 1.36 2.41 1.84 1.25 NM_008379 
1434079_s_at Mcm2 1.84 4.18 2.56 3.05 NM_008564 
1435232_x_at Mrpl15 2.2 1.97 1.67 2.9 NM_025300 
1452192_at Naf1 5.7 4.67 1.65 4.73 
XR_032374 /// 
XR_032626 
1420477_at Nap1l1 1.9 1.68 2.2 1.68 
NM_001146707 /// 
NM_015781 
1436707_x_at Ncaph -2.35 7.6 20.88 3.76 NM_144818 
1416972_at Nhp2l1 2.31 2.37 1.7 1.88 NM_011482 
1416973_at Nhp2l1 1.91 2.11 2.05 1.76 NM_011482 
1437238_x_at Nmd3 2.24 1.84 2.06 3.77 NM_133787 
1428870_at Nolc1 4.89 3.42 2.01 4.16 
NM_001039351 /// 
NM_001039352 /// 
NM_001039353 /// 
NM_053086 
1424019_at Nop2 1.9 2.39 1.27 2.52 NM_138747 
1426533_at Nop56 2.06 4.74 1.66 3.9 NM_024193 
1455035_s_at Nop56 3.19 3.14 2.89 2.52 NM_024193 
1416073_a_at Nup85 3.33 6.81 4.49 5.34 NM_001002929 
1437520_a_at Nup85 3.13 6.64 1.61 2.42 NM_001002929 
1420142_s_at Pa2g4 2.3 6.21 1.33 1.57 NM_011119 
1450854_at Pa2g4 2.34 4.59 2.06 1.97 NM_011119 
1456117_at Rrp1b 3.71 5.12 -1.19 4.06 NM_028244 
1426853_at Set 2.37 3.52 -1.02 1.46 NM_023871 
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1437370_at Sgol2 1.02 1.11 3.87 1.14 NM_199007 
1448321_at Smoc1 3.63 3.58 3.09 3.63 
NM_001146217 /// 
NM_022316 
1431087_at Spc24 -1.42 2.99 14.46 1.42 NM_026282 
1415849_s_at Stmn1 -1.57 3.11 4.91 1.87 NM_019641 
1423441_at Tfb2m 2.05 1.2 2.25 2.13 NM_008249 
1416345_at Timm8a1 4.3 5.75 2.03 4.26 NM_013898 
1454694_a_at Top2a -1.65 3.58 13.89 3.46 NM_011623 
1417373_a_at Tuba4a 1.61 2.21 1.82 1.13 NM_009447 
1433698_a_at Txnl4a 2.24 1.65 1.58 2.75 
NM_001038608 /// 
NM_001042408 /// 
NM_025299 /// 
NM_178604 
1434125_at Utp15 2.03 1.51 1.4 2.2 NM_178918 
1454846_at Utp15 1.81 1.73 -1.22 2.18 NM_178918 
1433746_at Wdr3 2.3 2.24 -1.16 1.92 NM_175552 
1423735_a_at Wdr36 2.62 1.67 1.37 2.42 
NM_001110015 /// 
NM_001110016 /// 
NM_144863 
1426496_at Wdr55 2.03 3.91 2.37 2.65 NM_026464 
1418442_at Xpo1 2.14 3.02 1.92 2.4 
NM_001035226 /// 
NM_134014 
1418443_at Xpo1 2.08 2.48 2.27 2.63 
NM_001035226 /// 
NM_134014 
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Appendix F. Differentially expressed transcripts in 
condition 1 and condition 2 
 
In this appendix, the full statistically significant differential expressed genes lists 
will be provided, in which condition 1 (M
+
/E
+
 vs M
+
/E
-
): the effect of exenatide 
under c-MYC activation, and condition 2 (M
-
/E
+
 vs M
-
/E
-
): the effects of exenatide 
without c-MYC activation. 
Table F.1. Differentially expressed transcripts in condition 1. 
Probe Set ID Gene Symbol Corrected p-value 
Fold change ratio (Treatment/Control) 
at different time points 
Ref_seq_id 
4 8 16 32 
1417612_at Ier5 2.97E-02 -2.41 -1.28 -2.26 -1.69 NM_010500 
1418057_at Tiam1 3.06E-02 -1.17 -1.20 -3.34 -1.86 
NM_001145886 /// NM_001145887 /// 
NM_009384 
1420909_at Vegfa 4.06E-02 -2.40 -1.52 -1.49 -1.61 
NM_001025250 /// NM_001025257 /// 
NM_001110266 /// NM_001110267 /// 
NM_001110268 /// NM_009505 
1422629_s_at Shroom3 4.87E-02 -1.61 1.10 -2.25 -1.24 
NM_001077595 /// NM_001077596 /// 
NM_015756 
1423099_a_at Mettl3 4.28E-02 -1.32 -1.57 -1.81 -2.04 NM_019721 
1425993_a_at Hsph1 4.28E-02 -1.77 -1.39 -2.11 -1.37 NM_013559 
1426406_at Setd8 2.97E-02 -2.61 -1.64 -2.15 -2.16 NM_030241 
1426965_at Rap2a 4.68E-02 -2.31 1.04 -2.08 -2.20 NM_029519 
1432431_s_at Macrod2 4.28E-02 -1.78 -1.84 -2.50 -1.07 NM_001013802 /// NM_028387 
1435030_at Upf2 4.63E-02 -3.21 1.02 -1.90 -1.16 NM_001081132 
1435551_at Fhod3 2.97E-02 -1.78 -1.48 -2.62 -2.88 NM_175276 
1428800_a_at Pus7l 4.68E-02 -1.33 -2.12 -1.84 -1.54 NM_172437 
1428945_at Uba6 3.23E-02 -1.99 -1.16 -4.63 -1.56 NM_172712 
1429073_at 2210015D19Rik 2.97E-02 -2.30 1.08 -1.02 -1.57 XM_001475228 /// XM_893272 
1429118_a_at Zh2c2 2.97E-02 1.03 1.01 -2.16 1.04 NM_026250 
1429682_at Fam46c 4.06E-02 -3.18 1.01 -3.21 -1.63 
NM_001142952 /// XR_001536 /// XR_002338 /// 
XR_005163 
1433641_at LOC100046891 /// Smad5 2.97E-02 -2.62 -1.61 -1.37 -1.49 NM_008541 /// XR_033104 
1434083_a_at Elmod1 4.28E-02 -1.25 -1.08 -2.06 1.01 NM_177769 
1434572_at Hdac9 3.49E-02 -3.10 -3.55 -1.59 -3.91 NM_024124 
1435074_at Tmem106b 3.98E-02 -2.17 -1.41 -1.56 -1.51 NM_027992 
1435717_at 4833428C12Rik 2.97E-02 -2.98 1.02 -2.88 -1.36  
1436650_at Filip1 2.97E-02 -3.85 -4.05 -6.58 -2.51 NM_001081243 
1440435_at Ky 4.28E-02 -2.38 -1.82 -1.62 -1.18 NM_024291 
1441578_at Ccdc86 3.16E-02 -1.85 -1.03 -1.22 -2.21 NM_023731 
1455970_at  2.97E-02 -4.76 -1.61 -2.12 -3.08  
1456092_at Kctd7 4.63E-02 -1.01 -1.09 -2.03 -1.03 NM_172509 
1458341_x_at  3.45E-02 -2.89 -2.93 -1.07 -1.91  
1459723_at Zdhhc22 2.97E-02 -3.19 -4.16 -3.50 -1.56 NM_001080943 
1419105_at Nr1h4 3.66E-02 1.30 1.09 2.59 -1.03 NM_009108 
1419874_x_at Zbtb16 2.97E-02 3.18 2.05 1.60 2.04 NM_001033324 
1424250_a_at Arhgef3 2.97E-02 2.44 4.21 1.89 7.71 NM_027871 
1425144_at Klk1b11 3.06E-02 2.24 -1.10 1.00 -1.00 NM_010640 
1425837_a_at Ccrn4l /// LOC100047134 2.97E-02 1.95 5.47 1.95 3.00 NM_009834 /// XM_001477322 
1435949_at Zc3h3 2.97E-02 2.78 1.86 1.15 1.62 NM_172121 
1439060_s_at Wipi1 4.98E-02 2.29 1.31 1.58 1.41 NM_145940 
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1442025_a_at  2.97E-02 3.97 3.65 2.22 4.08  
1450779_at Fabp7 4.91E-02 1.20 -1.09 5.23 1.02 NM_021272 
1437989_at Pde8b 2.97E-02 1.16 -1.14 2.93 1.28 NM_172263 
1445709_at Mdm1 2.97E-02 1.18 9.29 -1.29 10.12 NM_010785 /// NM_148922 
1456321_at Nipal1 4.63E-02 1.39 2.33 1.03 2.20 NM_001081205 
1456518_at 4930422I07Rik 4.06E-02 1.03 -1.07 2.04 -1.02 NM_001142943 /// XM_150216 /// XM_918228 
1457132_at  4.06E-02 2.57 3.04 1.70 3.26  
1459957_at  9.47E-03 -1.10 -1.07 4.91 1.05  
 
 
Table F.2. Differentially expressed transcripts in condition 2 
Probe Set ID Gene Symbol Corrected p-value 
Fold change ratio (Treatment/Control) 
at different time points 
Ref_seq_id 
4 8 16 32 
1418176_at Vdr 4.61E-02 -1.25 -2.61 -1.80 -1.90 NM_009504 
1421147_at Terf2 2.64E-02 -1.96 -1.95 -2.58 -1.56 NM_001083118 /// NM_009353 
1422556_at Gna13 1.32E-02 -1.44 -1.28 -3.40 -1.12 NM_010303 
1422629_s_at Shroom3 9.54E-03 -2.53 -1.67 -1.81 -1.29 NM_001077595 /// NM_001077596 /// NM_015756 
1425274_at Asph 6.19E-03 1.05 1.02 -3.29 -1.10 NM_023066 /// NM_133723 
1451419_at Spsb4 2.83E-02 -3.31 -3.08 -2.73 -1.11 NM_145134 
1452207_at Cited2 3.37E-03 -5.01 -6.71 -3.78 -3.22 NM_010828 
1428637_at Dyrk2 /// LOC100044376 2.25E-03 -2.25 -3.36 -2.11 -1.49 NM_001014390 /// XR_030576 
1433205_at Ndfip2 2.25E-03 1.08 -2.68 -1.03 -1.00 NM_029561 
1434572_at Hdac9 1.00E-04 -5.22 -3.45 -13.81 -4.84 NM_024124 
1436368_at Slc16a10 3.37E-03 -2.08 -1.49 -2.19 -1.56 NM_001114332 /// NM_028247 
1436650_at Filip1 4.01E-02 -6.31 -3.12 1.03 -2.64 NM_001081243 
1439753_x_at Six4 4.73E-03 -2.93 -3.08 -2.65 -1.75 NM_011382 
1439836_at Asb15 2.44E-02 -2.88 -5.39 -2.12 -1.06 NM_080847 
1440435_at Ky 3.19E-02 -1.83 -2.38 -1.39 -1.71 NM_024291 
1441881_x_at Fam101a 2.60E-02 -2.16 -1.73 -2.28 -1.42 NM_028443 
1442077_at 2310076G05Rik 1.08E-02 1.01 1.01 -3.44 -1.00  
1455970_at  3.82E-02 -2.62 -2.34 -1.87 -2.38  
1456862_at Six4 3.37E-03 -2.31 -3.05 -2.69 -1.60  
1458081_at  2.50E-02 -2.01 -1.54 -1.89 -1.11  
1458341_x_at  3.36E-02 -1.99 -1.73 -2.34 -2.30  
1416125_at Fkbp5 4.25E-02 2.04 2.04 3.97 1.84 NM_010220 
1416129_at Errfi1 4.83E-03 2.79 5.07 4.35 2.21 NM_133753 
1418183_a_at Cyth1 4.73E-03 2.27 2.19 2.27 1.75 NM_001112699 /// NM_001112700 /// NM_011180 
1419100_at Serpina3n 2.44E-02 1.23 1.01 2.15 1.10 NM_009252 
1424250_a_at Arhgef3 8.06E-03 3.33 2.48 8.16 5.70 NM_027871 
1425837_a_at Ccrn4l /// LOC100047134 2.25E-03 5.05 6.97 2.55 2.69 NM_009834 /// XM_001477322 
1429379_at Lyve1 1.94E-02 1.76 2.42 9.76 2.08 NM_053247 
1433575_at Sox4 2.60E-02 4.57 2.85 2.98 3.58 NM_009238 
1434465_x_at Vldlr 3.82E-02 3.02 1.99 3.05 3.25 NM_013703 
1434496_at Plk3 8.06E-03 1.68 2.74 2.57 2.72 NM_013807 
1449007_at Btg3 /// EG654432 2.65E-02 1.47 1.80 2.75 1.54 NM_009770 /// NR_002700 
1451053_a_at Mdm1 1.04E-02 4.61 7.18 5.06 4.68 NM_010785 /// NM_148922 
1433762_at C630043F03Rik 2.65E-02 1.59 2.20 1.70 1.26  
1435893_at Vldlr 3.53E-03 2.28 1.76 4.91 2.93 NM_013703 
1441687_at Wnt4 4.91E-02 2.29 3.38 5.06 2.10 NM_009523 
1457132_at  1.03E-02 2.57 6.69 2.96 2.14  
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E-mail address: hugo@maths.warwick.ac.uk (H.A.Endocrine dynamics spans a wide range of time scales, from rapid responses to physiological challenges
to with slow responses that adapt the system to the demands placed on it. We outline a non-linear aver-
aging procedure to extract the slower dynamics in a way that accounts properly for the non-linear
dynamics of the faster time scale and is applicable to a hierarchy of more than two time scales, although
we restrict our discussion to two scales for the sake of clarity. The procedure is exact if the slow time scale
is inﬁnitely slow (the dimensionless e-quantity is the period of the fast time scale ﬂuctuation times an
upper bound to the slow time scale rate of change). However, even for an imperfect separation of time
scales we ﬁnd that this construction provides an excellent approximation for the slow-time dynamics
at considerably reduced computational cost. Besides the computation advantage, the averaged equation
provided a qualitative insight into the interaction of the time scales. We demonstrate the procedure and
its advantages by applying the theory to the model described by Tolic´ et al. [I.M. Tolic´, E. Mosekilde, J.
Sturis, Modeling the insulin–glucose feedback system: the signiﬁcance of pulsatile insulin secretion, J.
Theor. Biol. 207 (2000) 361–375.] for ultradian dynamics of the glucose–insulin homeostasis feedback
system, extended to include b-cell dynamics. We ﬁnd that the dynamics of the b-cell mass are dependent
not only on the glycemic load (amount of glucose administered to the system), but also on the way this
load is applied (i.e. three meals daily versus constant infusion), effects that are lost in the inappropriate
methods used by the earlier authors. Furthermore, we ﬁnd that the loss of the protection against apop-
tosis conferred by insulin that occurs at elevated levels of insulin has a functional role in keeping the b-
cell mass in check without compromising regulatory function. We also ﬁnd that replenishment of b-cells
from a rapidly proliferating pool of cells, as opposed to the slow turn-over which characterises fully dif-
ferentiated b-cells, is essential to the prevention of type 1 diabetes.
 2011 Elsevier Inc. All rights reserved.1. Introduction often be treated using a quasi-steady state approximation (upNeuroendocrine control systems respond rapidly to physiologi-
cal challenges while concurrently undergoing adaptation on much
slower time scales (e.g [11,36]). Moreover, an interplay prevails
between processes at disparate scales: the slow adaptation is
dependent on the fast events. Such an interplay is a pervasive
characteristic of many biological systems.
As is well known, the dynamics of such systems can be ana-
lysed by considering separate and distinct dynamical systems
that correspond to the biological system as it operates on two
or more time scales. In such procedures, the approximation usu-
ally is exact if the slower component is ‘‘inﬁnitely slower’’ than
the faster component (see e.g. [19], for examples and applica-
tions). On a given time scale, the slower variables are ‘‘frozen’’
and ﬁgure as constant parameters, whereas the faster ones canll rights reserved.
van den Berg).to boundary or transition layers) in which the fast variable is
essentially replaced by a function which relates its (fast-time sys-
tem) equilibrium value to the prevailing values of the slower vari-
ables. Similarly, in those cases where the fast-time system does
not equilibrate but tends to a periodic solution (e.g., a limit cycle
or the stationary response to periodic forcing), intuition would
suggest that the fast variables might be replaced by a long-term
average. However, this intuition need not be correct. We outline
a homogenisation method to tackle such problems on two time
scales (see [28] for an introduction to homogenisation tech-
niques). The type of system we have in mind describes the
dynamics of an organism’s physiology (or the relevant part there-
of) together with the dynamics of the (neuro)endocrine system
that regulates this physiology. We apply the method to a well-
established model of the regulation of glucose concentration in
the blood plasma, which we extend with a slow component,
viz. the dynamics of the mass of endocrine cells. A diagrammatic
representation of this system is given in Fig. 1.
Y.-F. Wang et al. /Mathematical Biosciences 235 (2012) 8–18 91.1. Introduction to the biological application
Glucose in the blood plasma provides an essential supply of
immediately available energy substrate to all tissues of the body
[35]. Adverse effects ensue when the concentration of glucose in
the blood plasma becomes either very low or very high; avoidance
of these effects deﬁnes a ‘‘euglycemic’’ range of values and, more-
over, endocrine control loops operate so as to keep the blood glu-
cose concentration in this range [43]. Whenever the supply of
glucose derived from dietary carbohydrate exceeds demand from
the tissues, the blood glucose level rises, stimulating the secretion
of the hormone insulin, which in turn stimulates the disposition of
glucose, either to be taken up as energy substrate rather than fatty
acids, or to be stored away as a storage polymer, which is glycogen
in liver, muscle, and kidneys, and lipid in adipose tissue [11]. When
energy demand outstrips supply, the blood glucose level drops and
insulin is not secreted. The resulting drop in the insulin concentra-
tion leads to a decrease of insulin-dependent uptake of glucose
from the bloodstream as well as an increase of the release of stor-
age-derived glucose from the liver, both of which have the effect of
restoring glucose levels. At low levels of glucose, the hormone glu-
cagon is released, which promotes the breakdown of glycogen and
fatty acids [6]. A paracrine interaction between insulin and gluca-
gon secretion has been proposed [14]. However, inasmuch as glu-
cagon plays a prominent role in humans only when glucose falls
signiﬁcantly below the euglycemic range [32], the focus here is
on the glucose–insulin feedback loop.
Insulin is a peptide hormone, consisting of two peptide chains
linked by disulphide bonds, and produced by the b-cells in the
so-called Islets of Langerhans, which are clusters of endocrine cells
found scattered throughout the predominantly exocrine pancreas
[6]. The total mass of b-cells changes over time: it continues to
do so during adult life and it has become apparent during the past
decade that the pathogenesis of both type 1 and type 2 diabetes in-
volves failure to maintain an appropriate b-cell mass [4,7,20,38].
The total mass is the combined result of three processes: prolifer-
ation (cell division), apoptosis (programmed cell death), and neo-
genesis (regeneration from a pool of rapidly dividing cells, which
themselves derive from pluripotent stem cells, or possibly de-dif-
ferentiated b-cells, or alternatively trans-differentiated pancreatic
cells); these processes are inﬂuenced by the levels of both glucoseFig. 1. Diagram of the extended Sturis–Tolic´ model. Squares are state variables, clouds ar
blunt ends: negative). A delay line marked sd intervenes between Ii and wgr . The state vari
recovered. Li: liver, source of glucose derived from glycogen breakdown. Pa: pancreas,
symbols.and insulin [3,5,9,10,16,22,34,45]. As a result, there is an interplay
between the fast, ultradian ﬂuctuations of glucose and insulin and
the slower (>days) changes in b-cell mass. This means that we need
to consider a fairly realistic, high-dimensional mathematical model
on the fast time scale in order to abstract the slow-time dynamics;
we choose the model developed by the Lyngby group (see [27] for a
review of several comparable models).
2. Theory: time-scale homogenisation
The dynamics of a system comprising both the regulated phys-
iology and the associated (neuro)endocrine system can, in many
cases, be represented as a dynamical system of the following form:
d
dt
x ¼ fðx;uÞ ð1Þ
where x is the state of the system, u represents an external input,
and f is the system’s dynamics. We assume that the state variables
in x and the input variables in u have been non-dimensionalised, so
that time t is the only unit-bearing quantity remaining. The input
u(t) is assumed to be a periodic function of time with period T.
We now outline a construction that decomposes the original
dynamics into two uncoupled systems of lower dynamical dimen-
sion. These two systems may be studied independently of one an-
other. The idea is to preserve the way in which features of the
dynamics affect the dynamics at the slow time scale, by construct-
ing the slow dynamics as a map that is speciﬁc for the fast-scale re-
gime. If this formulation seems obscure: the application in Section 3
provides examples.
For physiological systems it may naturally be assumed that the
rates of change are bounded, that is, for each of the n state vari-
ables, there is a ﬁnite number ni such that the dynamics of xi
satisﬁes
jfiðx;uÞj < ni < þ1 ð2Þ
as x and u range over all physiologically attainable values. Without
loss of generality, the state variables can be ordered so that
n1 P n2 P   P nn > 0
(i.e., fastest ﬁrst). Scaling of the fi with respect to the corresponding
n leads toe sources/sinks. Dotted lines indicate functional dependence (arrowheads: positive;
able Q is the relative b-cell mass; with Q ﬁxed at 1, the original Sturis–Tolic´ model is
site of b-cells which are a source of insulin. See Table 1 for an explanation of the
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dt
x ¼ n  fðx;uÞ ð3Þ
where n is a diagonal matrix with the ni on its main diagonal and f i
is a dimensionless quantity satisfying jf⁄j 6 1. We are interested in
the case where some variables are ‘‘rapid’’ (i.e. oscillate on a time
scale of order T) and others are ‘‘slow’’. That is to say, we consider
the case where n1P T1 nn and we assume that there exists an
m 6 n such that niT is a small parameter (i.e., niT 1) for m 6 i 6 n.
Anticipating the separation of time scales, we write
xðtÞ ¼ x½0ðuðtÞ; sðtÞÞ þ x½1ðsðtÞÞ ð4Þ
where the fast component x[0] depends on a fast time u and a slow
time s, whereas the slow component x[1] depends on slow time s
only. These two times are deﬁned as follows:
u ¼ t
T
 t
T
 
ð5Þ
s ¼ nmT
t
T
 
ð6Þ
where bxc denotes the largest integer smaller than or equal to x. The
input is similarly decomposed;
uðtÞ ¼ u½0ðuðtÞ; sðtÞÞ þ u½1ðsðtÞÞ: ð7Þ
Let us write
@
@u
x½0 ¼ Tn  fðx½0;u½0;x½1;u½1Þ ð8Þ
for u 2 [0,1). To follow the fast dynamics, Eq. (8) is integrated from
u = 0 to u = 1 subject to initial condition x[0] = 0 at u = 0. Now de-
ﬁne the following variation: for g 6 nmT and i = m, . . . ,n:
dx½1i ðs;gÞ ¼ Tni
Z g=ðnmTÞ
0
f i ðx½0;u½0; x½1;u½1Þdu ð9Þ
(this variation may be regarded as a total differential sensu [31, p.
724]). Dividing Eq. (9) by g and specifying for g = nmT, this becomes:
dx½1i ðs;gÞ
nmT
¼ ni
nm
Z 1
0
f i ðx½0;u½0; x½1;u½1Þdu ð10Þ
for i = 1, . . . ,n. In the limit nmT? 0, the following expressions are
exact:
d
du
x½0i ¼ Tnif i ðx½0;u½0;x½1;u½1Þ for i ¼ 1; . . . m 1 ð11Þ
d
ds
x½1i ¼
ni
nm
Z 1
0
f i ðx½0;u½0; x½1;u½1Þdu for i ¼ m; . . .n ð12Þ
where for iP m we have x½0i  0; s now denotes the argument of the
R# R function x½1i ðÞ, and the operator @/@u has been replaced by
d/du without impunity since u is restricted to the interval [0,1).
If we let x½1mþ ¼ x½1m ; . . . ; x½1n
 
then for i < m we have x½1i ¼ Xi x½1mþ
 
,
where X1 x
½1
mþ
 
; . . . ;Xm1 x
½1
mþ
  
is a parametrical representation
of the slow manifold of the dynamics of the system (or a branch
of this manifold). The fast variables x1, . . . ,xm1 move close to
through a forced limit cycle of period T (and exactly so in the limit
nmT? 0). The slow manifold can and generally will be varying in
slow time s. It may be desirable to have the slow variable represent
a cycle average, rather than the start-of-cycle value which depends
on the arbitrary assignment of phase value 0; this is not problem-
atic but would render the notation somewhat more cumbersome
and less perspicacious.3. Calculation: application to the regulation of the glucose
concentration in the blood plasma
We apply time-scale homogenisation to glycemic homeostasis,
which is representative of a well-studied and important physiolog-
ical system in which fast (regulatory) and slow (adaptive) re-
sponses interact in a way that is essential to the system’s
operation, both in health and disease.3.1. The extended Sturis–Tolic´ model
The model for glucose dynamics as originally proposed by [39]
and subsequently further developed by Tolic´ et al. [40] is depicted
diagrammatically in Fig. 1 and is described by the following system
of ordinary differential equations:
dG
dt
¼ winðtÞ  wiiðGÞ  widðG; IiÞ þ wgrðG;w3Þ  wgxðGÞ ð13Þ
dIp
dt
¼ QwisðGÞ U
Ip
Vp
 Ii
Vi
 
 Ip
sp
ð14Þ
dIi
dt
¼ U Ip
Vp
 Ii
V i
 
 Ii
si
ð15Þ
dw1
dt
¼ 3ðIp w1Þ
sd
ð16Þ
dw2
dt
¼ 3ðw1 w2Þ
sd
ð17Þ
dw3
dt
¼ 3ðw2 w3Þ
sd
ð18Þ
dQ
dt
¼ ðqðIpÞ  lðGÞÞQðtÞ þ wngðGÞ ð19Þ
where we have adapted the notation slightly to facilitate cross-ref-
erencing. In the model, the state variable G(t) denotes the blood
plasma content of glucose whereas Ip(t) denotes the blood plasma
content of insulin (so that G/Vg and Ip/Vp are plasma concentrations)
and Ii(t) is the amount of insulin in the interstitial spaces of the
body tissues. Furthermore, w1(t), w2(t), and w3(t) are auxiliary state
variables that mimic a delay of duration sd in the release of glucose
from hepatic glycogen stores, in response to Ip (see [27], for a more
detailed explanation); and Q(t) is the b-cell mass, which is a slow
state variable presently added to the original model. The input is
the forcing function win(t), which represents the ﬂux of glucose into
the blood stream from external sources. The parameter U repre-
sents the diffusive exchange of insulin between blood and intersti-
tial space; Vp and Vi are the distribution volumes of blood plasma
and interstitial space, respectively, for insulin. The parameter sp
represents the mean life time of an insulin molecule in the blood
plasma, whereas si represents the mean life time of an insulin mol-
ecule in the interstitial space. These dependencies are modelled in
the Sturis–Tolic´ model by means of plausible, empirical functional
relationships, which are listed in Appendix A.
As indicated in Fig. 1, there are a number of rates and ﬂuxes that
depend in various different ways on the state variables. Glucose-
uptake by the tissue depends on the plasma glucose level only in
the case of insulin-independent uptake (wii), but also on the plasma
insulin level in the case of insulin-dependent glucose uptake (wid).
When glucose levels become very high, the kidneys begin to ex-
crete glucose; this ﬂux is indicated as wgx. Two ﬂuxes contribute
to increases of plasma glucose: these are the input from the food
(or glucose administered by an injection or infusion), denoted as
win, which is treated as a forcing function in the present model.
The second ﬂux is glucose secreted by the liver; this glucose release
ﬂux wgr is also dependent on both plasma glucose and plasma insu-
lin. Glucose stimulates the secretion of insulin, and thus the insulin
secretion wis is glucose-dependent.
x1 = Ip/
Iref
x2 = G/
Gref
x3 = Ii/Iref x4 = w1/
Iref
x5 = w2/
Iref
x6 = w3/
Iref
x7 = Q
n1 = 4.8 n2 = 0.11 n3 = 0.066 n4 = 0.028 n5 = 0.028 n6 = 0.028 n7 = 8.7 	 107
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b-cell mass, which involves three processes: b-cell proliferation,
whose speciﬁc rate q is assumed to depend on plasma insulin;
b-cell death, occurring at a speciﬁc rate l that depends on both
plasma glucose and insulin, and a neogenesis ﬂux wng which also
depends on both plasma glucose and insulin. Empirical formulas
for these dependencies, as well as a justiﬁcation, are given in
Appendices A and B. Inasmuch as the contribution of neogenesis
remains to be fully elucidated and may be considered controver-
sial, we shall analyse the model ﬁrst on the assumption that this
term is absent.
The glucose inputwin(t) can assume various forms. It may be set
to a constant value, as can be arranged under experimental condi-
tions where glucose is administered by means of an infusion, or it
may be time-varying. If win is set to a constant value, ultradian
oscillations may become prominent feature of the dynamics, as
shown by Tolic´ et al. [40]. Here we choose as standard reference
a periodic function with a period of 24 h and three ‘‘meal peaks’’
in every day, as shown in the top panel of Fig. 2. Under this partic-
ular input, the system settles on a stationary forced cycle within a
few days, also shown in Fig. 2.3.2. Analysis without neogenesis of b-cells
To analyse the dynamics in the absence of neogenesis, we set
w^ng ¼ 0. It will emerge that the resulting b-cell dynamics is very
slow on this assumption, which can be taken as indirect evidence
that neogenesis is an important factor in rapid (i.e., hours/days
rather than months or years) adaptation, provided we accept the
parameter values taken from the literature.
Following the method outlined in Section 2, the steps are to
render the system dimensionless, except for time, determine the
maximum absolute rates (the ns), and to rank the scaled variables0 5 1
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Fig. 2. Reference cycle. Top: glucose input; middle: plasma glucose content; boaccording to these rates. Choosing 10 g as the reference value for
glucose and 44 mU as the reference value for insulin, we ﬁnd the
following ranking (ns all in min1; Q is already dimensionless):0 15 20
0 15 20
0 15 20
e of day (hour)
ttom: plasma (black line) and interstitial space (grey line) insulin content.A time-scale separation at m = 7 is apparent, with small param-
eter nmT = 8.7 	 107 min1 	 (24 	 60 min) = 0.00125; a unit of
slow time s thus corresponding to 800 days.
The theory of Section 2 now prescribes that the dynamics in
slow time for x½17 is derived using Eq. (12), whereas the variables
x½11 ; . . . x
½1
6 are to be obtained as functions of x
½1
7 on the basis of
the slow-manifold condition, which corresponds to the stationary
forced cycle in fast time when x½17 is held at a ﬁxed value. These
relations can be obtained numerically without trouble: results
are shown in Fig. 3. Since the reference cycle corresponds to a fairly
high glycemic load, higher loads may be regarded as hyperglyce-
mic. At such loads, the dynamics of the b-cell mass has two ﬁxed
points: a lower unstable one and a higher stable point. The exis-
tence of the unstable ﬁxed point, referred to as a ‘‘pathological
ﬁxed point’’ by [41], indicates that catastrophic involution of b-cell
mass will occur when x7 becomes lower than this equilibrium va-
lue. It will then decay to zero: the loss of b-cells leads to further
hyperglycemia and lower insulinemia, which leads to further b-cell
losses [41]. Such a process may underlie non-autoimmune diabetes
mellitus, as described by [15].
As the glycemic load increases, these two ﬁxed points move to-
gether and collide. At even higher glycemic loads, the globally
attracting point is the trivial equilibrium Q = 0, that is, zero b-cell
mass. The decrease in the stable equilibrium value with increasing
glycemic load is due to an increased b-cell death rate at such high
Fig. 3. Dynamics of b-cell mass on the slow time scale. Top: relative daily change of b-cell mass, for various glycemic loads (black curves, from top to bottom: 1, 2, 2.5, and 3
times the reference input; grey curves, from top to bottom: 0.5 and 0 times the reference input). Middle: ﬁxed point of the b-cell dynamics as a function of the relative
glycemic load (solid line: stable branch; dashed line: unstable branch). Bottom: fast-time scale glucose stationary cycle characteristics (dotted line: average value; bottom
and top of ﬁlled region: minimum and maximum values).
12 Y.-F. Wang et al. /Mathematical Biosciences 235 (2012) 8–18loads, both as a result of higher glucose toxicity [10], and of in-
creased susceptibility to apoptosis at higher insulin levels [16];
the latter authors describe this situation as a ‘‘sweet spot’’ for insu-
lin in the high pico-molar range, which corresponds to order 1 lev-
els in the scaled system.
As might be expected from the strong separation of time scales,
the approximation for the slow-time scale dynamics is excellent.
Fig. 4 compares the dynamics according to the approximation
(which is simple and 1-dimensional) to the dynamics of the origi-
nal, 7-dimensional, system, in an overfeeding and an underfeeding
simulation. The results are indistinguishable: thus, the long-term
dynamics is well-captured by the approximation. The full system
was numerically integrated in fast time using an explicit Runge–
Kutta method of order 2(1), which is the Mathematica default
method [37]. The slow system was evaluated using Euler-forward
with a step size of one day, giving virtually the same result at lessthan a thousandth of the computational cost (run time; excluding
the one-time cost of establishing the dynamics of x7, which costs
about 1% of the full-system’s run time).
In formulating a mathematical model for the long-term dynam-
ics of the b-cell mass, it is tempting, although incorrect, to repre-
sent the glycemic load as a constant that represents the average
of the daily cycle (e.g., [8,41]; Ribbing et al., [33]). However, the
dynamics of x½17 in slow time s does in fact depend critically on
the ‘‘temporal ﬁne structure’’ of glucose uptake on the fast time
scale t, through the integration in Eq. (12). Such dependence is ne-
glected by an approach that replaces glucose uptake by its short-
term average. This becomes readily apparent when we consider
the case where the glycemic load is assimilated as a constant infu-
sion (set to zero for the ﬁrst 30 minutes after midnight, to enforce a
24-hour cycle) instead of a daily 3-meal cycle. It is found that the
long-term dynamics of the b-cell mass is strikingly different: the
Fig. 4. Simulations of overfeeding (left) and (underfeeding) right. On day 1000, the glycemic load is changed to 2.5 (left) or 0.1 (right) normal; on day 11,000 the load is
restored to the normal value. Dotted line: slow glucose; dot-dashed line: slow plasma insulin; dashed line: slow b-cell mass. Thin lines show the results of a direct simulation
of the 7-dimensional system. (‘‘Relative value’’ refers to scaling by Gref and Iref, as explained in the text; Q = x7 = 1 corresponds to the stationary value of b-cell mass if the
standard-cycle glycemic load were administered at a constant rate; stationary values can be read off from Fig. 3).
Fig. 5. Dynamics of b-cell mass on the slow time scale: relative daily change of b-
cell mass, for various glycemic loads, administered as a constant infusion (black
curves, from left to right: 1, 2, 2.5, and 3 times the reference input; grey curves,
from left to right: 0 and 0.5 times the reference input).
Fig. 6. Dynamics of b-cell mass on the slow time scale: recovery to normal values
after addition or destruction of b-cells at time t = 0. (‘‘Relative value’’ has the
meaning explained in the caption for Fig. 4).
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tem achieves near-perfect regulation of the average glucose level
even at a hyperglycemic load that is 4 times higher than normal,
as shown in Fig. 5. Comparison with the case iai !1 (not shown)
shows that decrease of insulin’s potency in inhibiting apoptosis at
high levels is responsible for keeping the b-mass in check without
compromising the ability to regulate: for iai !1, the ﬁxed point of
x7 increases sharply with load, even though normalisation of glu-
cose levels is already achieved at x7-values comparable to those
indicated in Fig. 5.3.3. Extended model with neogenesis of b-cells
The response dynamics shown in Fig. 4 is very slow. An example
of such sluggish dynamics is shown in Fig. 6: if 80% of the b-cell
mass is destroyed, it takes about 50 years to recover. This means
that the subject will be effectively diabetic for much of his or her
lifetime; the baseline turn-over dynamics of b-cells is too sluggish
to respond adequately to such challenges. However, in reality,
recovery from such damage is accomplished within a few weeks’
time [5]. It has been proposed that the slowly proliferating b-cell
pool may, under certain conditions, be replenished by differentia-
tion of cells from a more quickly proliferating pool of progenitorcells [7,34] that is phenotypically distinct from the differentiated
b-cells themselves [1]. A competing hypothesis is that b-cells
themselves are capable of rapid proliferation [9,20,25]. The two
hypotheses may be reconciled if the rapidly proliferating pool of
cells is derived (by a process akin to dedifferentiation) from adult
b-cells, since such cells are readily driven back into cell cycle by
activation of the proto-oncogene c-myc [30]. Here, the pool of pro-
liferators will be treated as a source term, an approach compatible
with either point of view. We shall refer, for the sake of clarity, to
the proliferator pool as ‘‘progenitors’’, with the caveat noted above.
We propose to describe the neogenesis of b-cells from progen-
itor cells by the following equation:
wngðGÞ¼ w^ng 1þexp ang;g 1
G=Vg
cng
  	 1
1þexp ang;i 1 Ii=Vging
  	 1
ð20Þ
with positive parameters w^ng;ang;g;ang;i; ing, and cng. This equation
is built from the same generic sigmoid building blocks used in the
original model, to represent graded responses to the relevant stim-
uli. The key assumption is that neogenesis is driven by prolonged
hyperglycemia [22] in conjunction with elevated insulin levels
[12]. It may be observed that the right-hand side of Eq. (20) behaves
like a soft AND-gate: the ﬂux wng is large when both glucose and
14 Y.-F. Wang et al. /Mathematical Biosciences 235 (2012) 8–18insulin levels are elevated. Prolonged concurrence of high glucose
and insulin levels may be associated with insufﬁciency, so it would
make sense to control b-cell mass compensation in this manner.
From a mechanistic point of view, it is known that the pathway reg-
ulating rapid b-cell proliferation can act like an AND-gate. Speciﬁ-
cally, the proto-oncogene gene c-myc, which encodes the
transcription factor c-Myc, which stimulates proliferation as well
as susceptibility to apoptosis [29] such that the net effect is loss
of b-cells unless an anti-apoptotic co-signal is present [30]. Expres-
sion of c-Myc is induced by glucose [18] whereas insulin induces an
anti-apoptotic signal [17]. Thus, whereas glucose alone induces a
net loss of b-cells [42], the simultaneous presence of glucose and
insulin would stimulate rapid proliferation, possibly via rapid (par-
tial) dedifferentiation of existing adult b-cells to the proliferative
phenotype. It has been suggested that this dual proliferation/apop-
tosis pathway acting via c-myc acts as a fail-safe that defaults to
b-cell loss unless both glucose and insulin are elevated [29].
The action of glucose is indirect and thought to be via glucagon-
like peptide 1 (GLP-1; [7]), an incretin and cytokine which is se-
creted by enteroendocrine L-cells. Since the half-life of GLP-1 is ex-
tremely short [23], an instantaneous functional dependence on
G/Vp appears warranted. In principle, wng should also depend on,
and be limited by, the amount of progenitor cells present in the
pancreas; in the present model, this pool is assumed to be non-lim-
iting and is thought of as an unlimited source.
When neogenesis is included in the model, recovery from par-
tial ablation of b-cell mass is much more rapid and in keepingFig. 7. Model with neogenesis: recovery to normal values after addition or destruction of
to slow-time approximation. Top panel: recovery over a month; bottom panel: recovery o
the normal stationary value is now different since the dynamics includes neogenesis).with the various values quoted in the literature (recovery in a 1
to 5 week period; see [5], for a review of the experimental data),
as shown in Fig. 7. The slow-time approximation is still excellent,
despite the fact that time-scale separation is now up to two or-
ders of magnitude worse due to the rapid b-cell expansion that
occurs when the b-cell mass is too low. The relationship between
d
ds x7 and x7 remains qualitatively the same, except that the lower,
unstable ﬁxed point (the pathological ﬁxed point) is now very
low and the positive rate of change that prevails when x7 lies
in between the ﬁxed points is now several orders of magnitude
larger.
If too much of the b-cell mass is destroyed, recovery takes dis-
proportionally longer, as shown in the bottom panel of Fig. 7: when
more than 
80% of the b-cells are destroyed, recovery takes the
best part of a year, which implies the subject is diabetic for a num-
ber of months until recovery occurs.
Type 1 diabetes is an illness due to autoimmunity directed
against b-cells [43]. The simulations in Fig. 7 suggest that there is
a critical level of ablation at which recovery becomes very much
slower. If the progenitor cells do not express the insulin-derived
antigen, or do so in sufﬁciently low levels to escape immune attack,
the progression to type 1 diabetes is a matter of wng being unable to
compensate for the losses, leading to a net diminishment of b-cell
mass until the critical depletion level is reached. If the progenitor
cells are also susceptible to immune attack, the rate of recovery
will be further compromised and the rate at which the b-cell mass
descends to the critical level may be accelerated.b-cells at time t = 0. Gray curves: direct simulation; circles: approximation according
ver a year. (‘‘Relative value’’ has the meaning explained in the caption for Fig. 4, but
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The interplay between the glycemic homeostasis feedback loop,
which operates on the ultradian time scale, and the adaptive
changes in b-cell mass, which happen on a days-to-months time
scale, is a typical feature of endocrinological and neuroendocrino-
logical regulation, where a slower adaptive feedback loop is super-
imposed on a more rapid feedback loop, the latter directly involved
with a physiological system, with the former regulating the level of
activity in some manner, e.g. by controlling rates of transcription,
translation, electrical activity (secretion), or, as in the present
example, number of endocrine cells [6]. Moreover, the dynamics
of such systems usually exhibits a strongly non-linear character
[19], which means that small variations in the precise time courses
of the fast processes (the temporal ﬁne structure) can have a
profound effect on the rates of change of the slow processes.
Time-scale separation can be a powerful tool to abstract a low-
dimensional dynamical system modeling the slow adaptation
process, which is considerably more easy to analyse and visualise.
In the present case, a 7-dimensional dynamics is reduced to
1-dimensional dynamics, which is straightforward to analyse;
indeed, as Fig. 3 shows, in qualitative terms the system is much like
logistic growth with an Allee effect.
When Eq. (12) is evaluated (in most cases this needs to be done
numerically), the causal relationships may be obscured somewhat.
For instance, in the present model, the rate of change of the b-mass
is dependent, in the direct, mechanistic sense of the word, on glu-
cose and insulin, as the model’s equations make explicit. However,
the time courses of glucose and insulin depend on the prevailing
b-cell mass, together with the input win, and as a result, in slow
time, the rate of change of the b-cell mass depends on the b-cell
mass itself in conjunction with the input waveform, i.e., the rate
of change in slow time is a functional of the input win(t), as is clear
from the integration over the fast-time scale cycle in Eq. (12). In
this way, the temporal ﬁne structure is taken into account, in anal-
ogy to similar spatial homogenisation procedures (see [13,19]).
The assumption in this paper has been that rapid compensation
in b-cell mass is driven by proliferation, based on the observation
that b-cells can be driven back into cell cycle by activation of
c-myc [30] and data on recovery from partial pancreatomy and
hyperglycemic challenge ([5]). However, it is also possible that
b-cells respond by adjusting the amount of hormone-producing
machinery per cell (and, concomitantly, cell volume) and that data
concerning short-term changes in numbers of b-cells are distorted
by the fact that temporarily depleted cells (degranulated cells) are
spuriously not counted as b-cells [2]. The relative importance of
such non-proliferative adaptation, which possibly depends on the
time scales and extend of challenge at hand, remains to be eluci-
dated in detail; whereas hypertrophy was held to be the main
mechanism for increases in b-cell mass in man until the last decade
[24,44], recent years have seen a change in emphasis towards pro-
liferation and neogenesis [5,21,30].
In the model considered here, all but one of the state variables
was fast. The Sturis–Tolic´ model can be extended with further slow
variables. One such variable might be the insulin sensitivity of the
body’s tissues, which plays a major role in the etiology of type 2
diabetes [35]. However, a more precise characterisation of the pro-
cess we have referred to as neogenesis is essential to make pro-
gress: in particular, the maximum rate at which this pool can
proliferate, as well as the rates at which it is replenished (which
may depend on the sources: b-cells are transdifferentiated pancre-
atic cells) are likely to be critical to the ability of neogenesis to fur-
nish the amount of new b-cells required. The present paper has
shown that the pathological ﬁxed point, ﬁrst noted and so termed
by [41], becomes a prominent factor only when neogenesis is im-
paired, and, moreover, that this pathological ﬁxed point has a valuethat is dependent on the diel time course of the rate at which glu-
cose is administered to the system. Whereas mathematical model-
ling can never replace the experiments that elucidate these
processes, it can help to characterise the functional consequences
of these ﬁndings along the lines outlined in the present paper.
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Appendix A. Functional relationships for rates and ﬂuxes
The ws are ﬂuxes and rates modelled by empirical functions: wii
represents insulin-independent glucose uptake by body cells:
wiiðGÞ ¼ w^ii d 1 exp 
G=Vg
cii;lo
( ) !
þ 1 d
1þ exp aii 1 G=Vgcii;hi
 n o
2
4
3
5
ðA:1Þ
where w^ii; cii;lo; cii;hi; d, and Vg are positive parameters (see Table 1 for
values). Insulin-dependent glucose uptake is represented by wid:
widðGÞ ¼
G=Vg
cid
w0 þ
w^id  w0
1þ exp aid ln ðIi=iidÞðV1i þ ðUsiÞ1Þ
n on o
2
4
3
5
ðA:2Þ
with positive parameters w0; w^id;aidcid, and iid. Endogenous release
of glucose is represented by wgr:
wgrðG;w3Þ¼ w^gr 1þexp agr;g 1
G=Vg
cgr
  	 1
1þexp agr;i 1w3=Vpigr
  	 1
ðA:3Þ
with positive parameters w^gr;agr;i;agr;g; igr, and cgr. Insulin secre-
tion from pancreatic b-cells is represented by wis:
wisðGÞ ¼ w^is 1þ exp ais 1
G=Vg
cis
  	 1
ðA:4Þ
with positive parameters w^is;ais, and cis. Renal excretion of glucose,
which becomes important at elevated glucose levels, is represented
by wgx:
wgx ¼ wgx ln 1þ agx exp
G=Vg
cgx
 	 	
ðA:5Þ
with positive parameters wgx;agx, and cgx. The proliferation rate of
the b-cells is assumed to be dependent on the insulin
concentration:
qðIpÞ ¼ q0 1þ d0
Ip
i0Vp þ Ip
 
ðA:6Þ
with positive parameters q0, a0, and i0. The death rate of the b-cells
is assumed to be dependent on the glucose concentration and the
interstitial insulin concentration:
lðG; IiÞ ¼ l^ 1þ Ii=Viiai
 
1þ exp a1  G=Vgc1
 a2 1 G=Vgc2
 4( ) !
ðA:7Þ
with positive parameters l^;a1;a2; c1, and c2. The above formulas
and the values listed in Table 1 have been taken from [40], with
the addition of two novel elements: glucose excretion (wgx), which
is necessary to represent hyperglycaemic challenges, and the b-cell
mass dynamics. Glucose excretion is based on the graph given in
Table 1
Notation and parameter values.
Parameter Value Units Interpretation
U 0.2 l min1 Blood/interstitial space permeability
Vp 3 l Insulin distribution volume
Vi 11 l Interstitial space volume
Vg 10 l Glucose distribution volume
sg 6 min Mean lifetime of insulin in plasma
si 100 min Mean lifetime of insulin in interstitial space
sd 36 min Response delay of glucose release
a1 1.86 – First sensitivity of b-cell death
a2 14.5 – Second sensitivity of b-cell death
aii 4.8 – Sensitivity of insulin-independent glucose uptake
aid 1.77 – Sensitivity of insulin-dependent glucose uptake
agr;i 7.54 – Insulin sensitivity of hepatic glucose release
agr;g 10 – Glucose sensitivity of hepatic glucose uptake
ais 6.67 – Sensitivity of insulin secretion
agx 0.00065 – Renal excretion parameter
ang;i 0.5 – Sensitivity of neogenesis to insulin
ang;g 0.5 – Sensitivity of neogenesis to glucose
c1 1.6 g l1 First pivot point of b-cell death rate
c2 2.6 g l1 Second pivot point of b-cell death rate
cii;lo 144 mg l
1 Pivot point of non-splanchnic insulin-independent glucose uptake
cii;hi 2 g l
1 Pivot point of splanchnic insulin-independent glucose uptake
cid 1 g l
1 Pivot point of insulin-dependent glucose uptake
cgr 2 g l
1 Pivot point of glucose release
cis 2 g l
1 Pivot point of insulin secretion
cgx 0.3 g l
1 Renal excretion parameter
cng 1.3 g l
1 Pivot point of neogenesis for glucose dependence
d 0.34 – Contribution of non-splanchnic insulin-independent glucose uptake
d0 0.64 – Insulin-sensitive portion of b-cell proliferation
i0 115 mU l1 Pivot point of b-cell proliferation rate
iid 80 mU l1 Pivot point of insulin-dependent glucose uptake
igr 26 mU l1 Pivot point of hepatic glucose release
iai 0.3 U l1 Pivot point for apoptosis inhibition
ing 30 mU l1 Pivot point for neogenesis for insulin dependence
w0 40 mg min1 Baseline of insulin-dependent glucose uptake
w^ii 0.21 g min
1 Maximum ﬂux: insulin-independent glucose uptake
w^id 0.94 g min
1 Maximum ﬂux: insulin-dependent glucose uptake
w^gr 0.18 g min
1 Maximum ﬂux: hepatic glucose release
w^is 0.21 U min
1 Maximum ﬂux: insulin secretion
w^ng 0.001 min
1 Maximum ﬂux: neogenesis of b-cell mass
wgx 29 mg min
1 Renal excretion parameter
q0 0.166 yr1 Baseline b-cell proliferation rate
l^ 0.311 yr1 Maximum b-cell death rate
The term ‘‘pivot point’’ refers to midrange values, saturation constants etc. of saturating responses.
Insulin units: 1 U ¼: 6.67 nmol.
Fig. B.8. Pancreatic b-cell death rate data and least-squares ﬁt of the formula used
in the model.
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the literature, as detailed in Appendix B.
Appendix B. Parameter estimation for b-cell dynamics
Whereas the fast time-scale parameters could be adopted from
[40], the rates of proliferation, death, and neogenesis of b-cells had
to be estimated from the experimental literature. Although the
model describes the human system, the parameter values here
are taken from experiments on rodents, which is a limitation. How-
ever, the parameters represent cellular characteristics which may
to a ﬁrst approximation be assumed to be transferrable from the
rodent to the human setting. An exception is the parameter w^ng,
but our method of estimating this parameter implicitly contains
the required scaling.
B.1. Death
Efanova et al. [10] reported fractions of surviving b-cells after 40
hours and exposure to varying levels of glucose. The average death
rate per hour over this interval can be estimated using the formula
ln{f}/(40 h) where f is the fraction of cells alive after 40 h ofexposure. Death rates thus obtained are plotted as a function of
the ambient glucose concentration in Fig. B.8. Eq. (A.7), which is
not intended as a mechanistic explanation but merely to capture
Fig. B.9. Pancreatic b-cell proliferation rate data and least-squares ﬁt of the
hyperbolic formula used in the model.
Fig. B.10. The Steil et al. experiment as simulated by the present model. After tw
interstitial space insulin content; bottom: b-cell mass.
Y.-F. Wang et al. /Mathematical Biosciences 235 (2012) 8–18 17the phenomenology, was ﬁtted to these data by non-linear least-
squares. However, it was found that these rates were several or-
ders of magnitude larger than the accepted b-cell turn-over rate
quoted in the literature [9,41], which may be attributed to the
unfavourable ex vivo conditions under which these data were ob-
tained. For this reason, the parameter was scaled l^ in such a way
that the standard cycle described in the main text would be char-
acterised by a balance of b-cell birth and death.
Johnson et al. [17] documented a direct anti-apoptotic effect of
insulin, quantiﬁed by various measures which showed broadly
similar trends in dependence upon insulin concentration, the effecto contbeing most pronounced at low insulin levels and diminishing
hyperbolically as insulin is increased to hyper-physiological levels.
Johnson and Alejandro [16] synthesised these trends in a single
graph, which shows that the relative potency of the anti-apoptotic
effect drops off more or less hyperbolically with insulin concentra-
tion I, i.e. as follows:
relative effect ¼ 1
iai þ I ðB:1Þ
where iai is approximately 0.3 U l1. The reciprocal of this protec-
tive effect appears as a prefactor of the death rate in Eq. (A.7).
B.2. Proliferation
Okada et al. [26] and Beith et al. [3] demonstrated that insulin
stimulates b-cell proliferation. Data taken from the latter paper
were used to ﬁt a simple hyperbolic model, Eq. (A.6), shown in
Fig. B.9.
B.3. Neogenesis
Neogenesis of b-cells remains to be fully characterised in quan-
titative terms. The formula used in this paper to represent the rate
at which b-cells are replenished is therefore speculative. To obtain
reasonable values for the relevant parameters (those with sub-
script NG), simulations were performed that mimicked an experi-
ment described by Steil et al. [38] in which rats were given
infusions of glucose that initially doubled the plasma glucose lev-
els. Within a day, euglycemia was re-established and the b-cell
mass had doubled. The simulations are shown in Fig. B.10.rol days, glucose is switched to an infusion. Top: plasma glucose content; middle:
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